http://www.prnewswire.co.uk/news-releases/elsevier-and-the-us-uk-fulbright-commission-reward-early-career-researchers-in-the-uk-695247371.html,Elsevier and the US-UK Fulbright Commission Reward Early Career Researchers in the UK,"<section class=""release-body container "" itemprop=""articleBody"">
    <div class=""row"">
                <div class=""col-sm-10 col-sm-offset-1"">
    	                   		 		 		 		 		 
		 		  		 	 					        	<p><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">LONDON</span></span></span>, <span class=""xn-chron"">October 5, 2018</span> /PRNewswire/ --</p> 
    












		                     										        	<p><a class=""linkOnClick"" data-include=""695247371"" target=""_blank"" href=""https://www.elsevier.com/"" rel=""nofollow"">Elsevier</a>, the information analytics business specializing in science and health, and the <a class=""linkOnClick"" data-include=""695247371"" target=""_blank"" href=""http://www.fulbright.org.uk/"" rel=""nofollow"">US-UK Fulbright Commission</a> are pleased to announce the winners of the UK Early Career Researcher Awards.</p> 
    












		                     							        <!--startclickprintexclude-->
                <!--endclickprintexclude-->
          </div>
        </div>
		
        <!-- 1 --> 
                  <div class=""row"">
                                          	<!--PRNE Version C Format Assets Start-->
<div class=""container"">
	<div class=""row"">
		<div class=""col-sm-10 col-sm-offset-1"">
			<div class=""gallery inline-carousel"">
				<div class=""gallery-carousel-main"">
																<!-- assetC https://mma.prnewswire.com/media/754761/US_UK_Fulbright_Commission_Logo.jpg?w=1600  --- https://mma.prnewswire.com/media/754761/US_UK_Fulbright_Commission_Logo.jpg?p=publish  -->
						<!-- https://mma.prnewswire.com/media/754761/US_UK_Fulbright_Commission_Logo.jpg?w=1600  --- https://mma.prnewswire.com/media/754761/US_UK_Fulbright_Commission_Logo.jpg?p=publish -- https://mma.prnewswire.com/media/754761/US_UK_Fulbright_Commission_Logo.jpg?w=950 -- $item.sourceUrl -->

    							
  <!-- image -->						<div class=""gallery-cell"">
							<figure>
																									<div class=""image lightbox-item "" data-asset-type=""Photo"" data-asset-id=""US_UK_Fulbright_Commission_Logo.jpg"" data-asset-label="""" data-src=""https://mma.prnewswire.com/media/754761/US_UK_Fulbright_Commission_Logo.jpg?w=1600"" data-sub-html=""US-UK Fulbright Commission Logo (PRNewsfoto/Elsevier)"" data-tweet-text=""US-UK Fulbright Commission Logo (PRNewsfoto/Elsevier)"" data-facebook-share-text=""US-UK Fulbright Commission Logo (PRNewsfoto/Elsevier)"" data-linkedin-text=""US-UK Fulbright Commission Logo (PRNewsfoto/Elsevier)"" data-download-url=""https://mma.prnewswire.com/media/754761/US_UK_Fulbright_Commission_Logo.jpg?w=1600"" data-pinterest-text=""US-UK Fulbright Commission Logo (PRNewsfoto/Elsevier)"" data-twitter-share-url=""https://mma.prnewswire.com/media/754761/US_UK_Fulbright_Commission_Logo.jpg?w=1600&amp;p=twitter"" data-linkedin-share-url=""https://mma.prnewswire.com/media/754761/US_UK_Fulbright_Commission_Logo.jpg?w=1600&amp;p=linkedin"" data-facebook-share-url=""https://mma.prnewswire.com/media/754761/US_UK_Fulbright_Commission_Logo.jpg?w=1600&amp;p=facebook"" data-pinterest-share-url=""https://mma.prnewswire.com/media/754761/US_UK_Fulbright_Commission_Logo.jpg?w=1600&amp;p=publish"" onclick=""omniture_corousal('Carousel lightbox Page','Photo Open','US_UK_Fulbright_Commission_Logo.jpg','')"">
  	  <img src=""https://mma.prnewswire.com/media/754761/US_UK_Fulbright_Commission_Logo.jpg?w=950"" id=""imageid_3"" alt=""US-UK Fulbright Commission Logo (PRNewsfoto/Elsevier)"" class=""gallery-thumb img-responsive"" rel=""newsImage"">
</div>
																								<figcaption>
									US-UK Fulbright Commission Logo (PRNewsfoto/Elsevier)
								</figcaption>
															</figure>
						</div>
									</div>
							</div>
							<!-- image -->									</div>
	</div>
</div>
 <!--PRNE Version C Format Assets End-->
                              </div>
                <div class=""row"">
          <div class=""col-sm-10 col-sm-offset-1"">
			      	<p>     (Logo: <a class=""linkOnClick"" data-include=""695247371"" target=""_blank"" href=""https://mma.prnewswire.com/media/754760/Elsevier_Logo.jpg"" rel=""nofollow"">https://mma.prnewswire.com/media/754760/Elsevier_Logo.jpg</a> )</p> 
    












                         					        	<p>     (Logo: <a class=""linkOnClick"" data-include=""695247371"" target=""_blank"" href=""https://mma.prnewswire.com/media/754761/US_UK_Fulbright_Commission_Logo.jpg"" rel=""nofollow"">https://mma.prnewswire.com/media/754761/US_UK_Fulbright_Commission_Logo.jpg</a> )<br> The UK represents under 1 percent of the global population yet produces 15 percent of the world's most highly cited articles<sup>[1]</sup>. To maintain this situation, continued investment in the national research base is essential.</p> 
    












		                     					        	<p>The UK Early Career Researcher Awards comprise two separate award programmes. As part of their joint mission to support young researchers in developing their careers, Elsevier and the US-UK Fulbright Commission have partnered in hosting the awards since 2011. Winners of these awards are chosen by an expert panel of judges, drawing on citation and publication information from Elsevier's <a class=""linkOnClick"" data-include=""695247371"" target=""_blank"" href=""http://www.elsevier.com/solutions/scopus"" rel=""nofollow"">Scopus</a> database.</p> 
    












		                     					        	<p>Elsevier and the US-UK Fulbright Commission announced the 2018 winners at an awards ceremony attended by over 75 senior figures from government, academia and industry.</p> 
    












		                     					        	<p>The six 2018 UK Early Career Researcher Award winners are:</p> 
    












		                     					        	 				<ul type=""disc""> 
    <li><b>Environmental Science</b>: Dr. <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Richard Millar</span></span>, from the <span class=""xn-org"">University of Oxford</span>, investigates the physical and economic consequences of climate change.</li> 
    <li><b>Medicine</b>: Dr. <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Sarah McGlasson</span></span>, a postdoctoral researcher at the <span class=""xn-org"">University of Edinburgh</span>, conducts research to understand how immune activation can lead to neurological damage.</li> 
    <li><b>Social Sciences</b>: Dr. <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Filippo Menga</span></span> explores the interplay between humans and the environment with a particular focus on water politics, at the University of Reading.</li> 
    <li><b>Physical Sciences</b>: Dr. Alex Ganose, from University College London, focuses on the discovery of energy materials, with a particular interest in photovoltaics and thermoelectrics.</li> 
    <li><b>Biochemistry, Genetics, Molecular Biology</b>: Dr. Serene Chen studies protein aggregates such as the alpha-synuclein protein, whose deposition is one of the hallmarks of Parkinson's disease, first at the <span class=""xn-org"">University of Cambridge</span> and now as a postdoctoral research fellow at Imperial College London.</li> 
    <li><b>Arts and Humanities</b>: Dr. <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Charlotte Wray</span></span>, from <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Royal Holloway</span></span>, studies atypical child development, such as risk of language disorder at school entry.</li> 
   </ul> 
   













		                     					        	<p><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Ron Mobed</span></span>, CEO of Elsevier, said: ""Today's early career researchers find themselves in an ever-more competitive environment while the future of science and indeed the sustainability of our planet depends on them. Supporting young scientists in building their careers and studying some of the most challenging questions of our time is critical. The UK Early Career Researcher Awards will hopefully be an encouragement to these young researchers to make a lasting impact and help transform our society for the better.""</p> 
    












		                     					        	<p>""We are very pleased to have partnered with Elsevier this year again in supporting researchers to further their careers,"" said <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Penny Egan</span></span>, Executive Director of the US-UK Fulbright Commission. ""These awards acknowledge the significant contributions of UK researchers in a range of disciplines, as well as the institutions that encourage the development of early career talent.""</p> 
    












		                     					        	<p>A second award category, also part of the UK Early Career Researcher Awards program, is the <b>Researchers</b><b>'</b><b> Choice Communication Award</b>. Introduced in 2015, this category aims to recognise researchers who have excelled in communicating the purpose, meaning and impact of their research to the wider public.</p> 
    












		                     					        	<p>This year's winner is Dr. <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Joanne Jordan</span></span>, of the University of <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Manchester</span></span></span>, who investigated the impact of climate change on the lives of the urban poor in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Dhaka, Bangladesh</span></span></span>. Using local performance art to highlight the impact of climate change as slum dwellers experience it in their daily lives, Joanne has brought her work to over 7,000 people including those she studied, policy makers, academics, students and the general public.  </p> 
    












		                     					        	<p>BBC presenter <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Adam Rutherford</span></span>, lead judge in this year's Researchers' Choice Communication Award, presented Dr. Jordan with the award. ""Dr. Jordan's <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Dhaka</span></span></span> project is fully immersive and impressive for recording such a rich experience from people on the frontline of the impact of climate change,"" he said. ""The resulting work has the potential to influence other people, and hopefully policy makers. It's a great example of scientific engagement that reaches diverse publics and has a genuine impact on viewers.""</p> 
    












		                     					        	<p><b>Notes to editors</b> </p> 
    












		                     					        	<p><sup>[1]</sup> Source: <a class=""linkOnClick"" data-include=""695247371"" target=""_blank"" href=""https://www.elsevier.com/research-intelligence/research-initiatives/beis2016"" rel=""nofollow"">International Comparative Performance of the UK Research Base 2016</a></p> 
    












		                     					        	<p><b>About the US-UK Fulbright Commission</b> </p> 
    












		                     					        	<p>The <a class=""linkOnClick"" data-include=""695247371"" target=""_blank"" href=""http://www.fulbright.org.uk/"" rel=""nofollow"">US-UK Fulbright Commission</a> was created by treaty on <span class=""xn-chron"">22 September 1948</span>. The Commission has been celebrating its 70 anniversary this year. We offer grants at postgraduate and postdoctoral level for study in any discipline and at any accredited institution in the US and UK, as well as a number of special exchange programmes for shorter projects and a social mobility programme for younger students. During the last six decades, approximately 15,000 UK nationals have studied in the US and 12,000 US nationals in the UK as part of the Fulbright Programme. Prominent alumni of the Fulbright Programme include poet <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Sylvia Plath</span></span>, Liam Byrne MP and Dr. <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Ben Broadbent</span></span>, Deputy Governor, Monetary Policy, Bank of <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">England</span></span></span>. <a class=""linkOnClick"" data-include=""695247371"" target=""_blank"" href=""http://www.fulbright.org.uk"" rel=""nofollow"">http://www.fulbright.org.uk</a></p> 
    












		                     					        	<p><b>About Elsevier</b> </p> 
    












		                     					        	<p><a class=""linkOnClick"" data-include=""695247371"" target=""_blank"" href=""https://www.elsevier.com/"" rel=""nofollow"">Elsevier</a> is a global information analytics business that helps institutions and professionals advance healthcare, open science and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&amp;D performance, clinical decision support and professional education, including <a class=""linkOnClick"" data-include=""695247371"" target=""_blank"" href=""https://www.elsevier.com/solutions/sciencedirect"" rel=""nofollow"">ScienceDirect</a>, <a class=""linkOnClick"" data-include=""695247371"" target=""_blank"" href=""https://www.elsevier.com/solutions/scopus"" rel=""nofollow"">Scopus</a>, <a class=""linkOnClick"" data-include=""695247371"" target=""_blank"" href=""https://www.elsevier.com/solutions/scival"" rel=""nofollow"">SciVal</a>, <a class=""linkOnClick"" data-include=""695247371"" target=""_blank"" href=""https://www.elsevier.com/solutions/clinicalkey"" rel=""nofollow"">ClinicalKey</a> and <a class=""linkOnClick"" data-include=""695247371"" target=""_blank"" href=""https://evolve.elsevier.com/education/sherpath/"" rel=""nofollow"">Sherpath</a>. Elsevier publishes over 2,500 digitized journals, including <a class=""linkOnClick"" data-include=""695247371"" target=""_blank"" href=""http://www.thelancet.com/"" rel=""nofollow""><i>The Lancet</i></a> and <a class=""linkOnClick"" data-include=""695247371"" target=""_blank"" href=""http://www.cell.com/"" rel=""nofollow""><i>Cell</i></a>, 38,000 e-book titles and many iconic reference works, including <a class=""linkOnClick"" data-include=""695247371"" target=""_blank"" href=""https://www.elsevier.com/books/grays-anatomy/standring/978-0-7020-5230-9"" rel=""nofollow""><i>Gray</i><i>'</i><i>s Anatomy</i></a>. Elsevier is part of <a class=""linkOnClick"" data-include=""695247371"" target=""_blank"" href=""http://www.relx.com/"" rel=""nofollow"">RELX Group</a>, a global provider of information and analytics for professionals and business customers across industries. <a class=""linkOnClick"" data-include=""695247371"" target=""_blank"" href=""https://www.elsevier.com/"" rel=""nofollow"">http://www.elsevier.com</a></p> 
    












		                     					        	<p><b>Media contact</b> </p> 
    












		                     					        	<p><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Sacha Boucherie</span></span>, Global Communications<br> Elsevier<br> +31-20-485-3564<br> <a class=""linkOnClick"" data-include=""695247371"" href=""mailto:s.boucherie@elsevier.com"" rel=""nofollow"">s.boucherie@elsevier.com</a><br> <a class=""linkOnClick"" data-include=""695247371"" href=""mailto:newsroom@elsevier.com"" rel=""nofollow"">newsroom@elsevier.com</a></p>  












		                     					        	<p> SOURCE Elsevier </p> 












		                 </div>
  </div>
  </section>"
http://www.prnewswire.co.uk/news-releases/national-thl-biobank-partners-with-bc-platforms-global-network-of-biobanks-694462491.html,National THL Biobank Partners with BC Platforms' Global Network of Biobanks,"<section class=""release-body container  no-margin-bottom "" itemprop=""articleBody"">
    <div class=""row"">
                <div class=""col-sm-10 col-sm-offset-1"">
    	                   		 		 		 		 		 
		 		  		 	 					        	<p><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">ZURICH</span></span></span> and <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">BOSTON</span></span></span>, <span class=""xn-chron"">September 27, 2018</span> /PRNewswire/ --</p> 
   <p style=""text-align: left""><b><i>Accelerates sharing of genomic and health data from more than 150,</i></b><b><i>000 subjects</i></b> </p> 
    












		                     										        	<p>BC Platforms, a world leader in secure genomic data management and analytics, announces the addition of the THL Biobank, hosted by the Finnish National Institute for Health and Welfare (THL), to its Global Network of Biobanks.</p> 
    












		                     							        <!--startclickprintexclude-->
                <!--endclickprintexclude-->
          </div>
        </div>
		
        <!-- 0 --> 
                <div class=""row"">
          <div class=""col-sm-10 col-sm-offset-1"">
			      	<p>THL Biobank brings to the Global network their extensive datasets from approximately 150,000 donors, that include multiomic cohorts necessary for accelerating drug development, diagnostics, biomarker validation, identification of disease risk factors, and stratification of patients. BC Platforms provides its BCRQUEST.com platform, a streamlined solution for secure data sharing, analytics and governance, enabling greater collaboration for scientific innovation.</p> 
    












                         					        	<p>This new partnership will link and integrate THL Biobank data sources to one bioanalytics platform in order to facilitate and support scientific research in the public interest. With over 20 years of experience in securely managing genomic and phenotypic data, BC Platforms has developed unique technology capable of providing researchers with tools to browse and analyze summary level information from data providers, such as biobanks, who have subscribed to the service.</p> 
    












		                     					        	<p><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Sirpa Soini</span></span>, THL Biobank Director comments that, ""<i>We are </i> <i>delighted </i> <i>to partner with a </i> <i>leader in this space</i><i> who can safely and securely provide our rich data sets to a broader researcher network. </i> <i>The service </i> <i>will provide academia and industry </i> <i>a</i><i> window to the existing data</i><i> and </i> <i>communication tools to </i> <i>prepare </i> <i>research proposals, coordinate collaboration, and request data and sample</i><i>s</i><i> for research projects</i><i>.</i><i>""</i></p> 
    












		                     					        	<p><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Tero Silvola</span></span>, CEO of BC Platforms, commented, ""<i>We are </i> <i>pleased</i><i> that </i> <i>THL</i><i> Biobank</i><i>, </i> <i>a</i><i> highly respected </i> <i>Finnish </i> <i>research biobank</i><i>, </i> <i>has agreed to provide their diverse </i> <i>and high quality </i> <i>data set</i><i>s</i><i> to our global network of biobanks. </i> <i>Using</i><i> our</i> <i>BCRQUEST</i><i>.com</i><i> platform</i><i>, biobanks can select which data from their collections to showcase in a secure and compliant manner to</i><i> the</i><i> world</i><i>'</i><i>s largest pharmaceutical R&amp;D teams</i><i> and establish future research projects</i><i>. The life science industry benefits from this global pool of harmonized biobank data</i><i> to gain scientific insights</i><i> with the goal </i> <i>of reducing</i><i> drug development</i><i> timelines</i><i> and bringing benefits to the patients worldwide</i><i>.</i><i>""</i><i> </i></p> 
    












		                     					        	<p><b>About BC Platforms</b> </p> 
    












		                     					        	<p>BC Platforms is a world leader in providing powerful genomic data management and analysis solutions. Our high performing genomic data management platform enables flexible data integration, secure analysis and interpretation of molecular and clinical information. The company has launched and opened a global network of biobanks, known as BCRQUEST.com, to provide genomic and clinical cohort data for pharmaceutical and medical research and development. BC Platforms' vision is to build the world's leading analytics platform for healthcare and industry by 2020, providing access to diverse genomic and clinical data and samples from more than 5 million subjects consolidated from a global network of biobanks.</p> 
    












		                     					        	<p>Founded in 1997 from an MIT Whitehead project spinoff, the Company has a strong scientific heritage underpinned by 20 years of working in close collaboration with a network of leading researchers, developers, manufacturers and vendors. BC Platforms has global operations with its headquarters in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Zurich, Switzerland</span></span></span>, research and development in Espoo, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Finland</span></span></span>, and sales and marketing in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">London</span></span></span>, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Boston</span></span></span>, and <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Vancouver</span></span></span>. For more information, please visit <a class=""linkOnClick"" data-include=""694462491"" target=""_blank"" href=""http://www.bcplatforms.com"" rel=""nofollow"">www.bcplatforms.com</a> or follow us on Twitter @BCPlatforms. </p> 
    












		                     					        	<p><b>About </b> <b>THL</b> </p> 
    












		                     					        	<p>THL (National Institute for Health and Welfare Terveyden ja Hyyvinvoinnin Laitos) is a Finnish Research and Development institute that aims to address applications of healthcare and scientific research data to help develop solutions to diseases and public health crises. Their overall mission is to promote better population health and help apply scientific knowledge to accomplish this goal.<a class=""linkOnClick"" data-include=""694462491"" target=""_blank"" href=""http://www.thl.fi/biobank"" rel=""nofollow"">www.thl.fi/biobank</a></p> 
    












		                     					        	<p><b>Contact information: </b>  </p> 
    












		                     					        	<p><b>BC Platforms AG</b> </p> 
    












		                     					        	<p><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Brett Villagrand</span></span><br> <a class=""linkOnClick"" data-include=""694462491"" href=""mailto:Brett.villagrand@bcplatforms.com"" rel=""nofollow"">Brett.villagrand@bcplatforms.com</a></p> 
    












		                     					        	<p><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Katja Stout</span></span><br> Scius Communications<br> <a class=""linkOnClick"" data-include=""694462491"" href=""mailto:katja@sciuscommunications.com"" rel=""nofollow"">katja@sciuscommunications.com</a></p>  












		                     					        	<p> SOURCE BC Platforms </p> 












		                 </div>
  </div>
  </section>"
http://www.prnewswire.co.uk/news-releases/world-heart-day-nearly-one-in-five-deaths-from-cardiovascular-disease-are-caused-by-air-pollution-a-694466531.html,"World Heart Day: Nearly One in Five Deaths From Cardiovascular Disease are Caused by Air Pollution, a Total of 3 Million Deaths Globally Every Year","<section class=""release-body container  no-margin-bottom "" itemprop=""articleBody"">
    <div class=""row"">
                <div class=""col-sm-10 col-sm-offset-1"">
    	                   		 		 		 		 		 
		 		  		 	 					        	<p><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">GENEVA</span></span></span>, <span class=""xn-chron"">September 27, 2018</span> /PRNewswire/ --</p> 
    












		                     										        	 				<ul type=""disc""> 
    <li><i>On World Heart Day</i><i> (WHD)</i><i>, <span class=""xn-chron"">29 September 2018</span>, World Heart Federation</i><i> (WHF)</i><i> is raising awareness of the </i> <i>link between poor air quality and cardiovascular disease (CVD</i><i>)</i> </li> 
   </ul> 
   













		                     							        <!--startclickprintexclude-->
                <!--endclickprintexclude-->
          </div>
        </div>
		
        <!-- 0 --> 
                <div class=""row"">
          <div class=""col-sm-10 col-sm-offset-1"">
			      	 				<ul type=""disc""> 
    <li><i>Outdoor and household air pollution are an increasingly important risk factor for CVD: air pollution is the cause of </i> <b><i>19% of all CVD deaths</i></b><i>, accounting for more than</i> <a class=""linkOnClick"" data-include=""694466531"" target=""_blank"" href=""https://www.ncbi.nlm.nih.gov/pubmed/28919119"" rel=""nofollow""><i>3</i> <i>million deaths each yea</i><i>r</i></a></li> 
   </ul> 
   













                         					        	 				<ul type=""disc""> 
    <li><a class=""linkOnClick"" data-include=""694466531"" target=""_blank"" href=""http://www.who.int/airpollution/events/conference/Air-Pollution_and_Health_Conference_Brochure_SavetheDate_FINAL_web5-EN.pdf.pdf?ua=1"" rel=""nofollow""><i>7</i> <i>million people</i></a><i> die prematurely every year from air pollution:</i> <a class=""linkOnClick"" data-include=""694466531"" target=""_blank"" href=""http://www.who.int/airpollution/events/conference/Air-Pollution_and_Health_Conference_Brochure_SavetheDate_FINAL_web5-EN.pdf.pdf?ua=1"" rel=""nofollow""><i>1.4 million from stroke and over 2 million from heart disease</i></a></li> 
   </ul> 
   













		                     					        	 				<ul type=""disc""> 
    <li><i>CVD is the world's biggest killer, causing over</i> <a class=""linkOnClick"" data-include=""694466531"" target=""_blank"" href=""http://www.who.int/cardiovascular_diseases/en/"" rel=""nofollow""><b><i>17.5 million deaths each year</i></b></a><b><i>.</i></b><i> </i> <i>WHD is the biggest awar</i><i>eness-raising campaign for CVD </i> <i>to improve heart health through educational and awareness activities</i></li> 
   </ul> 
   













		                     					        	<p>This year, on 29 September, the World Heart Federation (WHF) is raising awareness of an increasingly important CVD risk factor: air pollution.</p> 
    












		                     					        	<p>     (Logo: <a class=""linkOnClick"" data-include=""694466531"" target=""_blank"" href=""https://mma.prnewswire.com/media/748087/World_Heart_Day_Logo.jpg"" rel=""nofollow"">https://mma.prnewswire.com/media/748087/World_Heart_Day_Logo.jpg</a> )<br> </p> 
    












		                     					        	<p>The latest scientific evidence by <a class=""linkOnClick"" data-include=""694466531"" target=""_blank"" href=""https://www.nature.com/articles/nrcardio.2017.207"" rel=""nofollow"">Nature</a> warns that exposure to nitrogen dioxide and fine particulate matter air pollution is clearly linked to CVD mortality. Poor air quality is also ranked as the 4<sup>th</sup> cause of Disability-Adjusted Life Year (DALY) - one lost year of 'healthy life' - according to latest <a class=""linkOnClick"" data-include=""694466531"" target=""_blank"" href=""https://vizhub.healthdata.org/"" rel=""nofollow"">Global Burden of Disease study</a> .</p> 
    












		                     					        	<p><b>Professor <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">David Wood</span></span></b><b>, WHF </b> <b>President</b>: ""<i>On World Heart Day, we are raising awareness of poor outdoor and household air quality as an increasingly important risk factor, and bringing together all those involved in cardiovascular health from every country in the w</i><i>orld in the fight to reduce CVD.</i><i>""</i></p> 
    












		                     					        	<p><b>My Heart, Your Heart</b> </p> 
    












		                     					        	<p>Created and led by WHF, World Heart Day aims to combat the rising number of people with cardiovascular disease (CVD), by promoting the importance of living a heart-healthy lifestyle.</p> 
    












		                     					        	<p>On 29 September, people all around the world will unite to fight CVD by holding awareness activities, sharing the <a class=""linkOnClick"" data-include=""694466531"" target=""_blank"" href=""https://www.youtube.com/watch?v=HVLF_RyE4iA&amp;feature=youtu.be"" rel=""nofollow"">campaign video</a>, organizing fundraising activities for their local heart foundation and illuminating iconic landmarks and buildings.</p> 
    












		                     					        	<p>Our campaign, in partnership with Manulife and Philips, includes a simple call to action: <b>Make your heart promise</b> . A promise to eat more healthily, to do more exercise and to say no to smoking. A promise as a healthcare professional to continue working to reduce the impact of CVD. A promise as a politician to implement a noncommunicable diseases action plan. A simple promise... for MY HEART, for YOUR HEART, for ALL OUR HEARTS.</p>  












		                     					        	<p> SOURCE World Heart Federation </p> 












		                 </div>
  </div>
  </section>"
http://www.prnewswire.co.uk/news-releases/nproxx-and-pronexos---ems-evolves-into-two-new-companies-694500431.html,NPROXX and Pronexos - EMS Evolves Into Two New Companies,"<section class=""release-body container "" itemprop=""articleBody"">
    <div class=""row"">
                <div class=""col-sm-10 col-sm-offset-1"">
    	                   		 		 		 		 		 
		 		  		 	 					        	<p>JÜLICH, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Germany</span></span></span> and ALMELO, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Netherlands</span></span></span>, <span class=""xn-chron"">September 27, 2018</span> /PRNewswire/ --</p> 
   <p style=""font-weight: bold"">Leading supplier of high-quality carbon fibre products and specialist manufacturing services divides as hydrogen economy takes off.</p> 
    












		                     										        	<p>EMS, a leading supplier of high-quality carbon fibre products and specialist manufacturing services evolves into two new companies: NPROXX and Pronexos. NPROXX will carry on the business and activities of hydrogen storage solutions using composite high pressure vessels, Pronexos will continue the balance of all other business activities so far conducted under the brand of EMS.</p> 
    












		                     							        <!--startclickprintexclude-->
                <!--endclickprintexclude-->
          </div>
        </div>
		
        <!-- 3 --> 
                  <div class=""row"">
                                          	<!--PRNE Version C Format Assets Start-->
<div class=""container"">
	<div class=""row"">
		<div class=""col-sm-10 col-sm-offset-1"">
			<div class=""gallery inline-carousel"">
				<div class=""gallery-carousel-main"">
																<!-- assetC https://mma.prnewswire.com/media/748980/NPROXX_Pronexos.jpg?w=1600  --- https://mma.prnewswire.com/media/748980/NPROXX_Pronexos.jpg?p=publish  -->
						<!-- https://mma.prnewswire.com/media/748980/NPROXX_Pronexos.jpg?w=1600  --- https://mma.prnewswire.com/media/748980/NPROXX_Pronexos.jpg?p=publish -- https://mma.prnewswire.com/media/748980/NPROXX_Pronexos.jpg?w=950 -- $item.sourceUrl -->

    							
  <!-- image -->						<div class=""gallery-cell"">
							<figure>
																									<div class=""image lightbox-item "" data-asset-type=""Photo"" data-asset-id=""NPROXX_Pronexos.jpg"" data-asset-label="""" data-src=""https://mma.prnewswire.com/media/748980/NPROXX_Pronexos.jpg?w=1600"" data-sub-html=""NPROXX is a world leader in high pressure hydrogen storage for both stationary and mobile applications. (PRNewsfoto/NPROXX)"" data-tweet-text=""NPROXX is a world leader in high pressure hydrogen storage for both stationary and mobile applications. (PRNewsfoto/NPROXX)"" data-facebook-share-text=""NPROXX is a world leader in high pressure hydrogen storage for both stationary and mobile applications. (PRNewsfoto/NPROXX)"" data-linkedin-text=""NPROXX is a world leader in high pressure hydrogen storage for both stationary and mobile applications. (PRNewsfoto/NPROXX)"" data-download-url=""https://mma.prnewswire.com/media/748980/NPROXX_Pronexos.jpg?w=1600"" data-pinterest-text=""NPROXX is a world leader in high pressure hydrogen storage for both stationary and mobile applications. (PRNewsfoto/NPROXX)"" data-twitter-share-url=""https://mma.prnewswire.com/media/748980/NPROXX_Pronexos.jpg?w=1600&amp;p=twitter"" data-linkedin-share-url=""https://mma.prnewswire.com/media/748980/NPROXX_Pronexos.jpg?w=1600&amp;p=linkedin"" data-facebook-share-url=""https://mma.prnewswire.com/media/748980/NPROXX_Pronexos.jpg?w=1600&amp;p=facebook"" data-pinterest-share-url=""https://mma.prnewswire.com/media/748980/NPROXX_Pronexos.jpg?w=1600&amp;p=publish"" onclick=""omniture_corousal('Carousel lightbox Page','Photo Open','NPROXX_Pronexos.jpg','')"">
  	  <img src=""https://mma.prnewswire.com/media/748980/NPROXX_Pronexos.jpg?w=950"" id=""imageid_5"" alt=""NPROXX is a world leader in high pressure hydrogen storage for both stationary and mobile applications. (PRNewsfoto/NPROXX)"" class=""gallery-thumb img-responsive"" rel=""newsImage"">
</div>
																								<figcaption>
									NPROXX is a world leader in high pressure hydrogen storage for both stationary and mobile applications. (PRNewsfoto/NPROXX)
								</figcaption>
															</figure>
						</div>
											<!-- assetC https://mma.prnewswire.com/media/748982/Pronexos_NPROXX.jpg?w=1600  --- https://mma.prnewswire.com/media/748982/Pronexos_NPROXX.jpg?p=publish  -->
						<!-- https://mma.prnewswire.com/media/748982/Pronexos_NPROXX.jpg?w=1600  --- https://mma.prnewswire.com/media/748982/Pronexos_NPROXX.jpg?p=publish -- https://mma.prnewswire.com/media/748982/Pronexos_NPROXX.jpg?w=950 -- $item.sourceUrl -->

    							
  <!-- image -->						<div class=""gallery-cell"">
							<figure>
																									<div class=""image lightbox-item "" data-asset-type=""Photo"" data-asset-id=""Pronexos_NPROXX.jpg"" data-asset-label="""" data-src=""https://mma.prnewswire.com/media/748982/Pronexos_NPROXX.jpg?w=1600"" data-sub-html=""Pronexos’ activities include carbon fibre rollers for the paper, film/foil and converting industries as well as specialist manufacturing for the aerospace and semiconductor industries. (PRNewsfoto/Pronexos)"" data-tweet-text=""Pronexos’ activities include carbon fibre rollers for the paper, film/foil and converting industries as well as specialist manufacturing for the aerospace and semiconductor industries. (PRNewsfoto/Pronexos)"" data-facebook-share-text=""Pronexos’ activities include carbon fibre rollers for the paper, film/foil and converting industries as well as specialist manufacturing for the aerospace and semiconductor industries. (PRNewsfoto/Pronexos)"" data-linkedin-text=""Pronexos’ activities include carbon fibre rollers for the paper, film/foil and converting industries as well as specialist manufacturing for the aerospace and semiconductor industries. (PRNewsfoto/Pronexos)"" data-download-url=""https://mma.prnewswire.com/media/748982/Pronexos_NPROXX.jpg?w=1600"" data-pinterest-text=""Pronexos’ activities include carbon fibre rollers for the paper, film/foil and converting industries as well as specialist manufacturing for the aerospace and semiconductor industries. (PRNewsfoto/Pronexos)"" data-twitter-share-url=""https://mma.prnewswire.com/media/748982/Pronexos_NPROXX.jpg?w=1600&amp;p=twitter"" data-linkedin-share-url=""https://mma.prnewswire.com/media/748982/Pronexos_NPROXX.jpg?w=1600&amp;p=linkedin"" data-facebook-share-url=""https://mma.prnewswire.com/media/748982/Pronexos_NPROXX.jpg?w=1600&amp;p=facebook"" data-pinterest-share-url=""https://mma.prnewswire.com/media/748982/Pronexos_NPROXX.jpg?w=1600&amp;p=publish"" onclick=""omniture_corousal('Carousel lightbox Page','Photo Open','Pronexos_NPROXX.jpg','')"">
  	  <img src=""https://mma.prnewswire.com/media/748982/Pronexos_NPROXX.jpg?w=950"" id=""imageid_5"" alt=""Pronexos’ activities include carbon fibre rollers for the paper, film/foil and converting industries as well as specialist manufacturing for the aerospace and semiconductor industries. (PRNewsfoto/Pronexos)"" class=""gallery-thumb img-responsive"" rel=""newsImage"">
</div>
																								<figcaption>
									Pronexos’ activities include carbon fibre rollers for the paper, film/foil and converting industries as well as specialist manufacturing for the aerospace and semiconductor industries. (PRNewsfoto/Pronexos)
								</figcaption>
															</figure>
						</div>
											<!-- assetC https://mma.prnewswire.com/media/748979/Pronexos_Logo.jpg?w=1600  --- https://mma.prnewswire.com/media/748979/Pronexos_Logo.jpg?p=publish  -->
						<!-- https://mma.prnewswire.com/media/748979/Pronexos_Logo.jpg?w=1600  --- https://mma.prnewswire.com/media/748979/Pronexos_Logo.jpg?p=publish -- https://mma.prnewswire.com/media/748979/Pronexos_Logo.jpg?w=950 -- $item.sourceUrl -->

    							
  <!-- image -->						<div class=""gallery-cell"">
							<figure>
																									<div class=""image lightbox-item "" data-asset-type=""Photo"" data-asset-id=""Pronexos_Logo.jpg"" data-asset-label="""" data-src=""https://mma.prnewswire.com/media/748979/Pronexos_Logo.jpg?w=1600"" data-sub-html=""Pronexos Logo (PRNewsfoto/Pronexos)"" data-tweet-text=""Pronexos Logo (PRNewsfoto/Pronexos)"" data-facebook-share-text=""Pronexos Logo (PRNewsfoto/Pronexos)"" data-linkedin-text=""Pronexos Logo (PRNewsfoto/Pronexos)"" data-download-url=""https://mma.prnewswire.com/media/748979/Pronexos_Logo.jpg?w=1600"" data-pinterest-text=""Pronexos Logo (PRNewsfoto/Pronexos)"" data-twitter-share-url=""https://mma.prnewswire.com/media/748979/Pronexos_Logo.jpg?w=1600&amp;p=twitter"" data-linkedin-share-url=""https://mma.prnewswire.com/media/748979/Pronexos_Logo.jpg?w=1600&amp;p=linkedin"" data-facebook-share-url=""https://mma.prnewswire.com/media/748979/Pronexos_Logo.jpg?w=1600&amp;p=facebook"" data-pinterest-share-url=""https://mma.prnewswire.com/media/748979/Pronexos_Logo.jpg?w=1600&amp;p=publish"" onclick=""omniture_corousal('Carousel lightbox Page','Photo Open','Pronexos_Logo.jpg','')"">
  	  <img src=""https://mma.prnewswire.com/media/748979/Pronexos_Logo.jpg?w=950"" id=""imageid_5"" alt=""Pronexos Logo (PRNewsfoto/Pronexos)"" class=""gallery-thumb img-responsive"" rel=""newsImage"">
</div>
																								<figcaption>
									Pronexos Logo (PRNewsfoto/Pronexos)
								</figcaption>
															</figure>
						</div>
									</div>
								<div class=""gallery-carousel-nav"">
											<!-- https://mma.prnewswire.com/media/748980/NPROXX_Pronexos.jpg?w=1600  --- https://mma.prnewswire.com/media/748980/NPROXX_Pronexos.jpg?p=publish -- https://mma.prnewswire.com/media/748980/NPROXX_Pronexos.jpg?w=950 -- $item.sourceUrl -->

    							
  <!-- image -->																																																																																							<img src=""https://mma.prnewswire.com/media/748980/NPROXX_Pronexos.jpg"" id=""imageid_1"" alt=""NPROXX is a world leader in high pressure hydrogen storage for both stationary and mobile applications. (PRNewsfoto/NPROXX)"" class=""img-responsive"" rel=""newsImage"">
																								<!-- https://mma.prnewswire.com/media/748982/Pronexos_NPROXX.jpg?w=1600  --- https://mma.prnewswire.com/media/748982/Pronexos_NPROXX.jpg?p=publish -- https://mma.prnewswire.com/media/748982/Pronexos_NPROXX.jpg?w=950 -- $item.sourceUrl -->

    							
  <!-- image -->																																																																																							<img src=""https://mma.prnewswire.com/media/748982/Pronexos_NPROXX.jpg"" id=""imageid_2"" alt=""Pronexos’ activities include carbon fibre rollers for the paper, film/foil and converting industries as well as specialist manufacturing for the aerospace and semiconductor industries. (PRNewsfoto/Pronexos)"" class=""img-responsive"" rel=""newsImage"">
																								<!-- https://mma.prnewswire.com/media/748979/Pronexos_Logo.jpg?w=1600  --- https://mma.prnewswire.com/media/748979/Pronexos_Logo.jpg?p=publish -- https://mma.prnewswire.com/media/748979/Pronexos_Logo.jpg?w=950 -- $item.sourceUrl -->

    							
  <!-- image -->																																																																																							<img src=""https://mma.prnewswire.com/media/748979/Pronexos_Logo.jpg"" id=""imageid_4"" alt=""Pronexos Logo (PRNewsfoto/Pronexos)"" class=""img-responsive"" rel=""newsImage"">
																						</div>
							</div>
							<!-- image -->											<!-- image -->											<!-- image -->									</div>
	</div>
</div>
 <!--PRNE Version C Format Assets End-->
                              </div>
                <div class=""row"">
          <div class=""col-sm-10 col-sm-offset-1"">
			      	<p>     (Logo: <a class=""linkOnClick"" data-include=""694500431"" target=""_blank"" href=""https://mma.prnewswire.com/media/748978/NPROXX_Logo.jpg"" rel=""nofollow"">https://mma.prnewswire.com/media/748978/NPROXX_Logo.jpg</a> )<br> </p> 
    












                         					        	<p>     (Logo: <a class=""linkOnClick"" data-include=""694500431"" target=""_blank"" href=""https://mma.prnewswire.com/media/748979/Pronexos_Logo.jpg"" rel=""nofollow"">https://mma.prnewswire.com/media/748979/Pronexos_Logo.jpg</a> )<br> </p> 
    












		                     					        	<p>     (Photo: <a class=""linkOnClick"" data-include=""694500431"" target=""_blank"" href=""https://mma.prnewswire.com/media/748980/NPROXX_Pronexos.jpg"" rel=""nofollow"">https://mma.prnewswire.com/media/748980/NPROXX_Pronexos.jpg</a> )<br> </p> 
    












		                     					        	<p>     (Photo: <a class=""linkOnClick"" data-include=""694500431"" target=""_blank"" href=""https://mma.prnewswire.com/media/748982/Pronexos_NPROXX.jpg"" rel=""nofollow"">https://mma.prnewswire.com/media/748982/Pronexos_NPROXX.jpg</a> )<br> </p> 
    












		                     					        	<p><b>Carbon fibre </b> <b>p</b><b>ressure </b> <b>v</b><b>essels</b><b> for the hydrogen economy</b>  </p> 
    












		                     					        	<p>""The reason for the split is the formation of the new hydrogen economy"", explains Reinhard Hinterreither, who will lead NPROXX as Managing Director together with <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Olivier Marques-Borras</span></span>.</p> 
    












		                     					        	<p>""We believe that hydrogen will be a key energy source in the future. And it is our strong ambition to make our solutions play a key role in this new exciting economy. For this reason we are from now on marketing our pressure vessels internationally under the fresh brand NPROXX.""</p> 
    












		                     					        	<p>As a first step of growth a new NPROXX head office will be opened at Heerlen, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">The Netherlands</span></span></span>,<br> 1 October while NPROXX's manufacturing capacities will be extended at the site in Jülich, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Germany</span></span></span>. Pronexos' activities, which include carbon fibre rollers for the paper, film/foil and converting industries as well as engineering, design and specialist manufacturing for the aerospace and semiconductor industries will be continued at both sites: Almelo (<span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">The Netherlands</span></span></span>) and Jülich (<span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Germany</span></span></span>). The name EMS will no longer be used.</p> 
    












		                     					        	<p>New websites are available on the domains <i><a class=""linkOnClick"" data-include=""694500431"" target=""_blank"" href=""http://www.nproxx.com"" rel=""nofollow"">http://www.nproxx.com</a></i> and <i><a class=""linkOnClick"" data-include=""694500431"" target=""_blank"" href=""http://www.pronexos.com"" rel=""nofollow"">http://www.pronexos.com</a>.</i></p> 
    












		                     					        	<p>NPROXX: <a class=""linkOnClick"" data-include=""694500431"" href=""mailto:info@nproxx.com"" rel=""nofollow"">info@nproxx.com</a>, +49(0)2461-65-7200<br> Pronexos: +31(0)54654-4030, <a class=""linkOnClick"" data-include=""694500431"" href=""mailto:info@pronexos.com"" rel=""nofollow"">info@pronexos.com</a></p>  












		                     					        	<p> SOURCE NPROXX and Pronexos </p> 












		                 </div>
  </div>
  </section>"
http://www.prnewswire.co.uk/news-releases/finalists-announced-european-social-innovation-competition-2018-enters-final-phase-694591581.html,Finalists Announced: European Social Innovation Competition 2018 Enters Final Phase,"<section class=""release-body container  no-margin-bottom "" itemprop=""articleBody"">
    <div class=""row"">
                <div class=""col-sm-10 col-sm-offset-1"">
    	                   					        	<p>The European Commission announces the finalists of the 2018 European Social Innovation Competition. Congratulations to all of them!</p> 
    












		                     		 		 		 		 		 
		 		  		 	 					        	<p><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">BRUSSELS</span></span></span>, <span class=""xn-chron"">Sept. 28, 2018</span> /PRNewswire/ -- <b>The 10 finalists – representing 10 different countries, namely <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Austria</span></span></span>, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Germany</span></span></span>, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Greece</span></span></span>, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Hungary</span></span></span>, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Italy</span></span></span>, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Romania</span></span></span>, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Slovenia</span></span></span>, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Spain</span></span></span>, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Sweden</span></span></span> and <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Ukraine</span></span></span> – are:</b></p> 
    












		                     												        <!--startclickprintexclude-->
                <!--endclickprintexclude-->
          </div>
        </div>
		
        <!-- 0 --> 
                <div class=""row"">
          <div class=""col-sm-10 col-sm-offset-1"">
			      	<p><a class=""linkOnClick"" data-include=""694591581"" href=""https://eusic.challenges.org/selected/65/career-bus/"" rel=""nofollow"" target=""_blank"">Career Bus</a> brings career orientation to young people living in rural areas by combining innovative technologies and a face-to-face interaction. Traveling to remote places, Career Bus will boost the employability and knowledge of young residents.</p> 
    












                         					        	<p><a class=""linkOnClick"" data-include=""694591581"" href=""https://eusic.challenges.org/selected/66/connectech/"" rel=""nofollow"" target=""_blank"">ConnecTech</a> offers modular coding courses, internships and mentoring from tech professionals to young people with physical impairments in order to expand employment opportunities and promote flexible working conditions.</p> 
    












		                     					        	<p><a class=""linkOnClick"" data-include=""694591581"" href=""https://eusic.challenges.org/selected/70/espigoladors-es-im-perfect-/"" rel=""nofollow"" target=""_blank"">es im-perfect</a> has set up a network of hubs that are helping to save fresh produce that would be wasted in conventional processing settings by turning it into jams, patés and other delicious products. Simultaneously, they offer employment opportunities for young people.</p> 
    












		                     					        	<p><a class=""linkOnClick"" data-include=""694591581"" href=""https://eusic.challenges.org/selected/71/gofunded/"" rel=""nofollow"" target=""_blank"">GoFundEd</a> is an online crowdfunding platform that enables students and teachers to move towards newer teaching and testing methods in order to equip young people with the relevant skills to find good employment or become successful entrepreneurs in their home country.</p> 
    












		                     					        	<p><a class=""linkOnClick"" data-include=""694591581"" href=""https://eusic.challenges.org/selected/72/heritagelab-bringing-the-past-to-the-future/"" rel=""nofollow"" target=""_blank"">Heritage Lab</a> teaches established innovation incubation methods to young people in small towns, supporting them in the launch of new businesses and services based on local cultural heritage that deserves appreciation.</p> 
    












		                     					        	<p><a class=""linkOnClick"" data-include=""694591581"" href=""https://eusic.challenges.org/selected/75/imagicase/"" rel=""nofollow"" target=""_blank"">imagiCase</a> introduces teenage girls to the tech field by providing them with a platform to develop their programming skills by means of fun practical projects such as customising mobile phone cases.</p> 
    












		                     					        	<p><a class=""linkOnClick"" data-include=""694591581"" href=""https://eusic.challenges.org/selected/79/more-than-one-perspective/"" rel=""nofollow"" target=""_blank"">MTOP goes digital</a> combines smart offline and online solutions to prepare young qualified refugees to enter the Austrian labour market. Long-lasting working relationships are ensured through post-placement support.</p> 
    












		                     					        	<p><a class=""linkOnClick"" data-include=""694591581"" href=""https://eusic.challenges.org/selected/85/revive-greece/"" rel=""nofollow"" target=""_blank"">REvive <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Greece</span></span></span></a> combines traditional classroom and e-learning methods to re-skill young unemployed Greeks and refugees in computer programming. It then connects them with companies from the IT sector, so that they can secure internships as software developers.</p> 
    












		                     					        	<p><a class=""linkOnClick"" data-include=""694591581"" href=""https://eusic.challenges.org/selected/88/scolargeno/"" rel=""nofollow"" target=""_blank"">ScOLARgeno</a><a class=""linkOnClick"" data-include=""694591581"" href=""https://eusic.challenges.org/"" rel=""nofollow"" target=""_blank""> </a>empowers secondary school students to act against climate change by supporting them in establishing cooperatives to plan and operate their own school photovoltaic energy generating systems. It hence prepares them to contribute to a more ecological economy of the future.</p> 
    












		                     					        	<p><a class=""linkOnClick"" data-include=""694591581"" href=""https://eusic.challenges.org/selected/93/ulisse-travels-in-international-signs/"" rel=""nofollow"" target=""_blank"">Ulisse</a> is the first ever European digital platform that creates, markets &amp; promotes local travel experiences and full holiday bundles designed by deaf people for deaf people. By doing so, it also fosters international sign language education.</p> 
    












		                     					        	<p>With the selection of the 10 strongest projects dedicated to the theme RE:THINK LOCAL, the Competition enters its final stage.</p> 
    












		                     					        	<p>The finalists were selected by a jury of international experts, among 30 semi-finalists covering a wide range of sectors and activities. These, in turn, were selected from a pool of 729 eligible entries from 39 countries. All semi-finalists participated in an <a class=""linkOnClick"" data-include=""694591581"" href=""https://eusic.challenges.org/european-social-innovation-competition-semi-finalists-gather-in-romania-for-3-days-of-training-and-support/"" rel=""nofollow"" target=""_blank"">intensive training and coaching programme</a> to develop their initiatives. </p> 
    












		                     					        	<p>The three winners of this year's competition will be announced at the Awards Ceremony on <span class=""xn-chron"">8 November 2018</span> in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Brussels</span></span></span> and will each receive a €50.000 prize to further develop their projects.</p> 
    












		                     					        	<p>We would also like to thank all semi-finalists and encourage tllhem to keep up the good work. All semi-finalists are invited to a fundraising training and to meet international investors at the Funders Fair that will take place in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Brussels</span></span></span> on the day of the Awards Ceremony. They are also all entitled and encouraged to re-enter the Competition next year for a chance to win the Impact Prize.</p> 
    












		                     					        	<p><b>More information about the Competition</b></p> 
    












		                     					        	<p>The European Social Innovation Competition is an initiative of the European Commission that awards three €50.000 prizes per year to the most innovative ideas developed to address societal issues in EU Member States and Horizon 2020 Associated countries. This year's theme is RE:THINK LOCAL and calls for projects that turn local challenges into opportunities for young people. </p> 
    












		                     					        	<p>The Competition takes place every year – each time with a different theme. It is held in memory of the Portuguese innovator <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Diogo Vasconcelos</span></span>. Individuals, organisations and companies from all EU Member States and Horizon 2020 associated countries can participate. It is a great opportunity for inspired people to get their social innovation ideas off the ground.</p> 
    












		                     					        	<p>The Competition is organised by the European Commission with support from Nesta, Kennisland, the European Network of Living Labs, Ashoka and Scholz &amp; Friends.</p> 
    












		                     					        	<p>For information on earlier editions and winning projects, visit <u><a class=""linkOnClick"" data-include=""694591581"" href=""http://eusic.challenges.org/"" rel=""nofollow"" target=""_blank"">http://eusic.challenges.org</a>.</u> <br>Questions about the Competition can be addressed to <u><a class=""linkOnClick"" data-include=""694591581"" href=""mailto:info@socialinnovationprize.eu"" rel=""nofollow"" target=""_blank"">info@socialinnovationprize.eu</a></u><br>Follow the Competition on Twitter: <u><a class=""linkOnClick"" data-include=""694591581"" href=""http://www.twitter.com/EUSocialInnov"" rel=""nofollow"" target=""_blank"">@EUSocialInnov</a></u> #diogochallenge<br>Subscribe to the Competition newsletter here: <u><a class=""linkOnClick"" data-include=""694591581"" href=""http://eusic.challenges.org/newsletter/"" rel=""nofollow"" target=""_blank"">http://eusic.challenges.org/newsletter/</a></u></p> 
    












		                     					        	<p><b>The Judging Panel</b></p> 
    












		                     					        	<p>The Competition's <a class=""linkOnClick"" data-include=""694591581"" href=""https://eusic.challenges.org/judging-panel/"" rel=""nofollow"" target=""_blank"">international jury</a> in 2018 is composed of:</p> 
    












		                     					        	 				<ul type=""disc"">
    <li><b><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Mikkel Andersen</span></span></b>, Danish Social Innovation Club (<span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Denmark</span></span></span>) </li>
    <li><b><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Sabine Biesheuvel</span></span></b>, BlueCity (<span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">The Netherlands</span></span></span>) </li>
    <li><b>Tuija Hirvikoski</b>, Laurea <span class=""xn-org"">University of Applied Sciences</span> (<span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Finland</span></span></span>) </li>
    <li><b><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Mirna Karzen</span></span></b>, Social Innovation Lab (<span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Croatia</span></span></span>) </li>
    <li><b><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Norbert Kunz</span></span></b>, Social Impact (<span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Germany</span></span></span>) </li>
    <li><b><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Vincenzo Linarello</span></span></b>, Goel (<span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Italy</span></span></span>) </li>
    <li><b><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Carina Lopes</span></span></b>, d-LAB (<span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Spain</span></span></span>) </li>
    <li><b><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Klaus Schach</span></span></b>, Centre for Social Innovation (<span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Austria</span></span></span>) </li>
    <li><b><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Stavros Tsompanidis</span></span></b>, Phee (<span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Greece</span></span></span>)  </li>
    <li><b><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Taoufik Vallipuram</span></span></b>, OuiShare (<span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">France</span></span></span>) </li>
    <li><b>Magdalena Zawodny-Barabanow</b>, Urbact Network BoostInno (<span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Poland</span></span></span>)</li>
   </ul>
   













		                     					        	<p><b>Social Innovation Toolkit released</b></p> 
    












		                     					        	<p>As a way to further encourage social innovation throughout <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Europe</span></span></span>, an inspiring and comprehensive toolkit on how to nurture good social innovation ideas and transform them into viable businesses is available on <a class=""linkOnClick"" data-include=""694591581"" href=""http://eusic.challenges.org/toolkit"" rel=""nofollow"" target=""_blank"">eusic.challgenes.org/toolkit</a>. </p> 
    












		                     					        	<p><b><i>Press contact:<br></i></b><b><i>European Social Innovation Competition Team<br></i></b><i><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Andrew Bennett</span></span><br></i>Phone +49-30-700186-371<br><a class=""linkOnClick"" data-include=""694591581"" href=""mailto:info@socialinnovationprize.eu"" rel=""nofollow"" target=""_blank"">info@socialinnovationprize.eu</a></p>  












		                     					        	<p> SOURCE European Social Innovation Competition </p> 












		                 </div>
  </div>
  </section>"
http://www.prnewswire.co.uk/news-releases/funding-awarded-to-ieso-digital-health-by-innovate-uk-will-advance-research-to-transform-patient-694687751.html,Funding Awarded to Ieso Digital Health by Innovate UK Will Advance Research to Transform Patient Outcomes in Mental Healthcare,"<section class=""release-body container "" itemprop=""articleBody"">
    <div class=""row"">
                <div class=""col-sm-10 col-sm-offset-1"">
    	                   		 		 		 		 		 
		 		  		 	 					        	<p><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">CAMBRIDGE, England</span></span></span>, <span class=""xn-chron"">September 29, 2018</span> /PRNewswire/ --</p> 
    












		                     										        	<p>Ieso Digital Health, the UK's flagship provider of digitally-enabled mental healthcare, is leading a project to dramatically improve mental healthcare treatment thanks to over £600,000 in funding from Innovate UK. The funding will be used to accelerate Ieso's pioneering work to advance digital mental healthcare solutions.  </p> 
    












		                     							        <!--startclickprintexclude-->
                <!--endclickprintexclude-->
          </div>
        </div>
		
        <!-- 1 --> 
                  <div class=""row"">
                                          	<!--PRNE Version C Format Assets Start-->
<div class=""container"">
	<div class=""row"">
		<div class=""col-sm-10 col-sm-offset-1"">
			<div class=""gallery inline-carousel"">
				<div class=""gallery-carousel-main"">
																<!-- assetC https://mma.prnewswire.com/media/751999/Dr_Valentin_Tablan_Ieso_Digital_Health.jpg?w=1600  --- https://mma.prnewswire.com/media/751999/Dr_Valentin_Tablan_Ieso_Digital_Health.jpg?p=publish  -->
						<!-- https://mma.prnewswire.com/media/751999/Dr_Valentin_Tablan_Ieso_Digital_Health.jpg?w=1600  --- https://mma.prnewswire.com/media/751999/Dr_Valentin_Tablan_Ieso_Digital_Health.jpg?p=publish -- https://mma.prnewswire.com/media/751999/Dr_Valentin_Tablan_Ieso_Digital_Health.jpg?w=950 -- $item.sourceUrl -->

    							
  <!-- image -->						<div class=""gallery-cell"">
							<figure>
																									<div class=""image lightbox-item "" data-asset-type=""Photo"" data-asset-id=""Dr_Valentin_Tablan_Ieso_Digital_Health.jpg"" data-asset-label="""" data-src=""https://mma.prnewswire.com/media/751999/Dr_Valentin_Tablan_Ieso_Digital_Health.jpg?w=1600"" data-sub-html=""Dr Valentin Tablan Ieso Digital Health (PRNewsfoto/Ieso Digital Health)"" data-tweet-text=""Dr Valentin Tablan Ieso Digital Health (PRNewsfoto/Ieso Digital Health)"" data-facebook-share-text=""Dr Valentin Tablan Ieso Digital Health (PRNewsfoto/Ieso Digital Health)"" data-linkedin-text=""Dr Valentin Tablan Ieso Digital Health (PRNewsfoto/Ieso Digital Health)"" data-download-url=""https://mma.prnewswire.com/media/751999/Dr_Valentin_Tablan_Ieso_Digital_Health.jpg?w=1600"" data-pinterest-text=""Dr Valentin Tablan Ieso Digital Health (PRNewsfoto/Ieso Digital Health)"" data-twitter-share-url=""https://mma.prnewswire.com/media/751999/Dr_Valentin_Tablan_Ieso_Digital_Health.jpg?w=1600&amp;p=twitter"" data-linkedin-share-url=""https://mma.prnewswire.com/media/751999/Dr_Valentin_Tablan_Ieso_Digital_Health.jpg?w=1600&amp;p=linkedin"" data-facebook-share-url=""https://mma.prnewswire.com/media/751999/Dr_Valentin_Tablan_Ieso_Digital_Health.jpg?w=1600&amp;p=facebook"" data-pinterest-share-url=""https://mma.prnewswire.com/media/751999/Dr_Valentin_Tablan_Ieso_Digital_Health.jpg?w=1600&amp;p=publish"" onclick=""omniture_corousal('Carousel lightbox Page','Photo Open','Dr_Valentin_Tablan_Ieso_Digital_Health.jpg','')"">
  	  <img src=""https://mma.prnewswire.com/media/751999/Dr_Valentin_Tablan_Ieso_Digital_Health.jpg?w=950"" id=""imageid_2"" alt=""Dr Valentin Tablan Ieso Digital Health (PRNewsfoto/Ieso Digital Health)"" class=""gallery-thumb img-responsive"" rel=""newsImage"">
</div>
																								<figcaption>
									Dr Valentin Tablan Ieso Digital Health (PRNewsfoto/Ieso Digital Health)
								</figcaption>
															</figure>
						</div>
									</div>
							</div>
							<!-- image -->									</div>
	</div>
</div>
 <!--PRNE Version C Format Assets End-->
                              </div>
                <div class=""row"">
          <div class=""col-sm-10 col-sm-offset-1"">
			      	<p>     (Photo: <a class=""linkOnClick"" data-include=""694687751"" target=""_blank"" href=""https://mma.prnewswire.com/media/751999/Dr_Valentin_Tablan_Ieso_Digital_Health.jpg"" rel=""nofollow"">https://mma.prnewswire.com/media/751999/Dr_Valentin_Tablan_Ieso_Digital_Health.jpg</a> )<br> </p> 
    












                         					        	<p>This grant was awarded as part of Innovate UK's 'Digital Health Technology Catalyst Round 2' which aims to speed up the development of commercial digital health solutions.</p> 
    












		                     					        	<p>Ieso is developing advanced software technology which integrates cognitive and behavioural biomarkers into a digital therapy platform. This allows the detection of patterns of thoughts and behaviour that may indicate changes in a patient's mental health.</p> 
    












		                     					        	<p>This information, in the hands of a clinician, allows care to be delivered in a more tailored manner to patients, by adapting the course of an intervention according to their biomarker indicators. It will also enable clinicians to act preventatively when those signs present themselves, offering people top-up interventions or getting them into immediate care, to avoid relapse.</p> 
    












		                     					        	<p><b>Dr <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Andy Blackwell</span></span>, Group Chief Science and Strategy Officer </b> <b>of Ieso Digital Health said: </b>  </p> 
    












		                     					        	<p><i>""</i><i>Ultimately</i><i>,</i><i> </i> <i>this is about accelerating </i> <i>improvements </i> <i>in the standards of </i> <i>mental health</i><i> treatment that patients are receiving. </i> <i>W</i><i>e need to </i> <i>be </i> <i>intervening</i><i> in a more </i> <i>timely</i><i> way and act </i> <i>preventatively</i><i> to stop people from suffering mental illness at all.</i><i> </i> <i>Sometimes </i> <i>it</i><i>'</i><i>s</i><i> hard for people to notice </i> <i>deterioration</i><i> in </i> <i>their</i><i> mental health </i> <i>until they are in a crisis</i><i>. </i> <i>If our data set can identify those signs earlier, we can offer a more personalised intervention to patients, increasing their chances of recove</i><i>ring and staying well</i><i>.</i><i>""</i> </p> 
    












		                     					        	<p><b>Dr <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Valentin Tablan</span></span>, Senior Vice President of Artificial Intelligence </b> <b>of Ieso Digital Health </b> <b>said:</b> </p> 
    












		                     					        	<p><i>""</i><i>Being able to access accurate data, collected passively by internet</i><i>-</i><i>connected devices, is a great advance in behavioural health, made possible by recent technological advances. The cognitive and behavioural biomarkers we are extracting from the data will help our therapists devise interventions that are better suited to the patients</i><i>'</i><i> needs, helping more people get better faster. Even more exciting is the use of these same biomarkers for relapse prevention, early detection of symptoms and, ultimately, for preventing the onset of mental health conditions altogether.</i><i>""</i> </p> 
    












		                     					        	<p>Ieso Digital Health is an award-winning pioneer of clinically validated and digitally-enabled mental health care and is redefining the way that mental health care is delivered by making high-quality cognitive behavioural therapy (CBT) accessible, accountable and affordable for the first time. The company recently announced it is the first provider in the world to augment one to one therapy in real-time with advanced analytics, machine learning, and natural language processing technologies.</p> 
    












		                     					        	<p>About Ieso Digital Health</p> 
    












		                     					        	 				<ul type=""disc""> 
    <li>Ieso is the UK's leading provider of online mental healthcare and is redefining the way that mental health care is delivered by making high-quality cognitive behavioural therapy (CBT) accessible, accountable and affordable for the first time. </li> 
    <li>Ieso is helping to create a modern mental health infrastructure in the UK with its transformative, digitally-enabled mental health care which is increasing access to high-quality care for patients by meeting them where they're at; online, on their mobile, PC or tablet.</li> 
    <li>Ieso has delivered more almost 120,000 therapy hours through its network of 500+ BABCP accredited therapists to date.</li> 
    <li>Founded by psychologists, Ieso's method has been clinically validated in a trial, published in The Lancet in 2009. Online CBT mirrors face-to-face therapy and involves real-time, personalised communication between a BABCP accredited therapist and a patient in therapy sessions. Ieso is available through the NHS Improving Access to Psychological Therapies (IAPT) programme.</li> 
    <li>Ieso is a multi-award-winning business and one of UK's fastest-growing technology companies, as lauded in the Deloitte Fast 50 awards. Ieso was also recognised as one of the Sunday Times <i>Disruptors to Watch.</i> The company was also awarded the accolade of <i>2017 Digital Innovation of the Year</i>.</li> 
    <li>Launched in the US in 2017 Ieso is accelerating growth there, with a blue-chip management team with deep industry expertise</li> 
   </ul> 
   













		                     					        	<p>C: <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Charlene Waterworth</span></span><br> E: <a class=""linkOnClick"" data-include=""694687751"" href=""mailto:c.waterworth@iesohealth.com"" rel=""nofollow"">c.waterworth@iesohealth.com</a><br> M: 012-236-08760<br> <br> C: Rachel Dalton<br> E: <a class=""linkOnClick"" data-include=""694687751"" href=""mailto:rdalton@rdcommunications.ie"" rel=""nofollow"">rdalton@rdcommunications.ie</a><br> M: +353-863-825-895<br> </p> 
   <br>  












		                     					        	<p> SOURCE Ieso Digital Health </p> 












		                 </div>
  </div>
  </section>"
http://www.prnewswire.co.uk/news-releases/enesi-pharma-and-public-health-england-enter-rd-collaboration-for-novel-needle-free-solid-dose-vaccine-694765451.html,Enesi Pharma and Public Health England Enter R&D Collaboration for Novel Needle-Free Solid-Dose Vaccine for Emergent Threat Pathogens,"<section class=""release-body container  no-margin-bottom "" itemprop=""articleBody"">
    <div class=""row"">
                <div class=""col-sm-10 col-sm-offset-1"">
    	                   		 		 		 		 		 
		 		  		 	 					        	<p><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">OXFORD, England</span></span></span>, <span class=""xn-chron"">October 1, 2018</span> /PRNewswire/ --</p> 
   <p style=""text-align: left""><b>Enesi Pharma</b><b>, </b> <b>an innovative</b><b> pharmaceutical</b><b> company developing unique injectable solid do</b><b>se</b><b> </b> <b>vaccine</b><b> products, </b> <b>announces</b><b> it has entered a</b><b> research and development collaboration with Public Health England (PHE), an executive agency of the UK Government</b><b>'</b><b>s Department of Health and Social Care. </b>  </p> 
    












		                     													        <!--startclickprintexclude-->
                <!--endclickprintexclude-->
          </div>
        </div>
		
        <!-- 0 --> 
                <div class=""row"">
          <div class=""col-sm-10 col-sm-offset-1"">
			      	<p>The collaboration is focused on the development and evaluation of a novel solid-dose formulation of a number of PHE's proprietary vaccine candidates including Anthrax recombinant Protective Antigen (rPA) and Crimean-Congo Haemorrhagic Fever (CCHF) for delivery via Enesi Pharma's ImplaVax® needle-free technology.</p> 
    












                         					        	<p>Pre-clinical testing of a range of ImplaVax enabled vaccines in animal models has evidenced regimen sparing and a reduced time to achieve threshold immunity against comparative conventional liquid vaccines administered using a needle and syringe. Such regimen sparing saves time and money, allowing more patients to be vaccinated more quickly from a fixed available production volume, potentially expanding coverage, preparedness and emergency response.</p> 
    












		                     					        	<p>The current vaccination schedules of many vaccines require multiple doses. An ImplaVax-enabled vaccine therefore has the potential to dramatically enhance vaccination programmes for military and other at-risk personnel as well as providing a rapidly deployable therapeutic option for individuals who have been exposed to the target infectious disease. ImplaVax enabled vaccines also benefit from extended thermal stability making a significant contribution to reducing the end to end cold chain logistical challenges, cost, and will greatly assist in optimising the cost effectiveness of the national strategic stockpile.</p> 
    












		                     					        	<p><b><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">David Hipkiss</span></span>, CEO of Enesi Pharma, </b> <b>commented</b><b>:</b> </p> 
    












		                     					        	<p><i>""</i><i>We are extremely encouraged by the positive responses we are seeing from institutions and companies to the potential advantages of our ImplaVax solid-dose vaccine platform across the spectrum of infectious diseases and allergies. In entering this new collaboration with Public Health England, we </i> <i>have an opportunity to apply our technology to address serious biological threat</i><i>s</i><i> that represents a high priority for at-risk personnel and for the wider population. </i> <i>PHE has access to </i> <i>world-leading </i> <i>scientific expertise</i><i> and resources</i><i> in this area, and we are excited to be working with them on this project</i><i> to provide further validation of our innovative approach</i><i>.</i><i>""</i> </p> 
    












		                     					        	<p><b>Prof. <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Miles Carroll</span></span></b><b>, </b> <b>Head of Research and Deputy Director</b><b> at Public Health England</b><b>, added:</b> </p> 
    












		                     					        	<p><i>""</i><i>The threat of </i> <i>emerging </i> <i>infections is an important public health consideration and we a</i><i>re intrigued by the potential for improvements that Enesi</i><i>'</i><i>s ImplaVax technology could bring to the vaccination process. These improvements could simplify and accelerate the process, while also providing a rapid means of treating exposed individuals. We are very much </i> <i>looking forward to working with Enesi to </i> <i>develop and </i> <i>evaluate</i><i> a </i> <i>range of </i> <i>solid-dose vaccine</i><i>s</i><i>.</i><i>""</i><i> </i>  </p> 
    












		                     					        	<p><b>ABOUT ENESI PHARMA</b> </p> 
    












		                     					        	<p>Enesi Pharma is an innovative pharmaceutical company developing novel products with potential to transform performance and delivery of vaccines and make a material impact on global healthcare.</p> 
    












		                     					        	<p>The company's primary focus is the development of novel solid dose vaccines against a range of infectious and other select diseases, working in partnership with global companies, government agencies and non-governmental organisations.</p> 
    












		                     					        	<p>Enesi's ImplaVax® formulation and device technologies offer significant potential benefits for patients, care givers, healthcare professionals and payers through enhanced effectiveness, safety, ease of use, reliability and stability, and are supported by a strong patient preference over a standard needle and syringe.</p> 
    












		                     					        	<p>Enesi's experienced leadership team has a proven track record in the successful development and commercialisation of innovative products delivering high value outcomes for all stakeholders.</p> 
    












		                     					        	<p>For more information visit <a class=""linkOnClick"" data-include=""694765451"" target=""_blank"" href=""http://www.enesipharma.com"" rel=""nofollow"">http://www.enesipharma.com</a> or follow Enesi on Twitter at <a class=""linkOnClick"" data-include=""694765451"" target=""_blank"" href=""http://www.twitter.com/enesi_pharma"" rel=""nofollow"">http://www.twitter.com/enesi_pharma</a></p> 
    












		                     					        	<p><b>ABOUT </b> <b>PUBLIC HEALTH <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">ENGLAND</span></span></span></b> </p> 
    












		                     					        	<p>PHE is the leading UK public health research organisation with national and international expertise in providing solutions advice and products to support national and local public health systems. Key focus areas include infectious disease therapeutics, vaccines, diagnostics &amp; R&amp;D, emergency preparedness &amp; response, radiation and chemical protection and wider public health issues such as health improvement and promotion, infant and adult screening, managing a network of public health intelligence observatories and other key public health interventions.</p> 
    












		                     					        	<p><b>FOR MORE INFORMATION</b> </p> 
    












		                     					        	<p><b>Enesi Pharma</b> </p> 
    












		                     					        	<p><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">David Hipkiss</span></span>, CEO<br> Tel: +44-(0)-7968-707-072<br> Email: <a class=""linkOnClick"" data-include=""694765451"" href=""mailto:david.hipkiss@enesipharma.com"" rel=""nofollow"">david.hipkiss@enesipharma.com</a></p> 
    












		                     					        	<p><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Mark Swallow</span></span>, Pip Batty (International Media Enquiries)<br> Citigate Dewe Rogerson<br> Tel: +44-(0)-20-7638-9571<br> Email: <a class=""linkOnClick"" data-include=""694765451"" href=""mailto:enesipharma@citigatedewerogerson.com"" rel=""nofollow"">enesipharma@citigatedewerogerson.com</a><br> Public<b> Health <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">England</span></span></span></b> <br> <a class=""linkOnClick"" data-include=""694765451"" href=""mailto:phe-pressoffice@phe.gov.uk"" rel=""nofollow"">phe-pressoffice@phe.gov.uk</a></p>  












		                     					        	<p> SOURCE Enesi Pharma </p> 












		                 </div>
  </div>
  </section>"
http://www.prnewswire.co.uk/news-releases/micron-and-atp-to-collaborate-on-ddr2-continuity-program-694766761.html,Micron and ATP to Collaborate on DDR2 Continuity Program,"<section class=""release-body container  no-margin-bottom "" itemprop=""articleBody"">
    <div class=""row"">
                <div class=""col-sm-10 col-sm-offset-1"">
    	                   		 		 		 		 		 
		 		  		 	 					        	<p><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">TAIPEI, Taiwan</span></span></span>, <span class=""xn-chron"">October 1, 2018</span> /PRNewswire/ --</p> 
   <p style=""font-weight: bold; text-align: center"">Partnership Agreement Ensures Legacy DRAM Module Supply Stability</p> 
    












		                     													        <!--startclickprintexclude-->
                <!--endclickprintexclude-->
          </div>
        </div>
		
        <!-- 0 --> 
                <div class=""row"">
          <div class=""col-sm-10 col-sm-offset-1"">
			      	<p>Recognizing the importance of obsolescence mitigation in embedded and industrial systems, two of the biggest names in advanced storage, memory and semiconductor technologies have teamed up to ensure the continuous supply of legacy DDR2 memory modules in the market. ATP, a leading manufacturer of high-performance industrial memory and storage solutions, will collaborate with global semiconductor leader Micron Technology, Inc. to continue manufacturing Micron DDR2 SO-DIMMs, UDIMMs and RDIMMs after Micron announced end-of-life (EOL) notices for these modules.</p> 
    












                         					        	<p>According to the collaboration agreement, ATP will produce DDR2 DRAM modules for customers that cannot upgrade to newer-generation platforms and still maintain the use of platforms supporting these memory types. With DDR2 still widely deployed in the US, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Japan</span></span></span> and <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Europe</span></span></span>, ATP and Micron expect these markets to benefit significantly from the consistent supply of DDR2 memory for industrial/embedded systems installed in high-reliability and mission-critical environments. All modules will be manufactured, tested and validated by ATP, according to the equivalent specifications and testing/validation processes of the respective Micron part number.</p> 
    












		                     					        	<p>""Micron is dedicated to maximizing customers' infrastructure investments by ensuring prolonged support for legacy systems and applications. Our proven partnership with ATP gives our customers the benefit of receiving similar Micron products and services to support their current platforms while ATP ensures the stability of their operations well into the future,"" said <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Kris Baxter</span></span>, vice president, Micron Technology, Inc.</p> 
    












		                     					        	<p>""A long product cycle is vital to the sustainability of industrial business operations,"" said <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Marco Mezger</span></span>, vice president, ATP Electronics, Inc. ""The DDR2 Continuity Program demonstrates ATP's enduring partnership with Micron as well as our shared commitment to extend supply stability, not only of the latest-generation products, but also of legacy memory modules to continue supporting the memory requirements of customers that are not yet able to make the transition. Through this collaboration, customers will be assured of steady supply to support their operations.""</p> 
    












		                     					        	<p>The DDR2 Continuity Program will be implemented on a staggered basis within three manufacturing phases. DDR2 DRAM modules from ATP will be available in select form factors and densities starting Q4 2018. Please check with your ATP contact for specific module configurations with ATP longevity extension or send an email to <a class=""linkOnClick"" data-include=""694766761"" href=""mailto:Info@atpinc.com"" rel=""nofollow"">Info@atpinc.com</a></p> 
    












		                     					        	<p><b>About ATP</b> </p> 
    












		                     					        	<p>ATP Electronics is a leading provider of high-performance, high-quality and high-endurance NAND flash products and DRAM modules. With over 25 years of manufacturing expertise, ATP ensures that all its products are designed and built to accomplish mission-critical tasks in industrial/automation, telecom, medical, automotive, and enterprise computing applications where high levels of technical proficiency, manufacturing quality, and wide operating temperature ranges are required. ATP is a certified Eco/Green partner of tier one OEMs and all ATP products are fully RoHS and <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">China RoHS</span></span> compliant. A true manufacturer, ATP manages every stage of the manufacturing process to ensure quality and product longevity, offering in-house design, testing, and tuning from component to product level. ATP supply chain support includes controlled/fixed BOMs and long-term product life cycles. For more information on ATP Electronics, please visit <a class=""linkOnClick"" data-include=""694766761"" target=""_blank"" href=""http://www.atpinc.com"" rel=""nofollow"">http://www.atpinc.com</a> or contact us at <a class=""linkOnClick"" data-include=""694766761"" href=""mailto:Info@atpinc.com"" rel=""nofollow"">Info@atpinc.com</a>.</p> 
    












		                     					        	<p><br> Media Contact:<br> <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Kelly Lin</span></span><br> <a class=""linkOnClick"" data-include=""694766761"" href=""mailto:Kellylin@tw.atpinc.com"" rel=""nofollow"">Kellylin@tw.atpinc.com</a><br> Tel: +886-226-596-368<br> 10F, No. 185, Tiding Blvd. Sec. 2 Neihu,<br> <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Taipei, Taiwan</span></span></span> 11493<br> </p>  












		                     					        	<p> SOURCE ATP Electronics </p> 












		                 </div>
  </div>
  </section>"
http://www.prnewswire.co.uk/news-releases/structural-health-monitoring-market-to-exhibit-1009-cagr-with-increasing-development-of-healthcare-694805671.html,Structural Health Monitoring Market to Exhibit 10.09% CAGR With Increasing Development of Healthcare Industry; Reports Transparency Market Research,"<section class=""release-body container  no-margin-bottom "" itemprop=""articleBody"">
    <div class=""row"">
                <div class=""col-sm-10 col-sm-offset-1"">
    	                   		 		 		 		 		 
		 		  		 	 					        	<p><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">ALBANY, New York</span></span></span>, <span class=""xn-chron"">October 1, 2018</span> /PRNewswire/ --</p> 
    












		                     													        <!--startclickprintexclude-->
                <!--endclickprintexclude-->
          </div>
        </div>
		
        <!-- 0 --> 
                <div class=""row"">
          <div class=""col-sm-10 col-sm-offset-1"">
			      	<p>In a recent report by Transparency Market Research (TMR), the global <a class=""linkOnClick"" data-include=""694805671"" target=""_blank"" href=""https://www.transparencymarketresearch.com/structural-health-monitoring-market.html"" rel=""nofollow"">structural health monitoring market</a> is expected to witness tremendous growth with the development of the healthcare industry. There are several prominent players in the market who are focusing mainly for a greater share in the market as compared to their competitors. The leading players of the market are anticipated to put more concentration on developing products of the healthcare industry. There is tough competition and one move of a single player summons other players to respond strategically. Therefore the structural health monitoring market offers immense growth opportunities due to the rising development of the healthcare business field in the years to come.</p> 
    












                         					        	<p>     (Logo: <a class=""linkOnClick"" data-include=""694805671"" target=""_blank"" href=""https://mma.prnewswire.com/media/664869/Transparency_Market_Research_Logo.jpg"" rel=""nofollow"">https://mma.prnewswire.com/media/664869/Transparency_Market_Research_Logo.jpg</a> )</p> 
    












		                     					        	<p><b>Get PDF Brochure for Research Insights at:</b> <a class=""linkOnClick"" data-include=""694805671"" target=""_blank"" href=""https://www.transparencymarketresearch.com/sample/sample.php?flag=B&amp;rep_id=11180"" rel=""nofollow"">https://www.transparencymarketresearch.com/sample/sample.php?flag=B&amp;rep_id=11180</a></p> 
    












		                     					        	<p>Some of the leading players in the global structural health monitoring market are OSMOS Group, National Instruments Corporation, Digitexx Data Systems, ACELLENT TECHNOLOGIES, INC., and Nova Metrix LLC. The regional and local players of the market are presumed to be relying on strategic alliance formation so that they can sustain themselves in the health monitoring market.</p> 
    












		                     					        	<p>As per the TMR reports, the global structural monitoring market is anticipated to display a 10.09% CAGR within the forecast period of 2017 to 2025. The valuation of the market during the aforementioned forecast period is of <span class=""xn-money"">US$4.09 mn</span> by 2025 which was earlier recorded at <span class=""xn-money"">US$1.57 mn</span> in 2016.</p> 
    












		                     					        	<p><b>Browse Research Release at</b> <a class=""linkOnClick"" data-include=""694805671"" target=""_blank"" href=""https://www.transparencymarketresearch.com/pressrelease/structural-health-monitoring-market.htm"" rel=""nofollow"">https://www.transparencymarketresearch.com/pressrelease/structural-health-monitoring-market.htm</a></p> 
    












		                     					        	<p><b><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Asia Pacific</span></span></span> to Witness Fast Growth with Substantial Development Projects</b> </p> 
    












		                     					        	<p>Owing to the boost of the structural health monitoring industry by the rapid pace of urbanization, that has surpassed all previous records, there is the necessity for reliable and strong infrastructure for all commercial, residential as well as industrial sectors. Therefore the market demand has mounted to new heights recently. A major role adding to the advantage of the global structural market is the developing industrial zones and well as town centers. There has been deployment in structural health monitoring systems which was necessitated by real estate industries in order to undergo fundamental changes. Therefore, the growth of the global structural health monitoring market is anticipated to depend on the recent advancements in the building and construction industry as well.</p> 
    












		                     					        	<p><b>Request a Sample of Report:</b> <a class=""linkOnClick"" data-include=""694805671"" target=""_blank"" href=""https://www.transparencymarketresearch.com/sample/sample.php?flag=S&amp;rep_id=11180"" rel=""nofollow"">https://www.transparencymarketresearch.com/sample/sample.php?flag=S&amp;rep_id=11180</a></p> 
    












		                     					        	<p>In terms of geography, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">North America</span></span></span> is anticipated to be dominating the market. This is due to the age old infrastructure like power plants, tunnels and bridges that are in need of structural health monitoring. Following the trails of <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">North America</span></span></span> is <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Europe</span></span></span> which may trim some of its revenue share and rather come down to the third position by the end of the forecast period.</p> 
    












		                     					        	<p><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Asia Pacific</span></span></span> is however predicted to exceed all other regions in terms of the rate of growth. Structural health monitoring is obtaining more popularity due to substantial development of building projects like those of smart cities, power plants and bridges. Most of the revenue share to be contributed by <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Asia Pacific</span></span></span> to the global market is from the developing nations of <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Japan</span></span></span> and <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">China</span></span></span>.</p> 
    












		                     					        	<p><b>Request For Discount On This Report:</b> <a class=""linkOnClick"" data-include=""694805671"" target=""_blank"" href=""https://www.transparencymarketresearch.com/sample/sample.php?flag=D&amp;rep_id=11180"" rel=""nofollow"">https://www.transparencymarketresearch.com/sample/sample.php?flag=D&amp;rep_id=11180</a></p> 
    












		                     					        	<p>Moreover, government is also taking efforts to improve the infrastructural standards of their construction industries all around the world. This would ensure safety of the newly constructed buildings for commercial, residential as well as healthcare purposes. Besides precautious measures in terms of new construction, the government of various regions is also anticipated to protect all historical monuments and ancient and cultural heritages. This is being done for enhancing the tourism industry along with the structural health monitoring market globally.</p> 
    












		                     					        	<p><b>High Expenditure for Structural Monitoring Restricting Market Growth</b> </p> 
    












		                     					        	<p>Lack of technological expertise seems to act as a hindrance for new players to enter into the market because of inexperience.</p> 
    












		                     					        	<p>Additionally, though various measures are taken in order to improve the structural health of buildings and centers around the world, there seems to be a heavy investment both in terms of labor and finance. The high expenditure investment for installment of sensors seems to be a major challenge for the growth and development of the structural health monitoring market in the years to come.</p> 
    












		                     					        	<p>The information presented in this review is based on a TMR report, titled,"" Structural Health Monitoring Market (Solution - Software, Hardware, and Services; Connectivity - Wired and Wireless; Application - Civil (Brides, Dams, and Tunnels) and Aviation) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025"".</p> 
    












		                     					        	<p><b>Get a Custom Report at</b> <a class=""linkOnClick"" data-include=""694805671"" target=""_blank"" href=""https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&amp;rep_id=11180"" rel=""nofollow"">https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&amp;rep_id=11180</a></p> 
    












		                     					        	<p><b>Global </b> <b>Structural Health Monitoring Market </b> <b>is segmented as follows:</b> </p> 
    












		                     					        	<p><b>Global Structural Health Monitoring Market by Solution</b> </p> 
    












		                     					        	 				<ul type=""disc""> 
    <li>Software</li> 
    <li>Hardware</li> 
    <li>Services</li> 
   </ul> 
   













		                     					        	<p><b>Global Structural Health Monitoring Market by Connectivity</b> </p> 
    












		                     					        	 				<ul type=""disc""> 
    <li>Wired</li> 
    <li>Wireless</li> 
   </ul> 
   













		                     					        	<p><b>Global Structural Health Monitoring Market by Application</b> </p> 
    












		                     					        	 				<ul type=""disc""> 
    <li>Civil 
     <ul type=""circle""> 
      <li>Bridges</li> 
      <li>Dams</li> 
      <li>Tunnels</li> 
     </ul> </li> 
    <li>Aviation</li> 
   </ul> 
   













		                     					        	<p><b>Global Structural Health Monitoring Market by Geography</b> </p> 
    












		                     					        	 				<ul type=""disc""> 
    <li><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">North America</span></span></span> 
     <ul type=""circle""> 
      <li>The U.S.</li> 
      <li><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Canada</span></span></span></li> 
      <li>Rest of <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">North America</span></span></span></li> 
     </ul> </li> 
    <li><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Europe</span></span></span> 
     <ul type=""circle""> 
      <li>The U.K</li> 
      <li><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Germany</span></span></span></li> 
      <li><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">France</span></span></span></li> 
      <li>Rest of <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Europe</span></span></span></li> 
     </ul> </li> 
    <li><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Asia Pacific</span></span></span> (APAC) 
     <ul type=""circle""> 
      <li><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">China</span></span></span></li> 
      <li><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Japan</span></span></span></li> 
      <li><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">India</span></span></span></li> 
      <li>Rest of APAC</li> 
     </ul> </li> 
    <li><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Middle East</span></span></span> and <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Africa</span></span></span> (MEA) 
     <ul type=""circle""> 
      <li>GCC Countries</li> 
      <li><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">South Africa</span></span></span></li> 
      <li>Rest of MEA</li> 
     </ul> </li> 
    <li><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">South America</span></span></span> 
     <ul type=""circle""> 
      <li><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Brazil</span></span></span></li> 
      <li>Rest of <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">South America</span></span></span></li> 
     </ul> </li> 
   </ul> 
   













		                     					        	<p><b>Browse More</b> <a class=""linkOnClick"" data-include=""694805671"" target=""_blank"" href=""https://www.transparencymarketresearch.com/ittelecom-market-reports-19.html"" rel=""nofollow""><b>IT &amp; Telecom Market Research Reports</b></a></p> 
    












		                     					        	<p><b>Popular Research Reports by TMR:</b> </p> 
    












		                     					        	 				<ul type=""disc""> 
    <li><b>Brain Computer Interface Market (Type - Invasive BCI, Partially Invasive BCI, and Noninvasive BCI; Technology - Electroencephalography (EEG), Electrocorticography (ECOG), Near Infrared Spectroscopy (NIRS), Functional Magnetic Resonance Imaging (fMRI), and Magnetoencephalography (MEG); Application - Health Care, Gaming and Entertainment, Communication, Defense and Aerospace, and Home Automation)</b><b>:</b> <a class=""linkOnClick"" data-include=""694805671"" target=""_blank"" href=""https://www.transparencymarketresearch.com/brain-computer-interface-market.html"" rel=""nofollow"">https://www.transparencymarketresearch.com/brain-computer-interface-market.html</a></li> 
    <li><b>Data Monetization Market ( Component - Platform, Software (Standalone and Suite), and Services (Professional Service, Data as a service); Method - Indirect Data Monetization, Direct Data Monetization; Industry Vertical - Telecom, E-Commerce and Retail, BFSI (Consumer Finance/Banking, Business Banking, Capital Markets, Insurance) Healthcare, Travel and Logistics; Application - Sales and Marketing, Supply Chain Management, Capital Asset Management, Remote Equipment Monitoring)</b><b>:</b> <a class=""linkOnClick"" data-include=""694805671"" target=""_blank"" href=""https://www.transparencymarketresearch.com/data-monetization-market.html"" rel=""nofollow"">https://www.transparencymarketresearch.com/data-monetization-market.html</a></li> 
    <li><b>Media Monitoring Tools Market (Component - Software Platform, Professional Services, Consulting Services, and Managed Services; End User - Large Enterprise and Small and Medium Enterprise; Application - Customer experience management, Network security management, Digital Asset Management, and Sales and Marketing Management; Industry - BFSI, Retail and Consumer Goods, IT and Telecommunication, Government, Media and Entertainment, and Travel and Hospitality)</b><b>:</b> <a class=""linkOnClick"" data-include=""694805671"" target=""_blank"" href=""https://www.transparencymarketresearch.com/media-monitoring-tools-market.html"" rel=""nofollow"">https://www.transparencymarketresearch.com/media-monitoring-tools-market.html</a></li> 
   </ul> 
   













		                     					        	<p><b>About Us</b> </p> 
    












		                     					        	<p>Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.</p> 
    












		                     					        	<p>Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.</p> 
    












		                     					        	<p>TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.</p> 
    












		                     					        	<p><b>Contact</b><br> <br> Mr. <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Rohit Bhisey</span></span><br> Transparency Market Research<br> State Tower,<br> 90 State Street,<br> Suite 700,<br> <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Albany NY</span></span></span> - 12207<br> <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">United States</span></span></span><br> Tel: +1-518-618-1030<br> <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">USA</span></span></span> - Canada Toll Free: 866-552-3453<br> <b>Email:</b> <a class=""linkOnClick"" data-include=""694805671"" href=""mailto:sales@transparencymarketresearch.com"" rel=""nofollow"">sales@transparencymarketresearch.com</a><u> </u><br> </p> 
    












		                     					        	<p><br> <b>Website</b>: <a class=""linkOnClick"" data-include=""694805671"" target=""_blank"" href=""https://www.transparencymarketresearch.com"" rel=""nofollow"">https://www.transparencymarketresearch.com</a></p> 
    












		                     					        	<p><b>Research Blog</b>: <a class=""linkOnClick"" data-include=""694805671"" target=""_blank"" href=""http://www.techyounme.com/"" rel=""nofollow"">http://www.techyounme.com/</a></p> 
   <br>  












		                     					        	<p> SOURCE Transparency Market Research </p> 












		                 </div>
  </div>
  </section>"
http://www.prnewswire.co.uk/news-releases/thoughtonomy-and-digiblu-come-together-to-deliver-first-intelligent-automation-saas-solution-in-africa-694876921.html,Thoughtonomy and DigiBlu Come Together to Deliver First Intelligent Automation SaaS Solution in Africa,"<section class=""release-body container  no-margin-bottom "" itemprop=""articleBody"">
    <div class=""row"">
                <div class=""col-sm-10 col-sm-offset-1"">
    	                   		 		 		 		 		 
		 		  		 	 					        	<p><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">LONDON</span></span></span> and <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">CAPE TOWN, South Africa</span></span></span>, <span class=""xn-chron"">October 2, 2018</span> /PRNewswire/ --</p> 
   <p style=""text-align: center""><b><i>New partnership provides businesses inside and outside <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Africa</span></span></span> with operational agility to scale quickly across the region</i></b> </p> 
    












		                     										        	<p>DigiBlu, the leader in digital workforce implementation across <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Africa</span></span></span>, and Thoughtonomy have signed a partnership to deliver the first SaaS based Intelligent Automation solution in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Africa</span></span></span>.</p> 
    












		                     							        <!--startclickprintexclude-->
                <!--endclickprintexclude-->
          </div>
        </div>
		
        <!-- 0 --> 
                <div class=""row"">
          <div class=""col-sm-10 col-sm-offset-1"">
			      	<p>Organisations across <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Africa</span></span></span> are now able to benefit from Thoughtonomy's Virtual Workforce® platform, along with DigiBlu's expertise in designing and delivering digital workforces.</p> 
    












                         					        	<p>Amongst the first organisations to be taking advantage of the new partnership is a premier South African financial services group, which is deploying the Intelligent Automation platform within its subsidiary in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Namibia</span></span></span> to process a number of core customer onboarding and account management processes which largely depend on systems at the parent in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">South Africa</span></span></span>.</p> 
    












		                     					        	<p><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Terry Walby</span></span>, CEO &amp; Founder of Thoughtonomy, said: ""Intelligent Automation offers organisations looking to set up or expand operations in emerging economies across <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Africa</span></span></span> a rapid, agile and cost-effective means to do so.""</p> 
    












		                     					        	<p>""By deploying a flexible virtual workforce within these operating units, businesses can deliver a first-rate service to customers without having to develop a sizeable infrastructure, which is invariably slow, difficult, or prohibitively expensive. Our platform also opens the door to a large number of AI capabilities, giving companies the flexibility to automate a wide variety of processes across their business without encountering technical barriers.  Already we're seeing clients benefiting from this innovative, infinitely scalable approach to international expansion.""</p> 
    












		                     					        	<p>DigiBlu becomes Thoughtonomy's first partner in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Africa</span></span></span> and will build out a dedicated Thoughtonomy delivery and managed service Centre of Excellence. Walby continued: ""We're delighted to partner with DigiBlu who are the standout experts in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Africa</span></span></span> when it comes to implementing a digital workforce, with a strong track record of supporting both African and international businesses.""</p> 
    












		                     					        	<p><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Steve Burke</span></span>, CEO DigiBlu, said: ""Thoughtonomy's Intelligent Automation platform will be a real game changer in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Africa</span></span></span>, enabling non-African organisations to enter new markets in the region, as well as allowing local businesses to expand their footprint, bringing greater investment and more jobs to emerging economies. We're hugely excited about the potential of this partnership and see huge opportunities for our clients across a range of sectors, including financial services, logistics and mining, to leapfrog into the 4<sup>th</sup> Industrial Revolution space while leveraging their legacy IT.""</p> 
    












		                     					        	<p>Thoughtonomy's Virtual Workforce integrates Artificial Intelligence (AI), Machine Learning and Robotic Process Automation (RPA) to emulate human workers in executing existing business processes. It frees up employees' time, allowing knowledge workers to focus on higher value tasks. Deployed as a Software as a Service (SaaS) platform, it allows companies to increase productivity rapidly.</p> 
    












		                     					        	<p>The partnership with DigiBlu supports Thoughtonomy's own strategy for international growth. It recently announced that it was moving to a 90% partner model in order to scale and expand its operations globally, building on two years of 300% revenue growth. The company was recently ranked in the top set of high-growth UK tech firms, placing fourth in the <a class=""linkOnClick"" data-include=""694876921"" target=""_blank"" href=""http://www.fasttrack.co.uk/league-tables/tech-track-100/league-table/"" rel=""nofollow"">Sunday Times Hiscox Fast Track 100</a> on the back of its rapid international expansion and organic growth.</p> 
    












		                     					        	<p><b>About </b> <b>DigiBlu</b> </p> 
    












		                     					        	<p>DigiBlu combines local footprint with global networks. Headquartered in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">South Africa</span></span></span>, DigiBlu serves clients across <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Africa</span></span></span> and in the UK and are wholly specialist in implementing RPA and Intelligent Automation and operating Digital Workforces. DigiBlu combines long experience in delivering digital-enabled business transformations and has deep operations, process and dev skills.</p> 
    












		                     					        	<p>Our RPA clients come from all industries and include the likes of FNB, Nedbank, Investec, Investec Asset Management, Old Mutual South Africa, Old Mutual Insure, Old Mutual Namibia, Discovery, Telkom, BCX and Bytes.</p> 
    












		                     					        	<p>For further information on DigiBlu, please see <a class=""linkOnClick"" data-include=""694876921"" target=""_blank"" href=""http://digiblu.co.za/"" rel=""nofollow"">http://digiblu.co.za/</a></p> 
    












		                     					        	<p><b>About Thoughtonomy</b> </p> 
    












		                     					        	<p>Thoughtonomy is an intelligent automation technology company that has created an award-winning platform to help companies of all sizes improve the productivity of their workforce. Combining the principles of cloud computing, software robotics and artificial intelligence in a single integrated platform, our customers enjoy frictionless deployment of a digital workforce that delivers fast, measurable results in an infinite number of roles.</p> 
    












		                     					        	<p>The company was founded in 2013 and now serves more than 200 clients in 29 countries across a wide range of verticals. In addition, to its <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">London</span></span></span> headquarters, the company has offices in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Manchester, New York</span></span></span> and <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Austin</span></span></span>.</p> 
    












		                     					        	<p>For further information on Thoughtonomy, please see <a class=""linkOnClick"" data-include=""694876921"" target=""_blank"" href=""http://thoughtonomy.com/"" rel=""nofollow"">http://thoughtonomy.com/</a></p>  












		                     					        	<p> SOURCE Thoughtonomy </p> 












		                 </div>
  </div>
  </section>"
http://www.prnewswire.co.uk/news-releases/scania-orders-new-installation-from-hd-wireless-to-smart-factory-lab-694880241.html,Scania Orders New Installation From H&D Wireless to Smart Factory Lab,"<section class=""release-body container  no-margin-bottom "" itemprop=""articleBody"">
    <div class=""row"">
                <div class=""col-sm-10 col-sm-offset-1"">
    	                   		 		 		 		 		 
		 		  		 	 					        	<p><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">STOCKHOLM</span></span></span>, <span class=""xn-chron"">October 2, 2018</span> /PRNewswire/ --</p> 
    












		                     										        	<p><b>H&amp;D Wireless extends its partnership with Scania through an additional installation of the GEPS indoor positioning system for Scania</b><b>'</b><b>s Smart Factory Lab concept in Södertälje. This order means that H&amp;D Wireless can demonstrate additional services in its concept of flow and workflow directly in the Smart Factory Lab facility.</b> </p> 
    












		                     							        <!--startclickprintexclude-->
                <!--endclickprintexclude-->
          </div>
        </div>
		
        <!-- 0 --> 
                <div class=""row"">
          <div class=""col-sm-10 col-sm-offset-1"">
			      	<p>     (Logo: <a class=""linkOnClick"" data-include=""694880241"" target=""_blank"" href=""https://mma.prnewswire.com/media/494475/H_and_D_Wireless_Logo.jpg"" rel=""nofollow"">https://mma.prnewswire.com/media/494475/H_and_D_Wireless_Logo.jpg</a> )</p> 
    












                         					        	<p>H&amp;D Wireless proprietary solution GEPS for Industry (Griffin Enterprise Positioning Services) enables a higher level of automation for manufacturing enterprises. The system enables digitization and visualization of physical processes, using radio positioning and artificial intelligence (AI) to identify and track management of materials, production bottlenecks, utilization rate of resources and unexpected machine interruptions, etc. The purpose is to lower manufacturing costs, reducing lead times and working capital.</p> 
    












		                     					        	<p>""We are much pleased with Scania's continued trust in our offering, which enables us to further develop and demonstrate the value of the GEPS system and the services it provides,"" says Pär Bergsten, CEO, H&amp;D Wireless.</p> 
    












		                     					        	<p>""We are very satisfied with our collaboration with H&amp;D Wireless, and because the newly established Smart Factory Lab is closely aligned with regular production this will be a convenient source of inspiration for our production and logistics managers,"" says <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Lars Hanson</span></span>, Project Manager, Smart Factory Lab, Scania.</p> 
    












		                     					        	<p><i>This information is such information that H&amp;D Wireless AB is required to disclose under the EU market abuse regulation. The information was provided, through the above contact person, for publication <span class=""xn-chron"">08:00am CET</span> on 2</i><i><sup>nd</sup></i><i> Oct</i><i> 2018.</i> </p> 
   <p style=""font-weight: bold"">About H&amp;D Wireless: </p> 
    












		                     					        	<p>H&amp;D Wireless is a Swedish supplier of technology and services within Internet of Things (IoT) and realtime positioning (RTLS+GPS) with the Cloud platforms Griffin and GEPS. H&amp;D Wireless was founded in 2009 and is among <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Sweden's</span></span></span> fastest growing and most decorated IoT companies, with more than 1 Million wireless products shipped to date for IoT, M2M solutions across the globe. The company develops and supplies solutions for digitalization and optimization of physical industry processes through Griffin Enterprise Positioning Service (GEPS ™) with built in artificial intelligence (AI), targeting Industry 4.0 and Smart factory applications. On <span class=""xn-chron"">December 22</span><sup>nd</sup>, 2017, H&amp;D Wireless was listed on Nasdaq First North.</p> 
    












		                     					        	<p><u><a class=""linkOnClick"" data-include=""694880241"" target=""_blank"" href=""http://www.hd-wireless.com"" rel=""nofollow"">www.hd-wireless.com</a></u>  </p>  












		                     					        	<p> SOURCE H&amp;D Wireless </p> 












		                 </div>
  </div>
  </section>"
http://www.prnewswire.co.uk/news-releases/tulane-national-primate-research-center-receives-the-100th-mediso-preclinical-pet-system-with-694880431.html,Tulane National Primate Research Center Receives the 100th Mediso Preclinical PET System With Installation of the MultiScan Large FOV Extreme Resolution (LFER150) PET/CT,"<section class=""release-body container "" itemprop=""articleBody"">
    <div class=""row"">
                <div class=""col-sm-10 col-sm-offset-1"">
    	                   		 		 		 		 		 
		 		  		 	 					        	<p><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">BOSTON</span></span></span>, <span class=""xn-chron"">October 2, 2018</span> /PRNewswire/ --</p> 
    












		                     										        	<p>With the successful installation of the 100<sup>th</sup> Mediso multi-modality preclinical PET system, the <a class=""linkOnClick"" data-include=""694880431"" target=""_blank"" href=""http://www2.tulane.edu/tnprc/"" rel=""nofollow"">Tulane National Primate Research Center</a><u> (TNPRC)</u>, division of the <span class=""xn-org"">Tulane University</span>, has become the fourth site in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">North America</span></span></span> to install the <a class=""linkOnClick"" data-include=""694880431"" target=""_blank"" href=""http://www.medisousa.com/multiscan/lfer"" rel=""nofollow"">MultiScan LFER150 PET/CT</a> preclinical imager.</p> 
    












		                     							        <!--startclickprintexclude-->
                <!--endclickprintexclude-->
          </div>
        </div>
		
        <!-- 2 --> 
                  <div class=""row"">
                                          	<!--PRNE Version C Format Assets Start-->
<div class=""container"">
	<div class=""row"">
		<div class=""col-sm-10 col-sm-offset-1"">
			<div class=""gallery inline-carousel"">
				<div class=""gallery-carousel-main"">
																<!-- assetC https://mma.prnewswire.com/media/752157/Mediso_MultiScan.jpg?w=1600  --- https://mma.prnewswire.com/media/752157/Mediso_MultiScan.jpg?p=publish  -->
						<!-- https://mma.prnewswire.com/media/752157/Mediso_MultiScan.jpg?w=1600  --- https://mma.prnewswire.com/media/752157/Mediso_MultiScan.jpg?p=publish -- https://mma.prnewswire.com/media/752157/Mediso_MultiScan.jpg?w=950 -- $item.sourceUrl -->

    							
  <!-- image -->						<div class=""gallery-cell"">
							<figure>
																									<div class=""image lightbox-item "" data-asset-type=""Photo"" data-asset-id=""Mediso_MultiScan.jpg"" data-asset-label="""" data-src=""https://mma.prnewswire.com/media/752157/Mediso_MultiScan.jpg?w=1600"" data-sub-html=""MultiScan LFER150 PET/CT preclinical imager (PRNewsfoto/Mediso Medical Imaging Systems)"" data-tweet-text=""MultiScan LFER150 PET/CT preclinical imager (PRNewsfoto/Mediso Medical Imaging Systems)"" data-facebook-share-text=""MultiScan LFER150 PET/CT preclinical imager (PRNewsfoto/Mediso Medical Imaging Systems)"" data-linkedin-text=""MultiScan LFER150 PET/CT preclinical imager (PRNewsfoto/Mediso Medical Imaging Systems)"" data-download-url=""https://mma.prnewswire.com/media/752157/Mediso_MultiScan.jpg?w=1600"" data-pinterest-text=""MultiScan LFER150 PET/CT preclinical imager (PRNewsfoto/Mediso Medical Imaging Systems)"" data-twitter-share-url=""https://mma.prnewswire.com/media/752157/Mediso_MultiScan.jpg?w=1600&amp;p=twitter"" data-linkedin-share-url=""https://mma.prnewswire.com/media/752157/Mediso_MultiScan.jpg?w=1600&amp;p=linkedin"" data-facebook-share-url=""https://mma.prnewswire.com/media/752157/Mediso_MultiScan.jpg?w=1600&amp;p=facebook"" data-pinterest-share-url=""https://mma.prnewswire.com/media/752157/Mediso_MultiScan.jpg?w=1600&amp;p=publish"" onclick=""omniture_corousal('Carousel lightbox Page','Photo Open','Mediso_MultiScan.jpg','')"">
  	  <img src=""https://mma.prnewswire.com/media/752157/Mediso_MultiScan.jpg?w=950"" id=""imageid_4"" alt=""MultiScan LFER150 PET/CT preclinical imager (PRNewsfoto/Mediso Medical Imaging Systems)"" class=""gallery-thumb img-responsive"" rel=""newsImage"">
</div>
																								<figcaption>
									MultiScan LFER150 PET/CT preclinical imager (PRNewsfoto/Mediso Medical Imaging Systems)
								</figcaption>
															</figure>
						</div>
											<!-- assetC https://mma.prnewswire.com/media/751911/Mediso_Logo.jpg?w=1600  --- https://mma.prnewswire.com/media/751911/Mediso_Logo.jpg?p=publish  -->
						<!-- https://mma.prnewswire.com/media/751911/Mediso_Logo.jpg?w=1600  --- https://mma.prnewswire.com/media/751911/Mediso_Logo.jpg?p=publish -- https://mma.prnewswire.com/media/751911/Mediso_Logo.jpg?w=950 -- $item.sourceUrl -->

    							
  <!-- image -->						<div class=""gallery-cell"">
							<figure>
																									<div class=""image lightbox-item "" data-asset-type=""Photo"" data-asset-id=""Mediso_Logo.jpg"" data-asset-label="""" data-src=""https://mma.prnewswire.com/media/751911/Mediso_Logo.jpg?w=1600"" data-sub-html=""Mediso Medical Imaging Systems Logo (PRNewsfoto/Mediso Medical Imaging Systems)"" data-tweet-text=""Mediso Medical Imaging Systems Logo (PRNewsfoto/Mediso Medical Imaging Systems)"" data-facebook-share-text=""Mediso Medical Imaging Systems Logo (PRNewsfoto/Mediso Medical Imaging Systems)"" data-linkedin-text=""Mediso Medical Imaging Systems Logo (PRNewsfoto/Mediso Medical Imaging Systems)"" data-download-url=""https://mma.prnewswire.com/media/751911/Mediso_Logo.jpg?w=1600"" data-pinterest-text=""Mediso Medical Imaging Systems Logo (PRNewsfoto/Mediso Medical Imaging Systems)"" data-twitter-share-url=""https://mma.prnewswire.com/media/751911/Mediso_Logo.jpg?w=1600&amp;p=twitter"" data-linkedin-share-url=""https://mma.prnewswire.com/media/751911/Mediso_Logo.jpg?w=1600&amp;p=linkedin"" data-facebook-share-url=""https://mma.prnewswire.com/media/751911/Mediso_Logo.jpg?w=1600&amp;p=facebook"" data-pinterest-share-url=""https://mma.prnewswire.com/media/751911/Mediso_Logo.jpg?w=1600&amp;p=publish"" onclick=""omniture_corousal('Carousel lightbox Page','Photo Open','Mediso_Logo.jpg','')"">
  	  <img src=""https://mma.prnewswire.com/media/751911/Mediso_Logo.jpg?w=950"" id=""imageid_4"" alt=""Mediso Medical Imaging Systems Logo (PRNewsfoto/Mediso Medical Imaging Systems)"" class=""gallery-thumb img-responsive"" rel=""newsImage"">
</div>
																								<figcaption>
									Mediso Medical Imaging Systems Logo (PRNewsfoto/Mediso Medical Imaging Systems)
								</figcaption>
															</figure>
						</div>
									</div>
								<div class=""gallery-carousel-nav"">
											<!-- https://mma.prnewswire.com/media/752157/Mediso_MultiScan.jpg?w=1600  --- https://mma.prnewswire.com/media/752157/Mediso_MultiScan.jpg?p=publish -- https://mma.prnewswire.com/media/752157/Mediso_MultiScan.jpg?w=950 -- $item.sourceUrl -->

    							
  <!-- image -->																																																																																							<img src=""https://mma.prnewswire.com/media/752157/Mediso_MultiScan.jpg"" id=""imageid_1"" alt=""MultiScan LFER150 PET/CT preclinical imager (PRNewsfoto/Mediso Medical Imaging Systems)"" class=""img-responsive"" rel=""newsImage"">
																								<!-- https://mma.prnewswire.com/media/751911/Mediso_Logo.jpg?w=1600  --- https://mma.prnewswire.com/media/751911/Mediso_Logo.jpg?p=publish -- https://mma.prnewswire.com/media/751911/Mediso_Logo.jpg?w=950 -- $item.sourceUrl -->

    							
  <!-- image -->																																																																																							<img src=""https://mma.prnewswire.com/media/751911/Mediso_Logo.jpg"" id=""imageid_3"" alt=""Mediso Medical Imaging Systems Logo (PRNewsfoto/Mediso Medical Imaging Systems)"" class=""img-responsive"" rel=""newsImage"">
																						</div>
							</div>
							<!-- image -->											<!-- image -->									</div>
	</div>
</div>
 <!--PRNE Version C Format Assets End-->
                              </div>
                <div class=""row"">
          <div class=""col-sm-10 col-sm-offset-1"">
			      	<p>     (Logo: <a class=""linkOnClick"" data-include=""694880431"" target=""_blank"" href=""https://mma.prnewswire.com/media/751910/Mediso_USA_Logo.jpg"" rel=""nofollow"">https://mma.prnewswire.com/media/751910/Mediso_USA_Logo.jpg</a> )<br> </p> 
    












                         					        	<p>     (Logo: <a class=""linkOnClick"" data-include=""694880431"" target=""_blank"" href=""https://mma.prnewswire.com/media/751911/Mediso_Logo.jpg"" rel=""nofollow"">https://mma.prnewswire.com/media/751911/Mediso_Logo.jpg</a> )</p> 
    












		                     					        	<p>     (Photo: <a class=""linkOnClick"" data-include=""694880431"" target=""_blank"" href=""https://mma.prnewswire.com/media/752157/Mediso_MultiScan.jpg"" rel=""nofollow"">https://mma.prnewswire.com/media/752157/Mediso_MultiScan.jpg</a> )<br> </p> 
    












		                     					        	<p>In keeping with the mission of the center, the <a class=""linkOnClick"" data-include=""694880431"" target=""_blank"" href=""http://www.medisousa.com/multiscan/lfer"" rel=""nofollow"">MultiScan LFER150 PET/CT</a> will help enable researchers to improve human and animal health by using non-invasive in-vivo imaging techniques to find better treatments for major infectious diseases. The MultiScan LFER 150 PET/CT is the only research-focused, large bore integrated PET/CT scanner supporting whole-body imaging of non-human primates (NHPs) and smaller animal models at sub-millimeter PET resolution. The system features the most versatile integrated PET/CT gantry ever built, enabling dynamic studies both in lying and sitting position, required for awake NHP studies. Due to its unique construction, CT and PET systems share the same field-of-view, eliminating the need for moving the subject during acquisition.</p> 
    












		                     					        	<p>The LFER150 PET/CT will support TNPRC's research program in infectious diseases, particularly in tuberculosis research focused on vaccine development, pathogenesis, and therapeutics.</p> 
    












		                     					        	<p>""We have invested years to make the LFER150 PET/CT a dedicated and effective tool for imaging nonhuman primates for both PET and CT modalities. We are proud to be working with prestigious institutions like the TNPRC"", says <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Illes Muller</span></span>, Managing Partner of Mediso <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">USA</span></span></span>. Like all preclinical PET/CT systems from Mediso, the LFER150 has been designed for quantitative assessment of PET and CT studies.</p> 
    












		                     					        	<p><b>About Mediso <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">USA</span></span></span>, LLC</b> </p> 
    












		                     					        	<p>Mediso <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">USA</span></span></span> distributes the preclinical imaging portfolio of Mediso in the U.S. and <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Canada</span></span></span> and provides the application development and technical support for life science research. The company's headquarters is located in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Boston, Massachusetts</span></span></span>. For more information, please visit <a class=""linkOnClick"" data-include=""694880431"" target=""_blank"" href=""http://www.medisousa.com"" rel=""nofollow"">http://www.medisousa.com</a>.</p> 
    












		                     					        	<p><b>About Mediso Ltd.</b> </p> 
    












		                     					        	<p><b>Mediso </b> <b>Ltd.</b> specializes in the field of nuclear and molecular imaging focused on the development, manufacturing, sales and servicing of multi-modality in-vivo imaging systems. It offers complete solutions from hardware design to quantification software, both for clinical patient care and high-level life science research. The nanoScan<sup>®</sup> family is the first-line choice for preclinical imaging including the world's first integrated preclinical PET/MRI, PET/CT, SPECT/CT and SPECT/MRI combinations.</p> 
    












		                     					        	<p><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Illes Muller</span></span>, <a class=""linkOnClick"" data-include=""694880431"" href=""mailto:info@medisousa.com"" rel=""nofollow"">info@medisousa.com</a>, +1-617-933-8771</p>  












		                     					        	<p> SOURCE Mediso Medical Imaging Systems </p> 












		                 </div>
  </div>
  </section>"
http://www.prnewswire.co.uk/news-releases/ryzodeg-offers-a-simpler-solution-with-once-daily-dosing-and-reduced-risk-of-nocturnal-hypoglycaemia-vs-insulin-glargine-u100-plus-insulin-aspart-694887841.html,Ryzodeg® Offers a Simpler Solution With Once-Daily Dosing and Reduced Risk of Nocturnal Hypoglycaemia vs Insulin Glargine U100 Plus Insulin Aspart,"<section class=""release-body container  no-margin-bottom "" itemprop=""articleBody"">
    <div class=""row"">
                <div class=""col-sm-10 col-sm-offset-1"">
    	                   		 		 		 		 		 
		 		  		 	 					        	<p><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">BERLIN</span></span></span>, <span class=""xn-chron"">October 2, 2018</span> /PRNewswire/ --</p> 
    












		                     													        <!--startclickprintexclude-->
                <!--endclickprintexclude-->
          </div>
        </div>
		
        <!-- 0 --> 
                <div class=""row"">
          <div class=""col-sm-10 col-sm-offset-1"">
			      	<p>When treated with once-daily Ryzodeg<sup>®</sup>, people with type 2 diabetes achieved similar blood sugar control with half the number of daily injections, significantly lower total daily insulin dose and significantly reduced risk of nocturnal hypoglycaemia in the Step by Step trial compared with once-daily insulin glargine U100 plus once-daily insulin aspart after 26 weeks. Ryzodeg<sup>®</sup> is a combination of insulin degludec and insulin aspart (IDegAsp) in one pen for the treatment of people with type 2 diabetes. The results from the Step by Step trial were presented today at the 54<sup>th</sup> Annual Meeting of the European Association for the Study of Diabetes (EASD 2018) in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Berlin, Germany</span></span></span>.<sup>[1]</sup></p> 
    












                         					        	<p>""Complicated treatment regimens that require multiple injections at different times of day can be difficult for patients to adhere to, potentially leading to poor blood sugar control,"" said Dr <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Athena Philis-Tsimikas</span></span>, Step by Step lead investigator and corporate vice president, Scripps Whittier Diabetes Institute. ""These trial results show that once-daily IDegAsp can offer people with type 2 diabetes a much simpler option with fewer injections compared with insulin glargine U100 plus insulin aspart, to achieve effective blood sugar control.""</p> 
    












		                     					        	<p>After 26 weeks, people in the once-daily Ryzodeg<sup>®</sup> treatment arm received 50% fewer injections and significantly fewer total daily insulin units (12%) compared with insulin glargine U100 plus insulin aspart.<sup>[1]</sup></p> 
    












		                     					        	<p>Once-daily Ryzodeg<sup>®</sup> demonstrated a statistically significant 45% lower rate of nocturnal severe or blood glucose (BG)-confirmed symptomatic hypoglycaemic episodes compared with insulin glargine U100 plus insulin aspart after 26 weeks. The rate of overall severe or BG-confirmed hypoglycaemic episodes was numerically lower for once-daily Ryzodeg<sup>®</sup> compared with insulin glargine U100 plus insulin aspart.<sup>[1]</sup></p> 
    












		                     					        	<p>""Hypoglycaemic episodes, especially at night, are often frightening for people with diabetes. Not only does once-daily Ryzodeg<sup>®</sup> offer a much simpler solution but it also significantly reduces the risk of nocturnal hypoglycaemia compared with basal-bolus treatment,"" said <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Mads Krogsgaard Thomsen</span></span>, executive vice president and chief science officer of Novo Nordisk. ""By reducing the number of daily injections, we hope that Ryzodeg<sup>®</sup> can help reduce the burden of diabetes, and make it easier for people with diabetes to comply with treatment and help them towards achieving better outcomes.""</p> 
    












		                     					        	<p><b>About </b> <b>the </b> <b>trial</b> </p> 
    












		                     					        	<p>The Step by Step trial compared the efficacy and safety of Ryzodeg<sup>®</sup> with insulin glargine U100 plus insulin aspart in people with type 2 diabetes treated with basal insulin, with or without oral antidiabetic treatment in need of insulin intensification.<sup>[1]</sup> The trial was a 38-week, international, open-label, randomised, treat-to-target trial involving 532 adults from seven countries.<sup>[1,2]</sup> If participants were not on target at Week 26 or Week 32, they went on to receive an intensified insulin regimen, as would happen in real-life clinical practice.<sup>[1]</sup> The primary endpoint was change from baseline in HbA<sub>1c</sub> after 26 weeks.<sup>[1,2]</sup> Key secondary endpoints included change from baseline in HbA<sub>1c</sub> after 38 weeks, responder rate (%) for HbA<sub>1c</sub> &lt;7% after 26 and 38 weeks, and number of treatment-emergent severe or BG-confirmed symptomatic hypoglycaemic episodes during 26 and 38 weeks.<sup>[1,2]</sup></p> 
    












		                     					        	<p><b>About </b> <b>Ryzodeg</b><b><sup>®</sup></b><sup> </sup></p> 
    












		                     					        	<p>Ryzodeg<sup>®</sup> is a combination of two distinct insulin analogues (insulin degludec and insulin aspart in the ratio of 70% and 30%), making it the first combination of a long-acting basal insulin and a mealtime insulin in one pen for people with type 1 and 2 diabetes.<sup>[3</sup><sup>-6]</sup> Ryzodeg<sup>®</sup> incorporates the benefits of the insulin degludec molecule.<sup>[7,8]</sup> Ryzodeg<sup>®</sup> is given as an injection once or twice daily with main meal(s).<sup>[4]</sup> Ryzodeg<sup>®</sup> offers a simpler regimen with fewer injections than basal and bolus therapy, in one pen.<sup>[3]</sup></p> 
    












		                     					        	<p>Ryzodeg<sup>®</sup> received its first regulatory approval in <span class=""xn-chron"">December 2012</span> and European Medicines Agency approval in <span class=""xn-chron"">January 2013</span>. Since then, Ryzodeg<sup>®</sup> has been approved in more than 90 countries, including the US in <span class=""xn-chron"">September 2015</span>. It is now commercially available in 20 countries.</p> 
    












		                     					        	<p><b>About Novo Nordisk</b> </p> 
    












		                     					        	<p><i>Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat </i> <i>obesity, haemophilia, growth disorders and other serious chronic diseases</i><i>. Headquartered in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Denmark</span></span></span>, Novo Nordisk employs approximately 43,100 people in 79 countries and markets its products in more than 170 countries. For more information, visit </i> <a class=""linkOnClick"" data-include=""694887841"" target=""_blank"" href=""https://www.novonordisk.com/"" rel=""nofollow""><i>novonordisk.com</i></a><i>, </i> <a class=""linkOnClick"" data-include=""694887841"" target=""_blank"" href=""http://www.facebook.com/novonordisk"" rel=""nofollow""><i>Facebook</i></a><i>, </i> <a class=""linkOnClick"" data-include=""694887841"" target=""_blank"" href=""http://www.twitter.com/novonordisk"" rel=""nofollow""><i>Twitter</i></a><i>, </i> <a class=""linkOnClick"" data-include=""694887841"" target=""_blank"" href=""http://www.linkedin.com/company/novo-nordisk"" rel=""nofollow""><i>LinkedIn</i></a><i>, </i> <a class=""linkOnClick"" data-include=""694887841"" target=""_blank"" href=""http://www.Youtube.com/novonordisk"" rel=""nofollow""><i>YouTube</i></a><i>.</i><i> </i>  </p> 
   <p style=""font-weight: bold"">References</p> 
    












		                     					        	<p>1.    Gupta Y, Astamirova K, Fita E, <i>et al.</i> Similar glycaemic control and less nocturnal hypoglycaemia with intensification of IDegAsp QD or BID vs glargine U100 QD + IAsp 1-3 in adults with type 2 diabetes. Abstract and poster presented at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD), <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Berlin, Germany</span></span></span>; <span class=""xn-chron"">1-5 October 2018</span>.</p> 
    












		                     					        	<p>2.    Clinicaltrials.gov. A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification. Available at: <a class=""linkOnClick"" data-include=""694887841"" target=""_blank"" href=""https://clinicaltrials.gov/ct2/show/NCT02906917?term=NN5401-4266&amp;rank=1"" rel=""nofollow"">https://clinicaltrials.gov/ct2/show/NCT02906917?term=NN5401-4266&amp;rank=1</a> Last accessed: <span class=""xn-chron"">September 2018</span>.</p> 
    












		                     					        	<p>3.    Heise T, Tack CJ, Cuddihy R<i>, et al.</i> A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naïve people with type 2 diabetes: a randomized, controlled trial. <i>Diabetes Care</i>. 2011; 34:669-674.</p> 
    












		                     					        	<p>4.    EMA. Ryzodeg<sup>®</sup> Summary of Product Characteristics. Available at: <a class=""linkOnClick"" data-include=""694887841"" target=""_blank"" href=""http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002499/WC500139011.pdf"" rel=""nofollow"">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002499/WC500139011.pdf</a> Last accessed: <span class=""xn-chron"">September 2018</span>.</p> 
    












		                     					        	<p>5.    Fulcher GR, Christiansen JS, Bantwal G<i>, et al.</i> Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial. <i>Diabetes Care</i>. 2014; 37:2084-2090.</p> 
    












		                     					        	<p>6.    De Rycke A, Mathieu C. Degludec - first of a new generation of insulins. <i>European Endocrinology</i>. 2011; 7:84-87.</p> 
    












		                     					        	<p>7.    Marso SP, McGuire DK, Zinman B<i>, et al.</i> Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. <i>N Engl J Med</i>. 2017; 377:723-732.</p> 
    












		                     					        	<p>8.    Haahr H, Fita EG, Heise T. A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic. Properties and Their Implications in Clinical Use. <i>Clin Pharmacokinet.</i> 2017; 56:339-354.</p> 
    












		                     					        	<p><b>Further information</b> </p> 
    












		                     					        	<p>Media:<br> Katrine Sperling        +45-4442-6718  <a class=""linkOnClick"" data-include=""694887841"" href=""mailto:krsp@novonordisk.com"" rel=""nofollow"">krsp@novonordisk.com</a><br> Åsa Josefsson           +45-3079-7708  <a class=""linkOnClick"" data-include=""694887841"" href=""mailto:aajf@novonordisk.com"" rel=""nofollow"">aajf@novonordisk.com</a><br> <br> Investors:<br> Peter Hugreffe Ankersen +45-3075-9085  <a class=""linkOnClick"" data-include=""694887841"" href=""mailto:phak@novonordisk.com"" rel=""nofollow"">phak@novonordisk.com</a><br> Anders Mikkelsen        +45-3079-4461  <a class=""linkOnClick"" data-include=""694887841"" href=""mailto:armk@novonordisk.com"" rel=""nofollow"">armk@novonordisk.com</a><br> Valdemar Borum Svarrer  +45-3079-0301  <a class=""linkOnClick"" data-include=""694887841"" href=""mailto:jvls@novonordisk.com"" rel=""nofollow"">jvls@novonordisk.com</a><br> </p>  












		                     					        	<p> SOURCE Novo Nordisk </p> 












		                 </div>
  </div>
  </section>"
http://www.prnewswire.co.uk/news-releases/kanazawa-university-research-new-co-polymers-for-highly-balanced-ambipolar-performing-organic-field-694891611.html,Kanazawa University Research: New Co-polymers for Highly Balanced Ambipolar Performing Organic Field-effect Transistors,"<section class=""release-body container "" itemprop=""articleBody"">
    <div class=""row"">
                <div class=""col-sm-10 col-sm-offset-1"">
    	                   		 		 		 		 		 
		 		  		 	 					        	<p>KANAZAWA, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Japan</span></span></span>, <span class=""xn-chron"">October 2, 2018</span> /PRNewswire/ --</p> 
    












		                     										        	<p>Researchers from Kanazawa University report in the <i>Journal of Materials Chemistry C</i> the design, synthesis and properties of two co-polymers for organic field-effect transistors with small bandgaps, a strong electron accepting building block that is highly planar, and that are easy to functionalize.</p> 
    












		                     							        <!--startclickprintexclude-->
                <!--endclickprintexclude-->
          </div>
        </div>
		
        <!-- 1 --> 
                  <div class=""row"">
                                          	<!--PRNE Version C Format Assets Start-->
<div class=""container"">
	<div class=""row"">
		<div class=""col-sm-10 col-sm-offset-1"">
			<div class=""gallery inline-carousel"">
				<div class=""gallery-carousel-main"">
																<!-- assetC https://mma.prnewswire.com/media/753103/Kanazawa_Univ_Research.jpg?w=1600  --- https://mma.prnewswire.com/media/753103/Kanazawa_Univ_Research.jpg?p=publish  -->
						<!-- https://mma.prnewswire.com/media/753103/Kanazawa_Univ_Research.jpg?w=1600  --- https://mma.prnewswire.com/media/753103/Kanazawa_Univ_Research.jpg?p=publish -- https://mma.prnewswire.com/media/753103/Kanazawa_Univ_Research.jpg?w=950 -- $item.sourceUrl -->

    							
  <!-- image -->						<div class=""gallery-cell"">
							<figure>
																									<div class=""image lightbox-item "" data-asset-type=""Photo"" data-asset-id=""Kanazawa_Univ_Research.jpg"" data-asset-label="""" data-src=""https://mma.prnewswire.com/media/753103/Kanazawa_Univ_Research.jpg?w=1600"" data-sub-html=""Chemical structures for a) PI-BTO and b) PIBDF-BTO, and (c) organic field effect transistor structure (PRNewsfoto/Kanazawa University)"" data-tweet-text=""Chemical structures for a) PI-BTO and b) PIBDF-BTO, and (c) organic field effect transistor structure (PRNewsfoto/Kanazawa University)"" data-facebook-share-text=""Chemical structures for a) PI-BTO and b) PIBDF-BTO, and (c) organic field effect transistor structure (PRNewsfoto/Kanazawa University)"" data-linkedin-text=""Chemical structures for a) PI-BTO and b) PIBDF-BTO, and (c) organic field effect transistor structure (PRNewsfoto/Kanazawa University)"" data-download-url=""https://mma.prnewswire.com/media/753103/Kanazawa_Univ_Research.jpg?w=1600"" data-pinterest-text=""Chemical structures for a) PI-BTO and b) PIBDF-BTO, and (c) organic field effect transistor structure (PRNewsfoto/Kanazawa University)"" data-twitter-share-url=""https://mma.prnewswire.com/media/753103/Kanazawa_Univ_Research.jpg?w=1600&amp;p=twitter"" data-linkedin-share-url=""https://mma.prnewswire.com/media/753103/Kanazawa_Univ_Research.jpg?w=1600&amp;p=linkedin"" data-facebook-share-url=""https://mma.prnewswire.com/media/753103/Kanazawa_Univ_Research.jpg?w=1600&amp;p=facebook"" data-pinterest-share-url=""https://mma.prnewswire.com/media/753103/Kanazawa_Univ_Research.jpg?w=1600&amp;p=publish"" onclick=""omniture_corousal('Carousel lightbox Page','Photo Open','Kanazawa_Univ_Research.jpg','')"">
  	  <img src=""https://mma.prnewswire.com/media/753103/Kanazawa_Univ_Research.jpg?w=950"" id=""imageid_2"" alt=""Chemical structures for a) PI-BTO and b) PIBDF-BTO, and (c) organic field effect transistor structure (PRNewsfoto/Kanazawa University)"" class=""gallery-thumb img-responsive"" rel=""newsImage"">
</div>
																								<figcaption>
									Chemical structures for a) PI-BTO and b) PIBDF-BTO, and (c) organic field effect transistor structure (PRNewsfoto/Kanazawa University)
								</figcaption>
															</figure>
						</div>
									</div>
							</div>
							<!-- image -->									</div>
	</div>
</div>
 <!--PRNE Version C Format Assets End-->
                              </div>
                <div class=""row"">
          <div class=""col-sm-10 col-sm-offset-1"">
			      	<p>     (Photo: <a class=""linkOnClick"" data-include=""694891611"" target=""_blank"" href=""https://mma.prnewswire.com/media/753103/Kanazawa_Univ_Research.jpg"" rel=""nofollow"">https://mma.prnewswire.com/media/753103/Kanazawa_Univ_Research.jpg</a> )<br> </p> 
    












                         					        	<p>Electronic devices made using polymers as active semiconducting layers are intensively studied, because they can be inexpensive and have advantageous electric and optoelectric properties and mechanical flexibility. The active layer can be processed in solution leading simple fabrication process. In particular, in organic field-effect transistors (OFETs) the use of co-polymers - polymers made from more than one type of monomer - composed of electron donor and electron acceptor units can result in very high charge carrier mobilities. Now, a collaboration between Kanazawa University in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Japan</span></span></span> and Dongguk University in Korea, led by <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Makoto Karakawa</span></span> and <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Yong-Young Noh</span></span>, reports in the Journal of Materials Chemistry C two new co-polymers for high-performance OFETs.</p> 
    












		                     					        	<p>To realize high-performance ambipolar OFETs it is important to achieve efficient injection of electrons and holes from an electrode into the highest occupied molecular orbital (HOMO) and the lowest unoccupied molecular orbital (LUMO). To this end, the semiconductor energy gap needs to be small. The authors designed, synthesized and evaluated electrical properties of two co-polymers with small bandgaps based on isoindigo, a strong electron accepting building block; the two co-polymers are called poly (isoindigo-bithio-phene-alkoxyl) (PI-BTO) and poly (isoindigobenzodifurandione-bithiophene-alkoxyl) (PIBDF-BTO). Their degree of crystallinity was investigated by atomic force microscopy and X-ray diffraction, and their photophysical and electrical properties were characterized.</p> 
    












		                     					        	<p>The idea behind PIBDF-BTO is that introducing the strong electron withdrawing BDF in the electron acceptor isoindigo unit of PI-BTO. The HOMO and LUMO of the polymer are deepened, leading to stronger intermolecular interaction and high field-effect mobility, on top of better crystallinity of the polymer chain. This polymer indeed exhibits higher field-effect electron and hole mobility and well-balanced ambipolar transport compared to PI-BTO. The lower bandgap of PIBFD-BTO compared to that of PI-BTO also results in more efficient ambipolar charge injection. Moreover, OFETs based on PIBDF-BTO were shown to be operationally stable under continuous cycling measurements. ""We believe isoindigo benzodifurandione to be a promising acceptor building block in donor-acceptor conjugated polymers for various applications"" conclude the authors.</p> 
    












		                     					        	<p><b>Background</b> </p> 
    












		                     					        	<p><b>Field-effect transistor</b>: transistors in which the conductivity between the drain and source terminals is controlled by an electric field generated by the voltage difference between the body and the gate of the transistor. If the semiconductor material the transistor is based on is a polymer, we talk of organic field-effect transistors. The device is ambipolar if electrons and holes move with the same effective diffusion coefficient, drift mobility and lifetime.</p> 
    












		                     					        	<p><b>Reference:</b> </p> 
    












		                     					        	<p>Tomotsugu Takaya, <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Melaku Dereje Mamo</span></span>, <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Makoto Karakawa</span></span> and <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Yong-Young Noh</span></span>, Isoindigo benzodifurandione based conjugated polymers for high performance organic field-effect transistors. <i>J. Mater. Chem. C</i>, <b>6</b>, 7822 (2018).</p> 
    












		                     					        	<p>DOI: 10.1039/C8TC02348D</p> 
   <p style=""font-weight: bold"">About Kanazawa University</p> 
    












		                     					        	<p>As the leading comprehensive university on the Sea of <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Japan</span></span></span> coast, Kanazawa University has contributed greatly to higher education and academic research in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Japan</span></span></span> since it was founded in 1949. The University has three colleges and 17 schools offering courses in subjects that include medicine, computer engineering, and humanities.</p> 
    












		                     					        	<p>The University is located on the coast of the Sea of <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Japan</span></span></span> in Kanazawa - a city rich in history and culture. The city of Kanazawa has a highly respected intellectual profile since the time of the fiefdom (1598-1867). Kanazawa University is divided into two main campuses: Kakuma and Takaramachi for its approximately 10,200 students including 600 from overseas.</p> 
    












		                     					        	<p>Kanazawa University website: <a class=""linkOnClick"" data-include=""694891611"" target=""_blank"" href=""http://www.kanazawa-u.ac.jp/e/"" rel=""nofollow"">http://www.kanazawa-u.ac.jp/e/</a></p> 
    












		                     					        	<p><b>Further information</b> </p> 
    












		                     					        	<p>Kanazawa University<br> Kakuma, Kanazawa, Ishikawa 920-1192, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">JAPAN</span></span></span><br> E-mail: <a class=""linkOnClick"" data-include=""694891611"" href=""mailto:intl.pr@adm.kanazawa-u.ac.jp"" rel=""nofollow"">intl.pr@adm.kanazawa-u.ac.jp</a><br> Tel: +81-(76)-264-5963</p>  












		                     					        	<p> SOURCE Kanazawa University </p> 












		                 </div>
  </div>
  </section>"
http://www.prnewswire.co.uk/news-releases/novasep-opens-27m-new-viral-vector-commercial-production-facility-694897041.html,Novasep Opens €27m New Viral Vector Commercial Production Facility,"<section class=""release-body container  no-margin-bottom "" itemprop=""articleBody"">
    <div class=""row"">
                <div class=""col-sm-10 col-sm-offset-1"">
    	                   		 		 		 		 		 
		 		  		 	 					        	<p><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">LYON, France</span></span></span>, <span class=""xn-chron"">October 2, 2018</span> /PRNewswire/ --</p> 
   <p style=""text-align: center""><b>With this new </b> <b>Viral </b> <b>Vector bioproduction </b> <b>facility</b><b>, Novasep </b> <b>confirms its leadership</b><b> position</b><b> and effectively addresses</b><b> the growing </b> <b>gene th</b><b>era</b><b>py </b> <b>market </b> <b>demand</b> </p> 
    












		                     										        	<p>Novasep, a leading supplier of services and technologies for the life sciences industry, has opened a new 27 M€ viral vector production facility in Seneffe, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Belgium</span></span></span>. The production of the first cGMP batches will start in H1 2019.</p> 
    












		                     							        <!--startclickprintexclude-->
                <!--endclickprintexclude-->
          </div>
        </div>
		
        <!-- 0 --> 
                <div class=""row"">
          <div class=""col-sm-10 col-sm-offset-1"">
			      	<p>This project, known as Senrise-IV, represents an operational and strategic step forward for Novasep. This facility features the bioproduction of viral vectors at commercial industrial scale in an integrated manner and with full control of the value creation chain. To this end, Novasep has doubled its on-site workforce with the creation of 75 positions.</p> 
    












                         					        	<p>The facility will feature two cGMP production lines: one dedicated to adherence cell culture for viral vectors in moderate quantities - to treat certain rare diseases or for lower dose indications - and one for suspension cell culture with bioreactors of 50 to 2000 liters to produce larger quantities. This equipment is designed to meet the growing demand of biopharmaceutical companies worldwide.</p> 
    












		                     					        	<p>The 2,000m² Senrise-IV facility meets the highest cGMP standards governing commercial production for biopharmaceutical use. A zero-risk approach thus remains a core priority with the separation of different production zones and effluent and material onsite decontamination.</p> 
    












		                     					        	<p>""<i>We are delighted to inaugurate this facility today. It was built i</i><i>n</i><i> record time thanks to the </i> <i>unwavering </i> <i>support of our experts</i><i>'</i><i> team. We </i> <i>are now</i><i> able to offer the market commercial production in addition to clinical production</i>,"" said <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Pierre Lunel</span></span>, Director of the Belgian site.</p> 
    












		                     					        	<p>""<i>In addition</i><i>, the</i><i> construction of </i> <i>'</i><i>Senefill</i><i>'</i><i>, </i> <i>our</i><i> fill &amp; finish commercial facility </i> <i>is ongoing on </i> <i>the same site, </i> <i>and </i> <i>will be operational before the end of 2019. This investment will allow Novasep to </i> <i>provide </i> <i>standalone</i><i> </i> <i>fill &amp; finish services </i> <i>or</i><i> integrated </i> <i>drug substance and drug product manufacturing for viral vectors, mAbs and other low volume biologics. We </i> <i>remain </i> <i>committed to efficiently </i> <i>respond to the strong market demand for orphan and targeted biopharmaceutical drugs as clinical pipelines mature</i>,"" commented <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Michel Spagnol</span></span>, Chairman and CEO of Novasep.</p> 
    












		                     					        	<p><b>For press information, click here</b><b>:</b> <a class=""linkOnClick"" data-include=""694897041"" target=""_blank"" href=""https://www.novasep.com/press-release-about-novasep.html"" rel=""nofollow"">https://www.novasep.com/press-release-about-novasep.html</a></p>  












		                     					        	<p> SOURCE Novasep </p> 












		                 </div>
  </div>
  </section>"
http://www.prnewswire.co.uk/news-releases/first-ever-opium-poppy-genome-assembled-695002381.html,First-ever Opium Poppy Genome Assembled,"<section class=""release-body container  no-margin-bottom "" itemprop=""articleBody"">
    <div class=""row"">
                <div class=""col-sm-10 col-sm-offset-1"">
    	                   		 		 		 		 		 
		 		  		 	 					        	<p><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">SHAANXI, China</span></span></span>, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">YORK, England</span></span></span> and NESS ZIONA, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Israel</span></span></span>, <span class=""xn-chron"">October 3, 2018</span> /PRNewswire/ --</p> 
   <p style=""text-align: center""><i>Data from collaboration among NRGene, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">China's</span></span></span></i> <i>Xi'an Jiaotong University</i><i>,</i> <i>and</i> <i>The Wellcome Sanger Institute and The University of <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">York, UK</span></span></span></i></p> 
    












		                     										        	<p>Xi'an Jiaotong University, The Wellcome Sanger Institute, The University of <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">York</span></span></span>, and <a class=""linkOnClick"" data-include=""695002381"" target=""_blank"" href=""http://www.nrgene.com/"" rel=""nofollow"">NRGene</a> have recently completed the world's first assembly of the opium poppy genome.</p> 
    












		                     							        <!--startclickprintexclude-->
                <!--endclickprintexclude-->
          </div>
        </div>
		
        <!-- 0 --> 
                <div class=""row"">
          <div class=""col-sm-10 col-sm-offset-1"">
			      	<p>""We're using the genome to find key gene clusters that can be leveraged to develop affordable and reliable medicine,"" says Professor <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Kai Ye</span></span> of Xi'an Jiaotong University. ""NRGene's technology quickly delivered an initial version of the assembly to allow further improvement.""</p> 
    












                         					        	<p>NRGene's <a class=""linkOnClick"" data-include=""695002381"" target=""_blank"" href=""http://www.nrgene.com/technology/denovomagic/"" rel=""nofollow"">DeNovoMAGIC</a><sup><u>[</u>™</sup><sup>]</sup> provided comprehensive results only a few weeks after receiving the raw material from the University of <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">York</span></span></span>. DeNovoMAGIC assembles Illumina reads into long sequences, delivering accurate assembly results to provide researchers with a complete picture of their varieties for in-depth research. The opium poppy genome project team supplemented NRGene's data with analysis from PacBio and a linkage map to further improve the result from NRGene's scaffold N50 at 15.6Mb, contig N50 at 121kb to the final product of scaffold N50 at 205Mb and contig N50 1.77Mb.</p> 
    












		                     					        	<p>The final assembly allows the teams to understand the species evolution and how metabolic pathways are constructed, providing a more in-depth picture of the plant's properties as a natural pharmaceutical. Opium has long been used as a natural pain killer; the poppy plant is the basis of the extracts used to create hydrocodone and codeine.</p> 
    












		                     					        	<p>""International cooperation across academic and corporate entities are now the norm,"" said Professor <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Ian Graham</span></span> from the University of <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">York</span></span></span>. ""Leveraging and sharing technologies and results, especially in terms of genome mapping, is providing a true paradigm shift in food and medical research.""</p> 
    












		                     					        	<p>Researchers around the world are leveraging <a class=""linkOnClick"" data-include=""695002381"" target=""_blank"" href=""http://www.nrgene.com/"" rel=""nofollow"">NRGene</a>'s technologies to accelerate agricultural research on animals and food and biofuel crops, such as wheat, soy, potato, and maize. <a class=""linkOnClick"" data-include=""695002381"" target=""_blank"" href=""http://www.nrgene.com/technology/genomagic/"" rel=""nofollow"">GenoMAGIC</a><sup><u>[</u>™</sup><sup>]</sup> enables researchers to easily relate genomic sequences with beneficial traits to accelerate and enhance genetic discovery and breeding. <a class=""linkOnClick"" data-include=""695002381"" target=""_blank"" href=""http://www.nrgene.com/technology/panmagic/"" rel=""nofollow"">PanMAGIC</a><sup><u>[</u>™</sup><sup>]</sup> produces an accurate genome-to-genome mapping and displays all types of sequence differences within the studied population including SNPs, InDels of any size, inversions, translocations, gene PAVs, and gene CNVs. ArrayMAGIC<sup>[</sup><sup>™</sup><sup>]</sup> maximizes the data found in microarrays/GBS to obtain high resolution genomic information by imputing back from SNPs to full genomic sequences.</p> 
    












		                     					        	<p>""Previously, NRGene's technology has been focused on increasing the world's food supply,"" said <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Gil Ronen</span></span>, CEO of NRGene. ""Projects like this have significant implications for improving health and quality of life.""</p> 
    












		                     					        	<p>The breakthrough, published in a recent issue of <a class=""linkOnClick"" data-include=""695002381"" target=""_blank"" href=""http://science.sciencemag.org/content/early/2018/08/29/science.aat4096"" rel=""nofollow""><i>Science</i></a>, reveals the origins of the pathway leading to production of the cough suppressant noscapine and the painkiller drugs codeine and morphine.</p> 
    












		                     					        	<p><b>About NRGene</b><br> <a class=""linkOnClick"" data-include=""695002381"" target=""_blank"" href=""http://www.nrgene.com/"" rel=""nofollow"">NRGene</a> is a genomic, big data company delivering cutting-edge software and algorithms to their clients to facilitate the modern genomics-based research that is revealing the function, complexity, and diversity of human, plant, and animal genomes that supports the most advanced medical research and sophisticated breeding programs. <a class=""linkOnClick"" data-include=""695002381"" target=""_blank"" href=""http://www.nrgene.com/"" rel=""nofollow"">NRGene</a> tools have already been employed by some of the leading agribiotech companies worldwide, as well as the most influential research teams in academia. <a class=""linkOnClick"" data-include=""695002381"" target=""_blank"" href=""http://www.nrgene.com"" rel=""nofollow"">http://www.nrgene.com</a>. Follow us: <a class=""linkOnClick"" data-include=""695002381"" target=""_blank"" href=""https://twitter.com/NRGene"" rel=""nofollow"">Twitter</a>, <a class=""linkOnClick"" data-include=""695002381"" target=""_blank"" href=""https://www.linkedin.com/company/1704972/"" rel=""nofollow"">LinkedIn</a>, and <a class=""linkOnClick"" data-include=""695002381"" target=""_blank"" href=""https://www.facebook.com/NRGene-Technologies-1003279819696574/?ref=br_rs"" rel=""nofollow"">Facebook</a>.</p> 
    












		                     					        	<p>  </p> 
    












		                     					        	<p><b>Media</b> <b>Contact</b><br> <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Amy Kenigsberg</span></span><br> K2 Global Communications<br> <a class=""linkOnClick"" data-include=""695002381"" href=""mailto:amy@k2-gc.com"" rel=""nofollow"">amy@k2-gc.com</a><br> +972-9-794-1681 (+2 GMT)<br> +1-913-440-4072 (+7 ET)<br> </p>  












		                     					        	<p> SOURCE NRGene </p> 












		                 </div>
  </div>
  </section>"
http://www.prnewswire.co.uk/news-releases/croma-pharma-gmbh-sets-the-course-for-entering-the-us-market-692472411.html,Croma-Pharma GmbH Sets the Course for Entering the US Market,"<section class=""release-body container  no-margin-bottom "" itemprop=""articleBody"">
    <div class=""row"">
                <div class=""col-sm-10 col-sm-offset-1"">
    	                   		 		 		 		 		 
		 		  		 	 					        	<p><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">VIENNA</span></span></span>, <span class=""xn-chron"">September 5, 2018</span> /PRNewswire/ --</p> 
    












		                     										        	<p><i>Croma</i><i>-Pharma GmbH (Croma) </i> <i>is establishing a joint ve</i><i>nture company with its long-time</i><i> partner Hugel, Inc.</i><i> to develop and commercialize botulinum toxin, HA filler and PDO thread products in US, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Canada</span></span></span>, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Australia</span></span></span> and <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">New Zealand</span></span></span>.</i> </p> 
    












		                     							        <!--startclickprintexclude-->
                <!--endclickprintexclude-->
          </div>
        </div>
		
        <!-- 0 --> 
                <div class=""row"">
          <div class=""col-sm-10 col-sm-offset-1"">
			      	<p>On <span class=""xn-chron"">Sept 5</span><sup>th</sup>, Croma has stated that the company is moving forward in its plan preparing a successful launch of its HA filler and PDO thread products on the US market.</p> 
    












                         					        	<p>The joint venture company will be established with Croma's Korean partner Hugel, Inc. Croma will be transferring its Botulax (Hugel´s botulinum toxin product) distribution rights for US, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Canada</span></span></span>, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Australia</span></span></span>, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">New Zealand</span></span></span>, and also the 100% shares of its <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Canada</span></span></span> and <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Australia</span></span></span> subsidiaries in exchange for 30% of the joint venture company. Hugel will invest <span class=""xn-money"">$90,000,000</span> in cash and future commitments and subscribe for equity representing 70% of the joint venture company. As a result of this transaction, the joint venture company will secure perpetual license to Croma's HA filler and PDO thread products and Hugel's botulinum toxin product in the aforementioned territories.  </p> 
    












		                     					        	<p>Said joint venture company will be in charge of developing and commercializing Croma's HA filler and PDO thread products and Hugel's Botulax product in the US, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Canada</span></span></span>, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Australia</span></span></span> and <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">New Zealand</span></span></span>, and spearheading all clinical, regulatory, and marketing operations in order to ensure successful entry of the above products in the territories. Additionally, the joint venture company will be collaborating with Croma for marketing activities in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Europe</span></span></span> for a successful launch.</p> 
    












		                     					        	<p>Croma's Managing Director, <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Andreas Prinz</span></span>, explained, ""By partnering with Hugel in these major aesthetic markets, we clear another hurdle in our international expansion process, while intensifying our relationship with Hugel. Both companies will certainly benefit from the experiences we make together in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">North America</span></span></span> and <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Australia</span></span></span>. Croma and Hugel will be moving closer together, based on mutual respect and trust.""</p> 
    












		                     					        	<p>Hugel's CEO, <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Jihoon Sohn</span></span>, stated, ""US is a huge market that currently accounts for the majority of the global botulinum toxin market."" He also added, ""We have taken the very first step of our global initiatives, and through it, we plan to further strengthen our global footprint with our long-term partner, Croma.""</p> 
    












		                     					        	<p><b><i>About Croma-Pharma GmbH</i></b><br> Founded in 1976, Croma-Pharma GmbH (Croma) is an Austrian family-owned company that specializes in the industrial production of hyaluronic acid syringes for the fields of medical aesthetics, ophthalmology and orthopaedics. Croma currently runs 12 international sales companies and distributes its products in more than 70 countries. Within its global sales network, Croma focuses with own branded products on minimally invasive aesthetic medicine. Besides a broad range of HA Fillers from the own production site, Croma markets PDO lifting threads, a Platelet Rich Plasma (PRP) system and a personalized skincare technology in its core strategic markets.</p> 
    












		                     					        	<p><b><i>About Hugel, Inc.</i></b><br> Hugel is a biopharmaceutical company developing and manufacturing botulinum toxin and HA filler products for use in not only medical aesthetic field, but also in medical therapeutic field. Hugel's botulinum toxin product, Botulax, is currently marketed in 26 countries worldwide. In addition, Botulax is expected to enter the world's largest markets such as US, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Europe</span></span></span>, and <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">China</span></span></span> soon. The Chaeum (Dermalax), Hugel's HA filler product, is currently exported to 14 countries and is expecting approvals in 6 additional countries, including <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">China</span></span></span>, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Brazil</span></span></span>, and <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Chile</span></span></span>.</p> 
    












		                     					        	<p>Contact<br> CROMA-PHARMA GmbH<br> Mag. Stefanie Höhn<br> Corporate Director Communications<br> Cromazeile 2<br> A-2100 Leobendorf<br> Phone .: +43-676-846-868-190<br> Mail: <a class=""linkOnClick"" data-include=""692472411"" href=""mailto:stefanie.hoehn@croma.at"" rel=""nofollow"">stefanie.hoehn@croma.at</a><br> Home: <a class=""linkOnClick"" data-include=""692472411"" target=""_blank"" href=""http://www.croma.at"" rel=""nofollow"">www.croma.at</a></p>  












		                     					        	<p> SOURCE Croma-Pharma GmbH </p> 












		                 </div>
  </div>
  </section>"
http://www.prnewswire.co.uk/news-releases/deneum-proves-feasibility-hypothesis-for-its-nuclear-fusion-power-station-concludes-1m-private-round-691932601.html,"Deneum Proves Feasibility Hypothesis for Its Nuclear Fusion Power Station, Concludes $1M Private Round","<section class=""release-body container  no-margin-bottom "" itemprop=""articleBody"">
    <div class=""row"">
                <div class=""col-sm-10 col-sm-offset-1"">
    	                   		 		 		 		 		 
		 		  		 	 					        	<p><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">TALLINN, Estonia</span></span></span>, <span class=""xn-chron"">August 28, 2018</span> /PRNewswire/ --</p> 
    












		                     													        <!--startclickprintexclude-->
                <!--endclickprintexclude-->
          </div>
        </div>
		
        <!-- 0 --> 
                <div class=""row"">
          <div class=""col-sm-10 col-sm-offset-1"">
			      	<p>Deneum, a company aiming to revolutionize global energy industry with the nuclear fusion Power Station, announced that it has successfully proved the feasibility hypothesis via its laboratory unit during the private demonstration. Deneum also concluded <span class=""xn-money"">$ 1M</span> during the private round first stage.<br> <br> Offering global market the Philosopher's stone of energy generation based on interaction between Titanium and Deuterium, Deneum has successfully concluded the first private demonstration of the Power Station laboratory unit. The demonstration held in Deneum R&amp;D laboratory in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Tallinn</span></span></span> implied the Power Station launch and main operating mode showcase. All the indicators including temperature fluctuation, pressure, vacuum density and others were measured and visually represented online via the public proprietary software provided by independent vendor.<br> <br> ""The main indicator of an appropriate interaction of the active body components within the Deneum Power Station is successful maintenance of a certain installation mode, in which amount of energy needed for launch, once consumed creates a thin level of resonance that implicates a self-sustaining reaction between titanium hydride and deuterium. This reaction is exothermic with a large amount of excess heat, which is then to some extent converted into electricity and partly used ""as is"" in the form of thermal energy.<br> We were able to achieve and maintain this effect during the demonstration. This makes it 63 successful feasibility tests in a row with this one carefully measured and documented, - comments Dmitry Samoylovskikh, Deneum CEO &amp; founder. - We're witnessing the largest particle physics breakthrough of the century, and Deneum team is very glad to make it happen"".<br> <br> The reaction produced by the active body components is self-sustaining, which means Power Station keeps on working without any further intervention once launched. Deuterium and Titanium worth <span class=""xn-money"">$20</span> installed into the Power Station can maintain a housing area of 100 sq. meters for up to 1 year with no need for recharge or additional service. This is an unprecedented level of energy efficiency beyond what any of the existing sources may offer, including traditional nuclear energy. The energy of Deneum Power Station is yet eco-friendly, renewable and radically cheap.<br> <br> Deneum team has successfully concluded the first stage of the ICO private round having raised <span class=""xn-money"">$ 1M</span>. The funding will be re-invested into further R&amp;D and Power Station G3 prototype development as well as deployment of Deneum own production line manufacturing the Power Station active body main components.<br> Deneum team is planning to conclude the second stage of the private sale round by the end of September aiming at <span class=""xn-money"">$ 2M</span> hard cap. The total funding to be raised during all stages of the ICO is estimated at <span class=""xn-money"">$ 90M</span>. </p>  












                         					        	<p> SOURCE Deneum </p> 












		                 </div>
  </div>
  </section>"
http://www.prnewswire.co.uk/news-releases/elsevier-closes-its-acquisition-of-aries-systems-692859071.html,Elsevier Closes its Acquisition of Aries Systems,"<section class=""release-body container  no-margin-bottom "" itemprop=""articleBody"">
    <div class=""row"">
                <div class=""col-sm-10 col-sm-offset-1"">
    	                   		 		 		 		 		 
		 		  		 	 					        	<p><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">NEW YORK</span></span></span>, <span class=""xn-chron"">September 10, 2018</span> /PRNewswire/ --</p> 
    












		                     										        	<p><a class=""linkOnClick"" data-include=""692859071"" target=""_blank"" href=""http://www.elsevier.com/"" rel=""nofollow"">Elsevier</a>, the global information analytics business specializing in science and health, today announced it has completed its acquisition of <a class=""linkOnClick"" data-include=""692859071"" target=""_blank"" href=""http://www.ariessys.com/"" rel=""nofollow"">Aries Systems</a>, a leader in scientific publication workflow solutions headquartered outside <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Boston, Massachusetts</span></span></span>. Aries' offerings are used by journals, books and other publications for manuscript submission, peer review, production tracking and eCommerce.</p> 
    












		                     							        <!--startclickprintexclude-->
                <!--endclickprintexclude-->
          </div>
        </div>
		
        <!-- 0 --> 
                <div class=""row"">
          <div class=""col-sm-10 col-sm-offset-1"">
			      	<p>""Elsevier's strategy is to unite content with technology to help our users and customers succeed and Aries will help us achieve that,"" said <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Dominic Feltham</span></span>, President Research, Elsevier. ""We admire the capabilities that Aries will bring to help us meet the evolving needs of our communities.""</p> 
    












                         					        	<p>The acquisition is in line with Elsevier's organic growth driven strategy, supported by acquisitions of innovative open science companies that are helping improve the research information ecosystem, following the acquisitions of Mendeley, SSRN, Plum Analytics and bepress.</p> 
    












		                     					        	<p>""Aries has always been committed to delivering solutions that help publishers, editors and scholars enhance the discovery and dissemination of knowledge, said <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Lyndon Holmes</span></span>, Aries' Founder. ""With Elsevier, Aries will be even stronger and better positioned with enhanced solutions and analytics to help our customers achieve their goals.""</p> 
    












		                     					        	<p><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Lyndon Holmes</span></span> provides more information on this announcement <a class=""linkOnClick"" data-include=""692859071"" target=""_blank"" href=""https://www.elsevier.com/connect/finding-the-best-long-term-home-for-aries-systems"" rel=""nofollow"">here</a> at Elsevier's online community, <i>Elsevier Connect</i>.</p> 
    












		                     					        	<p><b>About Elsevier</b> </p> 
    












		                     					        	<p><a class=""linkOnClick"" data-include=""692859071"" target=""_blank"" href=""https://www.elsevier.com/"" rel=""nofollow"">Elsevier</a> is a global information analytics business that helps institutions and professionals advance healthcare, open science and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&amp;D performance, clinical decision support and professional education, including <a class=""linkOnClick"" data-include=""692859071"" target=""_blank"" href=""https://www.elsevier.com/solutions/sciencedirect"" rel=""nofollow"">ScienceDirect</a>, <a class=""linkOnClick"" data-include=""692859071"" target=""_blank"" href=""https://www.elsevier.com/solutions/scopus"" rel=""nofollow"">Scopus</a>, <a class=""linkOnClick"" data-include=""692859071"" target=""_blank"" href=""https://www.elsevier.com/solutions/scival"" rel=""nofollow"">SciVal</a>, <a class=""linkOnClick"" data-include=""692859071"" target=""_blank"" href=""https://www.elsevier.com/solutions/clinicalkey"" rel=""nofollow"">ClinicalKey</a> and <a class=""linkOnClick"" data-include=""692859071"" target=""_blank"" href=""https://evolve.elsevier.com/education/sherpath/"" rel=""nofollow"">Sherpath</a>. Elsevier publishes over 2,500 digitized journals, including <a class=""linkOnClick"" data-include=""692859071"" target=""_blank"" href=""http://www.thelancet.com/"" rel=""nofollow""><i>The Lancet</i></a> and <a class=""linkOnClick"" data-include=""692859071"" target=""_blank"" href=""http://www.cell.com/"" rel=""nofollow""><i>Cell</i></a>, 38,000 e-book titles and many iconic reference works, including <a class=""linkOnClick"" data-include=""692859071"" target=""_blank"" href=""https://www.elsevier.com/books/grays-anatomy/standring/978-0-7020-5230-9"" rel=""nofollow""><i>Gray</i><i>'</i><i>s Anatomy</i></a>. Elsevier is part of <a class=""linkOnClick"" data-include=""692859071"" target=""_blank"" href=""http://www.relx.com/"" rel=""nofollow"">RELX Group</a>, a global provider of information and analytics for professionals and business customers across industries. <a class=""linkOnClick"" data-include=""692859071"" target=""_blank"" href=""https://www.elsevier.com/"" rel=""nofollow"">www.elsevier.com</a></p> 
    












		                     					        	<p><b>Media contact</b><br> <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Tom Reller</span></span>, Global Communications<br> Elsevier<br> <a class=""linkOnClick"" data-include=""692859071"" href=""mailto:t.reller@elsevier.com"" rel=""nofollow"">t.reller@elsevier.com</a><br> </p>  












		                     					        	<p> SOURCE Elsevier </p> 












		                 </div>
  </div>
  </section>"
http://www.prnewswire.co.uk/news-releases/cognitionx-secures-over-3-million-in-funding-for-its-new-ai-advice-platform-684674521.html,CognitionX Secures Over $3 Million in Funding for Its New AI Advice Platform,"<section class=""release-body container "" itemprop=""articleBody"">
    <div class=""row"">
                <div class=""col-sm-10 col-sm-offset-1"">
    	                   		 		 		 		 		 
		 		  		 	 					        	<p><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">LONDON</span></span></span>, <span class=""xn-chron"">June 6, 2018</span> /PRNewswire/ --</p> 
   <p style=""text-align: center""><i>Platform that connects organisations to AI experts and accelerate adoption is backed by a group of leading Angels including <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Brent Hoberman</span></span>, <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Esther Dyson</span></span>, <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Joanna Shields</span></span> and <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">William Tunstall-Pedoe</span></span> </i>  </p> 
    












		                     										        	<p><a class=""linkOnClick"" data-include=""684674521"" target=""_blank"" href=""https://cognitionx.com/"" rel=""nofollow"">CognitionX</a> has secured more than <span class=""xn-money"">$3 million</span> in funding for its newly-released AI advice platform, which connects organisations to a global on-demand network of AI experts including tech specialists, business people and academics.</p> 
    












		                     							        <!--startclickprintexclude-->
                <!--endclickprintexclude-->
          </div>
        </div>
		
        <!-- 1 --> 
                  <div class=""row"">
                                          	<!--PRNE Version C Format Assets Start-->
<div class=""container"">
	<div class=""row"">
		<div class=""col-sm-10 col-sm-offset-1"">
			<div class=""gallery inline-carousel"">
				<div class=""gallery-carousel-main"">
																<!-- assetC https://mma.prnewswire.com/media/702115/CognitionX_co_founders.jpg?w=1600  --- https://mma.prnewswire.com/media/702115/CognitionX_co_founders.jpg?p=publish  -->
						<!-- https://mma.prnewswire.com/media/702115/CognitionX_co_founders.jpg?w=1600  --- https://mma.prnewswire.com/media/702115/CognitionX_co_founders.jpg?p=publish -- https://mma.prnewswire.com/media/702115/CognitionX_co_founders.jpg?w=950 -- $item.sourceUrl -->

    							
  <!-- image -->						<div class=""gallery-cell"">
							<figure>
																									<div class=""image lightbox-item "" data-asset-type=""Photo"" data-asset-id=""CognitionX_co_founders.jpg"" data-asset-label="""" data-src=""https://mma.prnewswire.com/media/702115/CognitionX_co_founders.jpg?w=1600"" data-sub-html=""CognitionX co-founders Charlie Muirhead and Tabitha Goldstaub. (PRNewsfoto/CognitionX)"" data-tweet-text=""CognitionX co-founders Charlie Muirhead and Tabitha Goldstaub. (PRNewsfoto/CognitionX)"" data-facebook-share-text=""CognitionX co-founders Charlie Muirhead and Tabitha Goldstaub. (PRNewsfoto/CognitionX)"" data-linkedin-text=""CognitionX co-founders Charlie Muirhead and Tabitha Goldstaub. (PRNewsfoto/CognitionX)"" data-download-url=""https://mma.prnewswire.com/media/702115/CognitionX_co_founders.jpg?w=1600"" data-pinterest-text=""CognitionX co-founders Charlie Muirhead and Tabitha Goldstaub. (PRNewsfoto/CognitionX)"" data-twitter-share-url=""https://mma.prnewswire.com/media/702115/CognitionX_co_founders.jpg?w=1600&amp;p=twitter"" data-linkedin-share-url=""https://mma.prnewswire.com/media/702115/CognitionX_co_founders.jpg?w=1600&amp;p=linkedin"" data-facebook-share-url=""https://mma.prnewswire.com/media/702115/CognitionX_co_founders.jpg?w=1600&amp;p=facebook"" data-pinterest-share-url=""https://mma.prnewswire.com/media/702115/CognitionX_co_founders.jpg?w=1600&amp;p=publish"" onclick=""omniture_corousal('Carousel lightbox Page','Photo Open','CognitionX_co_founders.jpg','')"">
  	  <img src=""https://mma.prnewswire.com/media/702115/CognitionX_co_founders.jpg?w=950"" id=""imageid_2"" alt=""CognitionX co-founders Charlie Muirhead and Tabitha Goldstaub. (PRNewsfoto/CognitionX)"" class=""gallery-thumb img-responsive"" rel=""newsImage"">
</div>
																								<figcaption>
									CognitionX co-founders Charlie Muirhead and Tabitha Goldstaub. (PRNewsfoto/CognitionX)
								</figcaption>
															</figure>
						</div>
									</div>
							</div>
							<!-- image -->									</div>
	</div>
</div>
 <!--PRNE Version C Format Assets End-->
                              </div>
                <div class=""row"">
          <div class=""col-sm-10 col-sm-offset-1"">
			      	<p>     (Photo: <a class=""linkOnClick"" data-include=""684674521"" target=""_blank"" href=""https://mma.prnewswire.com/media/702115/CognitionX_co_founders.jpg"" rel=""nofollow"">https://mma.prnewswire.com/media/702115/CognitionX_co_founders.jpg</a> )<br> </p> 
    












                         					        	<p>The seven-figure investment comes from a range of leading figures in the technology community. Key investors include: <a class=""linkOnClick"" data-include=""684674521"" target=""_blank"" href=""https://twitter.com/brenthoberman?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor"" rel=""nofollow""><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Brent Hoberman CBE</span></span></a>, Executive Chairman at Founders Factory, Co-Founder and Non-Executive Director at MADE.COM, Executive Chairman at firstminute capital and Co-Founder of lastminute.com, start-up investor <a class=""linkOnClick"" data-include=""684674521"" target=""_blank"" href=""https://twitter.com/edyson?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor"" rel=""nofollow""><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Esther Dyson</span></span></a> who focuses on healthcare technology. <a class=""linkOnClick"" data-include=""684674521"" target=""_blank"" href=""https://www.joannashields.com/"" rel=""nofollow""><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Joanna Shields</span></span></a>, Group CEO of BenevolentAI, a leader in the use of AI for scientific discovery, who previously served as the UK's first Minister for Internet Safety and Security, former Trade Secretary and entrepreneur <a class=""linkOnClick"" data-include=""684674521"" target=""_blank"" href=""https://twitter.com/thelordyoung?lang=en"" rel=""nofollow"">Lord Young</a> and <a class=""linkOnClick"" data-include=""684674521"" target=""_blank"" href=""http://www.williamtp.com/"" rel=""nofollow""><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">William Tunstall-Pedoe</span></span></a>, whose Evi business was acquired by Amazon and used to create Alexa.</p> 
    












		                     					        	<p>By using CognitionX to privately ask a question, select an expert and get on-demand answers tailored to them, organisations will save the time and money that is often poured into scouring the web, looking internally and employing consultancies.</p> 
    












		                     					        	<p>The first release focuses on the use of AI to transform HR and Recruitment, tracking over 350 software vendors. With expansion into other areas including chatbots and financial services already planned, CognitionX will help organisations form their plans across all departments, make decisions about the use of AI, and accelerate their speed of implementation. This direct connection to scarce on-demand AI knowledge is set to transform and grow the current technology consulting market, which has always charged for access to their expertise and advice.</p> 
    












		                     					        	<p>""AI is at the point where organisations need to define their strategy and start deployment, not in 10 years, but right now,"" said <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Charlie Muirhead</span></span>, CEO and Founder of CognitionX. ""We want to transform the way knowledge and expert advice is accessed. Web search has many merits, but organisations need advice specific to their needs across departments. Sometimes they may even have the expertise internally, but often end up turning to consultancies for this.""</p> 
    












		                     					        	<p>""What they really want is ad hoc questions from anyone across the organisation answered by experts, at the time they choose. CognitionX's AI advice platform will not only give them  access to the experts on our network and directory of products, but also their own internal experts, dramatically reducing the time and cost of moving their AI plans forward. The platform launches with comprehensive coverage of HR and growth from there.""</p> 
    












		                     					        	<p>The CognitionX AI Advice Platform, available free of use to organisations and experts, is in alpha release now and available to all. It is expected to go into beta <span class=""xn-chron"">September 2018</span>. From today, users will get access to the Directory of HR AI products and services, the expert network, daily news and smart alerts.</p> 
    












		                     					        	<p>The premium ""Pro"" subscription of £100 per month is also available now. Pro users receive the added benefit of analytics, deep market insight and priority access to events including <a class=""linkOnClick"" data-include=""684674521"" target=""_blank"" href=""https://cogx.co/"" rel=""nofollow"">CogX</a>, the annual festival of AI. <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">London</span></span></span>-based CogX 2018 will welcome over 4,500 confirmed attendees (expecting up to 6,000) and 300 speakers on <span class=""xn-chron"">June 11-12</span>, making it one of the world's largest AI gatherings. <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Joanna Shields</span></span> will deliver CogX 2018's opening keynote. An ""Enterprise"" version of the platform for large organisations is also in development.</p> 
    












		                     					        	<p>""We have a unique opportunity to catalyse adoption of artificial intelligence in the UK,"" added <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Tabitha Goldstaub</span></span>, Co-Founder of CognitionX. ""Our platform helps to remove the barriers to deployment, by reducing the time it takes to make decisions and find the right AI services to use. As industry and government gain more confidence in implementing AI, we will see the technology adopted more often and more successfully. As long as the challenging ethical considerations are understood, AI is designed responsibly, and the benefits fairly distributed, this will lead to a brighter future for the country.""</p> 
    












		                     					        	<p><b>About CognitionX</b> </p> 
    












		                     					        	<p>CognitionX is the AI Advice Platform that connects organisations with a global on-demand network of AI experts. The platform allows experts in AI from the around the world to share invaluable expertise with organisations of any size and sector who want to tap into that knowledge.</p> 
    












		                     					        	<p>Through the platform, organisations can find an answer to their AI question very quickly, regardless of where they are. AI experts can either share knowledge for free or charge a fee.</p> 
    












		                     					        	<p>Founded in 2015 CognitionX's mission is to bring clarity to, and accelerate adoption of, AI across all organisations from global enterprises to startups, and help ensure a safe and responsible transition to an AI-driven society. Through its freemium model, CognitionX's expert network helps level the playing field, by making scarce AI expertise accessible to all, and provide a new way for experts to monetise their knowledge.</p> 
    












		                     					        	<p><u><a class=""linkOnClick"" data-include=""684674521"" target=""_blank"" href=""https://cognitionx.com/"" rel=""nofollow"">https://cognitionx.com/</a></u> </p> 
    












		                     					        	<p><u><a class=""linkOnClick"" data-include=""684674521"" target=""_blank"" href=""https://twitter.com/cognition_x"" rel=""nofollow"">@cognition_x</a></u>  </p> 
    












		                     					        	<p><u><a class=""linkOnClick"" data-include=""684674521"" target=""_blank"" href=""https://www.linkedin.com/company/cognitionx/"" rel=""nofollow"">https://www.linkedin.com/company/cognitionx/</a></u> </p>  












		                     					        	<p> SOURCE CognitionX </p> 












		                 </div>
  </div>
  </section>"
http://www.prnewswire.co.uk/news-releases/williams-and-unipart-launch-vehicle-battery-joint-venture-692929421.html,Williams and Unipart Launch Vehicle Battery Joint Venture,"<section class=""release-body container  no-margin-bottom "" itemprop=""articleBody"">
    <div class=""row"">
                <div class=""col-sm-10 col-sm-offset-1"">
    	                   		 		 		 		 		 
		 		  		 	 					        	<p><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">COVENTRY, England</span></span></span>, <span class=""xn-chron"">Sept. 11, 2018</span> /PRNewswire/ --</p> 
    












		                     										        	 				<ul type=""disc"">
    <li><b>Hyperbat Limited is a Williams Advanced Engineering and Unipart Manufacturing Group joint venture</b> </li>
    <li><b><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Coventry</span></span></span> site to open in early 2019, creating around 90 new, high-value, high-tech jobs</b> </li>
    <li><b>First customer is Aston Martin</b></li>
   </ul>  
   













		                     							        <!--startclickprintexclude-->
                <!--endclickprintexclude-->
          </div>
        </div>
		
        <!-- 0 --> 
                <div class=""row"">
          <div class=""col-sm-10 col-sm-offset-1"">
			      	<p>To download a broadcast quality CGI fly-through video of the Hyperbat Limited factory click <a class=""linkOnClick"" data-include=""692929421"" href=""https://vimeo.com/288754671/7b72a71d80"" rel=""nofollow"" target=""_blank"">here</a>.</p> 
    












                         					        	<p>The UK's largest independent vehicle battery manufacturer will open in early 2019 in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Coventry</span></span></span>, creating around ninety new jobs, at a new, multi-million pound, high-tech facility that will produce batteries for future hybrid and electric vehicles.</p> 
    












		                     					        	<p>The factory will be operated by a new joint venture, also unveiled today and named <a class=""linkOnClick"" data-include=""692929421"" href=""http://www.hyperbat.com/"" rel=""nofollow"" target=""_blank"">Hyperbat Limited</a> (Hyperbat), combining the strengths of two of the UK's leading companies, Williams Advanced Engineering and Unipart Manufacturing Group. The move has been welcomed by the Secretary of State for Business, Energy and Industrial Strategy as a significant step forward in the UK's contribution to reducing carbon emissions.</p> 
    












		                     					        	<p>The new company and factory combine world-leading expertise in manufacturing, logistics and safe, innovative, high performance vehicle battery technology from Unipart and Williams. The facility provides a secure future supply chain for UK-based car-makers as their vehicles transition to electric power, with the potential to provide similar solutions to developing marine and aircraft projects in future. Following construction, Hyperbat will begin production at the site in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Coventry</span></span></span> in early 2019.  The launch customer for Hyperbat batteries is the Aston Martin Rapide E, which will be a limited production run.</p> 
    












		                     					        	<p>""Hybrid and electric vehicles will play a key part in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Britain's</span></span></span> cleaner and greener future and this new high-tech facility – inspired by a government funded Advanced Propulsion Centre project - will develop new vehicle battery technologies and create high-skilled jobs in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Coventry</span></span></span>,"" said Business Secretary <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Greg Clark</span></span>.  ""Through the Industrial Strategy, the government is building on our world leading strengths in auto manufacturing and clean growth, making the UK the go-to place for these technologies and boosting the economic opportunities presented by our transition to a low-carbon economy.""</p> 
    












		                     					        	<p>Williams Advanced Engineering has years of experience electrifying vehicles, from powering all the cars on the grid of the ABB FIA Formula E championship in rugged and competitive conditions to projects as varied as the Vanda Electrics Dendrobium electric hypercar and Jaguar Vector Racing world speed record-breaking electric boat. In <span class=""xn-chron"">April 2018</span> Williams Advanced Engineering won the Queen's Award for Enterprise in the Innovation category for its work translating learning from the Formula E battery project into commercial applications.</p> 
    












		                     					        	<p>Unipart is well-known for its expertise in automotive manufacturing, logistics and supply. It will use its manufacturing and technological expertise to produce this more environmentally-progressive equipment to fuel the future of road transport. Unipart will convert a century-old building, which most recently produced vehicle exhausts, to produce more environmentally-friendly equipment to power the future of road transport.</p> 
    












		                     					        	<p>""Today marks a proud day as we bring together two innovative companies to deliver cutting edge technology that will literally power the future of sustainable transport in the UK and beyond,"" said <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Craig Wilson</span></span>, Managing Director of Williams Advanced Engineering. ""We are pleased to be working with Unipart, growing a new capability for our sector in this country for hybrid and electric vehicles, securing the on-shore supply chain for the long-term.  Hyperbat will also deliver into high performance battery applications beyond automotive, delivering innovative technology and high value manufacturing, as well as jobs for the next generation workforce.""</p> 
    












		                     					        	<p><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Carol Burke</span></span>, Managing Director of Unipart Manufacturing Group, said: ""We are delighted to be working with Williams Advanced Engineering on this venture.  We have developed an advanced manufacturing facility on our <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Coventry</span></span></span> site – the very site in which the British auto industry produced some of its first petrol vehicles.  It is fitting that this site will now provide clean, sustainable electric batteries that can be tailored to individual auto manufacturer's requirements and available to a wide range of companies seeking to introduce electric vehicles into their ranges.""</p> 
    












		                     					        	<p>The joint venture was inspired by H1PERBAT - an Advanced Propulsion Centre (APC)-funded, <a class=""linkOnClick"" data-include=""692929421"" href=""https://www.williamsf1.com/advanced-engineering/news/2017/04/williams-advanced-engineering-led-consortium-wins-apc-support-for-uk-battery-build-facility"" rel=""nofollow"" target=""_blank"">Williams Advanced Engineering-led consortium of organisations</a>, set up in 2017, which also includes Unipart, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Coventry</span></span></span> University, Aston Martin and others.  It was established to build a high performance, low volume, flexible battery capability in the UK.  The joint venture will also draw on work undertaken by H1PERBAT, which also looked at second life options for car batteries, enabling a long-term sustainable future for the products in both the vehicles and beyond.</p> 
    












		                     					        	<p>The products from the facility will meet global vehicle battery standards, including ISO26262 from the outset.  An example will be exhibited on the Williams Advanced Engineering stand at the <a class=""linkOnClick"" data-include=""692929421"" href=""https://www.cenex-lcv.co.uk/"" rel=""nofollow"" target=""_blank"">Cenex Low Carbon Vehicles Show</a> (Hall3 stand 602) from 12-13 of September.  Williams personnel will also be on the UK's <a class=""linkOnClick"" data-include=""692929421"" href=""https://www.apcuk.co.uk/article/apc-champion-british-innovation-usa/"" rel=""nofollow"" target=""_blank"">Advanced Propulsion Centre stand</a> at the Battery Show in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Novi, Michigan</span></span></span>, USA from 11-13 September to brief industry executives on Hyperbat Limited and its capabilities to power future electric vehicles.</p> 
    












		                     					        	<p>The factory will open in early 2019 at the Unipart site in Beresford Avenue, which also houses the Institute for Advanced Manufacturing and Engineering (AME), a partnership between Unipart and Coventry University.  The AME will develop the skills and capabilities for the future, both for Hyperbat and for the broader electric vehicle supply chain.</p> 
    












		                     					        	<p>Burke continued: ""Using some of the most advanced manufacturing capabilities in this field, Hyperbat's production facilities will be highly adaptable to meet the changing requirements of future demands, while also addressing opportunities from non-automotive sectors looking to introduce sustainable propulsion into their product ranges.""</p> 
    












		                     					        	<p>A site opening event will take place in early 2019 for stakeholders and customers ahead of construction, with production at the facility getting under way in Q1 2019.  Additional customers for Hyperbat will be announced in due course.</p> 
    












		                     					        	<p><b>Contact</b> – <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Matthew Knowles</span></span>, +44(0)7483-016-079, <a class=""linkOnClick"" data-include=""692929421"" href=""mailto:matthew.knowles@williamsf1.com"" rel=""nofollow"" target=""_blank"">matthew.knowles@williamsf1.com</a></p> 
    












		                     					        	<p> </p>  












		                     					        	<p> SOURCE Unipart </p> 












		                   <h4>Related Links</h4>
     <p>
                            		<a title=""Link to http://www.hyperbat.com/"" href=""http://www.hyperbat.com/"" class=""linkOnClick"" data-include=""692929421"" rel=""nofollow"" target=""_blank"">http://www.hyperbat.com/</a><br>
      	   </p></div>
  </div>
  </section>"
http://www.prnewswire.co.uk/news-releases/oxygen-vs-nanochip-scientists-show-the-vulnerability-of-a-promising-two-dimensional-semiconductor-to-694342781.html,"Oxygen vs. Nanochip: Scientists Show the Vulnerability of a Promising Two-Dimensional Semiconductor to Air, and Discover New Catalyst","<section class=""release-body container "" itemprop=""articleBody"">
    <div class=""row"">
                <div class=""col-sm-10 col-sm-offset-1"">
    	                   		 		 		 		 		 
		 		  		 	 					        	<p><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">MOSCOW</span></span></span>, <span class=""xn-chron"">September 26, 2018</span> /PRNewswire/ --</p> 
    












		                     													        <!--startclickprintexclude-->
                <!--endclickprintexclude-->
          </div>
        </div>
		
        <!-- 1 --> 
                  <div class=""row"">
                                          	<!--PRNE Version C Format Assets Start-->
<div class=""container"">
	<div class=""row"">
		<div class=""col-sm-10 col-sm-offset-1"">
			<div class=""gallery inline-carousel"">
				<div class=""gallery-carousel-main"">
																<!-- assetC https://mma.prnewswire.com/media/749456/NUST_MISiS_MoS2.jpg?w=1600  --- https://mma.prnewswire.com/media/749456/NUST_MISiS_MoS2.jpg?p=publish  -->
						<!-- https://mma.prnewswire.com/media/749456/NUST_MISiS_MoS2.jpg?w=1600  --- https://mma.prnewswire.com/media/749456/NUST_MISiS_MoS2.jpg?p=publish -- https://mma.prnewswire.com/media/749456/NUST_MISiS_MoS2.jpg?w=950 -- $item.sourceUrl -->

    							
  <!-- image -->						<div class=""gallery-cell"">
							<figure>
																									<div class=""image lightbox-item "" data-asset-type=""Photo"" data-asset-id=""NUST_MISiS_MoS2.jpg"" data-asset-label="""" data-src=""https://mma.prnewswire.com/media/749456/NUST_MISiS_MoS2.jpg?w=1600"" data-sub-html=""Pic.1 Left - an experimental image of MoS2 with defects resulting from environmental exposure (obtained by scanning tunneling microscope STM), middle – the results of the simulation of the STM image, right – the model of the layer’s atomic structure. (PRNewsfoto/NUST MISiS)"" data-tweet-text=""Pic.1 Left - an experimental image of MoS2 with defects resulting from environmental exposure (obtained by scanning tunneling microscope STM), middle – the results of the simulation of the STM image, right – the model of the layer’s atomic structure. (PRNewsfoto/NUST MISiS)"" data-facebook-share-text=""Pic.1 Left - an experimental image of MoS2 with defects resulting from environmental exposure (obtained by scanning tunneling microscope STM), middle – the results of the simulation of the STM image, right – the model of the layer’s atomic structure. (PRNewsfoto/NUST MISiS)"" data-linkedin-text=""Pic.1 Left - an experimental image of MoS2 with defects resulting from environmental exposure (obtained by scanning tunneling microscope STM), middle – the results of the simulation of the STM image, right – the model of the layer’s atomic structure. (PRNewsfoto/NUST MISiS)"" data-download-url=""https://mma.prnewswire.com/media/749456/NUST_MISiS_MoS2.jpg?w=1600"" data-pinterest-text=""Pic.1 Left - an experimental image of MoS2 with defects resulting from environmental exposure (obtained by scanning tunneling microscope STM), middle – the results of the simulation of the STM image, right – the model of the layer’s atomic structure. (PRNewsfoto/NUST MISiS)"" data-twitter-share-url=""https://mma.prnewswire.com/media/749456/NUST_MISiS_MoS2.jpg?w=1600&amp;p=twitter"" data-linkedin-share-url=""https://mma.prnewswire.com/media/749456/NUST_MISiS_MoS2.jpg?w=1600&amp;p=linkedin"" data-facebook-share-url=""https://mma.prnewswire.com/media/749456/NUST_MISiS_MoS2.jpg?w=1600&amp;p=facebook"" data-pinterest-share-url=""https://mma.prnewswire.com/media/749456/NUST_MISiS_MoS2.jpg?w=1600&amp;p=publish"" onclick=""omniture_corousal('Carousel lightbox Page','Photo Open','NUST_MISiS_MoS2.jpg','')"">
  	  <img src=""https://mma.prnewswire.com/media/749456/NUST_MISiS_MoS2.jpg?w=950"" id=""imageid_3"" alt=""Pic.1 Left - an experimental image of MoS2 with defects resulting from environmental exposure (obtained by scanning tunneling microscope STM), middle – the results of the simulation of the STM image, right – the model of the layer’s atomic structure. (PRNewsfoto/NUST MISiS)"" class=""gallery-thumb img-responsive"" rel=""newsImage"">
</div>
																								<figcaption>
									Pic.1 Left - an experimental image of MoS2 with defects resulting from environmental exposure (obtained by scanning tunneling microscope STM), middle – the results of the simulation of the STM image, right – the model of the layer’s atomic structure. (PRNewsfoto/NUST MISiS)
								</figcaption>
															</figure>
						</div>
									</div>
							</div>
							<!-- image -->									</div>
	</div>
</div>
 <!--PRNE Version C Format Assets End-->
                              </div>
                <div class=""row"">
          <div class=""col-sm-10 col-sm-offset-1"">
			      	<p><b>For the first time ever, an international team of </b> <b>scientists</b><b> from NUST MISIS, </b> <b>the </b> <b>Hungarian Academy of Sciences, </b> <b>the </b> <b>University of Namur (<span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Belgium</span></span></span>), </b> <b>and </b> <b>Korea Research Institute</b><b> for Standards &amp; Science</b><b> has</b><b> managed to trace in detail the </b> <b>structural changes</b><b> of two-dimensional molybdenum disulfide under long-term environmental impact. </b> <b>The new data narrow</b><b>s</b><b> the scope of its potential application in microelec</b><b>tronics and at the same time </b> <b>open</b><b>s</b><b> up new prospects for the use of</b><b> two-dimensional materials as </b> <b>catalyst</b><b>s</b><b>. </b> <b>The research results have been published in </b> <b>the </b> <b>international scientific journal</b> <a class=""linkOnClick"" data-include=""694342781"" target=""_blank"" href=""https://www.nature.com/articles/s41557-018-0136-2"" rel=""nofollow""><b>Nature Chemistry.</b></a></p> 
    












                         					        	<p>     (Photo: <a class=""linkOnClick"" data-include=""694342781"" target=""_blank"" href=""https://mma.prnewswire.com/media/749456/NUST_MISiS_MoS2.jpg"" rel=""nofollow"">https://mma.prnewswire.com/media/749456/NUST_MISiS_MoS2.jpg</a> )<br>      (Logo: <a class=""linkOnClick"" data-include=""694342781"" target=""_blank"" href=""http://mma.prnewswire.com/media/484501/NUST_MISIS_Logo.jpg"" rel=""nofollow"">http://mma.prnewswire.com/media/484501/NUST_MISIS_Logo.jpg</a> )<br> </p> 
    












		                     					        	<p>Molybdenum disulfide (MoS<sub>2</sub>) is considered a promising basis for a variety of ultra-small electronic devices such as high-frequency detectors, rectifiers, and transistors, so research teams around the world are actively studying its two-dimensional format, nanofilm. However, the new research conducted by NUST MISIS scientists has demonstrated that when this two-dimensional material is significantly oxidized in air, it turns into another connection.</p> 
    












		                     					        	<p>Any electronic device using MoS<sub>2,</sub> without proper protection would simply stop working relatively quickly. To potentially use MoS<sub>2</sub> in microelectronics, the devices would have to be encapsulated.</p> 
    












		                     					        	<p><i>""</i><i>For the first time ever, we have managed to experimentally </i> <i>prove </i> <i>that a single-layer molybdenum disulfide </i> <i>strongly degrades </i> <i>under environmental conditions</i><i>, oxidizing and turning</i><i> into a solid solution </i> <i>MoS</i><i><sub>2-x</sub></i><i>O</i><i><sub>x</sub></i>. <i>The </i> <i>functions</i><i> of a two-dimensional semiconductor without defects and losses can be </i> <i>implemented</i><i> </i> <i>with</i><i> molybdenum diselenides, another material with a similar structure</i><i>,</i><i>""</i> said <b><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Pavel Sorokin</span></span>,</b><b> head of</b><b> the research team and</b><b> leading researcher at the NUST MISIS Laboratory of Inorganic Nanomaterials. </b></p> 
    












		                     					        	<p>In the experiments, two-dimensional layers of molybdenum disulfide obtained as a result of the stratification of molybdenum disulfide crystals by ultrasound, were maintained in environmental conditions at normal room temperature and lighting for long periods (more than a year and a half), during which scientists observed the changes in the structure of its surface.</p> 
    












		                     					        	<p><i>""</i><i>Thanks to </i> <i>the </i> <i>use of </i> <i>tunnel</i><i>ing</i><i> microscopy, we were able to track the structural changes of crystals of two-dimensional sulfur disulfide at the atomic </i> <i>level during long-term </i> <i>exposure</i><i> </i> <i>to</i><i> </i> <i>environmental conditions. </i> <i>We have </i> <i>discovered</i><i> that the material previously considered stable is </i> <i>actually </i> <i>subject to spontaneous oxidation, </i> <i>but at the same time, </i> <i>the original crystal structure of </i> <i>MoS</i><i><sub>2</sub></i><i> </i> <i>monolayers</i><i> retains</i><i> formations of</i><i> </i> <i>MoS</i><i><sub>2-x</sub></i><i>O</i><i><sub>x</sub></i><i> solid solutions</i><i>. </i> <i>Our simulations have allowed </i> <i>us </i> <i>to pro</i><i>pose a mechanism of forming</i><i> such solid solutions, and the results of </i> <i>the </i> <i>theoret</i><i>ical calculations are in complete</i><i> agreement with </i> <i>our </i> <i>experimental measurements,</i><i>""</i> - said <b><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Zakhar Popov</span></span>, one of </b> <b>the co-authors of the study and </b> <b>a</b><b> senior researcher at the NUST MISIS Laboratory of Inorganic Nanomaterials. </b></p> 
    












		                     					        	<p><i>""</i><i>The </i> <i>study</i><i>'</i><i>s second key discovery is the new material that </i> <i>the monolayer of the molybdenum disulfide turns </i> <i>into </i> <i>is a</i><i> two-dimensional crystal</i><i> of a solid solution MoS</i><i><sub>2-x</sub></i><i>O</i><i><sub>x</sub></i><i><sub>,</sub></i><i> which is an effective catalyst for electromechanical processes</i><i>,""</i> <b>concluded Sorokin.</b></p>  












		                     					        	<p> SOURCE National University of Science and Technology MISiS </p> 












		                 </div>
  </div>
  </section>"
http://www.prnewswire.co.uk/news-releases/microland-positioned-as-a-major-contender-and-star-performer-in-everest-groups-peak-matrix-for-solutions-it-infrastructure-services-automation-2018-694357541.html,Microland Positioned as a Major Contender and Star Performer in Everest Group's PEAK Matrix™ for Solutions: IT Infrastructure Services Automation 2018,"<section class=""release-body container  no-margin-bottom "" itemprop=""articleBody"">
    <div class=""row"">
                <div class=""col-sm-10 col-sm-offset-1"">
    	                   		 		 		 		 		 
		 		  		 	 					        	<p><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">BANGALORE, India</span></span></span>, <span class=""xn-chron"">September 26, 2018</span> /PRNewswire/ --</p> 
    












		                     										        	<p>Microland, a <a class=""linkOnClick"" data-include=""694357541"" target=""_blank"" href=""https://www.microland.com/digital-acceleration"" rel=""nofollow"">Digital Accelerator</a>, today announced that it has been positioned as a 'Major Contender' and 'Star Performer' in Everest Group's PEAK Matrix<sup>™</sup> for Solutions: IT Infrastructure Services Automation 2018.</p> 
    












		                     							        <!--startclickprintexclude-->
                <!--endclickprintexclude-->
          </div>
        </div>
		
        <!-- 0 --> 
                <div class=""row"">
          <div class=""col-sm-10 col-sm-offset-1"">
			      	<p>     (Logo: <a class=""linkOnClick"" data-include=""694357541"" target=""_blank"" href=""https://mma.prnewswire.com/media/717242/Microland_Logo.jpg"" rel=""nofollow"">https://mma.prnewswire.com/media/717242/Microland_Logo.jpg</a> )<br> <br> As a part of this assessment, Everest Group analyzed 20 leading service providers on a combination of analyst assessment and feedback, collated from client interviews. The PEAK Matrix is a composite framework that provides an objective, data-driven, and comparative assessment of IT services automation providers based on their vision &amp; capability and market impact.</p> 
    












                         					        	<p><a class=""linkOnClick"" data-include=""694357541"" target=""_blank"" href=""https://www.microland.com/insights/analyst-insights/everest-group-peak-matrix-for-solutions-it-infrastructure-services-automation-2018"" rel=""nofollow"">(Click here to access the report)</a></p> 
    












		                     					        	<p>The 'Star Performer' status, which based on the greatest positive relative year-on-year movement, is a validation of the company's focus on intelligent automation as a key driver of digital transformation in Client ecosystems. Microland has built intelligent, deep analytics driven automation platform that enables zero touch operations for all components of IT infrastructure - networks, cloud, data center, and end-user computing. It focuses on ensuring minimal human intervention across all stages of IT infra life cycle - assessment, deployment/migration, management, and ROI measurement.</p> 
    












		                     					        	<p><b>""</b>We are excited to be included second time in a row in the Everest Group PEAK Matrix for Automation. Our improved positioning in the 2018 report is a clear testimony of Microland's investments towards enhancing predictability of operations using analytics and automation leading to improved ROI from IT investments and higher customer satisfaction. We have focused on building a comprehensive <a class=""linkOnClick"" data-include=""694357541"" target=""_blank"" href=""https://www.microland.com/edge/differentiators"" rel=""nofollow"">Automation suite</a>, with AI, Analytics and Machine learning as its backbone, that caters holistically to the Digital needs of enterprise clients,"" said <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Sharad Heda</span></span>, Chief of Staff, Microland Limited.</p> 
    












		                     					        	<p>""Driven by digitalization, the IT infrastructure services landscape is undergoing a significant shift with the primary focus changing from cost efficiency to digital enablement. Microland has made credible investments in developing in-house automation platforms and solutions focused on addressing the digital requirements of clients. In addition to investments in tools and technologies, its ability to drive high satisfaction levels among clients; flexibility in addressing client needs; proactive approach in showcasing innovation; and agile implementation methodologies have enabled Microland to position itself as a Major Contender and Star Performer,"" said Chirajeet Sengupta, Partner, Information Technology Services at Everest Group.</p> 
    












		                     					        	<p><b>About Microland:</b> </p> 
    












		                     					        	<p>Microland accelerates the digital transformation journey for global enterprises enabling them to deliver high-value business outcomes to their clients. Headquartered in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Bangalore, India</span></span></span>, Microland has more than 3,800 professionals across its offices in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Australia</span></span></span>, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Europe</span></span></span>, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">India</span></span></span>, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Middle East</span></span></span> and North America. Microland enables global enterprises to become more agile and innovative by integration of emerging technologies and the application of automation, analytics and predictive intelligence to their business processes.</p> 
    












		                     					        	<p>For more info: <a class=""linkOnClick"" data-include=""694357541"" target=""_blank"" href=""http://www.microland.com"" rel=""nofollow"">http://www.microland.com</a></p> 
   <br>  












		                     					        	<p> SOURCE Microland </p> 












		                 </div>
  </div>
  </section>"
http://www.prnewswire.co.uk/news-releases/cqc-and-jsr-corp-issue-statement-on-their-quantum-computing-project-695122901.html,CQC and JSR Corp. Issue Statement on Their Quantum Computing Project,"<section class=""release-body container  no-margin-bottom "" itemprop=""articleBody"">
    <div class=""row"">
                <div class=""col-sm-10 col-sm-offset-1"">
    	                   		 		 		 		 		 
		 		  		 	 					        	<p><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">CAMBRIDGE, England</span></span></span>, <span class=""xn-chron"">October 4, 2018</span> /PRNewswire/ --</p> 
   <p style=""text-align: center""><b><i>Results signal </i></b> <b><i>important </i></b> <b><i>advances in</i></b><b><i> the commercialization of</i></b><b><i> Quantum Chemistry</i></b><b><i> applications</i></b> </p> 
    












		                     										        	<p>Cambridge Quantum Computing (""CQC"") is pleased to announce that following extensive experimentation and joint collaboration with JSR Corporation (""JSR""), in a project that commenced in Q3 2017, they have successfully implemented state-of-the-art quantum algorithms to calculate the excited states of molecules that take into account multi-reference characteristics.</p> 
    












		                     							        <!--startclickprintexclude-->
                <!--endclickprintexclude-->
          </div>
        </div>
		
        <!-- 0 --> 
                <div class=""row"">
          <div class=""col-sm-10 col-sm-offset-1"">
			      	<p>Quantum chemistry is seen as the first real-world application of quantum computing, where new computational methods can achieve results in the design and discovery of new materials that has not, until now, been possible. Successfully implementing quantum algorithms that account for multi-reference states represents, for the first time, a new advance in building a solid foundation for the simulation of more complex quantum chemistry applications, and move from merely experimental and theoretical use cases for quantum computing to actual real-world applications that have the potential to affect society in fundamental and profound ways. This quantum application therefore means that chemical and pharmaceutical companies and anyone who is interested in new material discovery now has a practical way to work with quantum computers that is not merely theoretical in scope.</p> 
    












                         					        	<p>CQC and JSR are part of the IBM Q Network, and further advanced work will continue with the implementation of CQC's quantum chemistry application on the state of-the-art quantum processor that IBM has developed. The quantum algorithms required for these tests are being designed to be seamlessly compatible with the <a class=""linkOnClick"" data-include=""695122901"" target=""_blank"" href=""https://qiskit.org/"" rel=""nofollow"">Qiskit</a> open-source quantum computing framework and have benefitted in their development by experiments that were implemented and tested on IBM's 16 qubit quantum computer in the <a class=""linkOnClick"" data-include=""695122901"" target=""_blank"" href=""https://quantumexperience.ng.bluemix.net/qx/experience"" rel=""nofollow"">IBM Q Experience</a>. This compatibility has been made possible due to the partnership between CQC and JSR with scientists from IBM, and is being implemented using a quantum compiler that is part of t|ket&gt; (CQC's proprietary and platform agnostic software stack and user interface).</p> 
    












		                     					        	<p><u><b>About Cambridge Quantum Computing</b></u> </p> 
    












		                     					        	<p>Established in 2014, Cambridge Quantum Computing (CQC) is a world leading independent quantum computing company combining expertise in Quantum Information Processing, Quantum Technologies, Artificial Intelligence, Quantum Chemistry, Optimisation and Pattern Recognition. CQC design solutions that will benefit from quantum computing even in its earliest forms.</p> 
    












		                     					        	<p>For more information about CQC, visit <a class=""linkOnClick"" data-include=""695122901"" target=""_blank"" href=""http://www.cambridgequantum.com"" rel=""nofollow"">http://www.cambridgequantum.com</a></p> 
    












		                     					        	<p><u><b>About JSR Corporation</b></u> </p> 
    












		                     					        	<p>JSR Corporation is a multinational company employing over 7,000 people worldwide and a world leading materials supplier in a variety of technology driven markets. JSR's global network is headquartered in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Tokyo</span></span></span> (<span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Japan</span></span></span>) and has factories and offices in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Japan</span></span></span>, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Europe</span></span></span>, US, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">China</span></span></span>, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Taiwan</span></span></span> and Korea.</p> 
    












		                     					        	<p>JSR is a research-oriented organization that pursues close collaborations with leading innovators in a number of industries that are a key to the present and future welfare of human society: electronic materials, life-sciences, synthetic rubbers, display and optical materials.</p> 
    












		                     					        	<p>For more information about JSR Corporation, visit <a class=""linkOnClick"" data-include=""695122901"" target=""_blank"" href=""http://www.jsr.co.jp/jsr_e/"" rel=""nofollow"">http://www.jsr.co.jp/jsr_e/</a></p>  












		                     					        	<p> SOURCE Cambridge Quantum Computing Limited </p> 












		                 </div>
  </div>
  </section>"
http://www.prnewswire.co.uk/news-releases/cambridge-pixel-targets-air-traffic-control-market-with-enhanced-radarview-display-software-695125551.html,Cambridge Pixel Targets Air Traffic Control Market With Enhanced RadarView Display Software,"<section class=""release-body container  no-margin-bottom "" itemprop=""articleBody"">
    <div class=""row"">
                <div class=""col-sm-10 col-sm-offset-1"">
    	                   		 		 		 		 		 
		 		  		 	 					        	<p><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">CAMBRIDGE, England</span></span></span>, <span class=""xn-chron"">October 4, 2018</span> /PRNewswire/ --</p> 
    












		                     													        <!--startclickprintexclude-->
                <!--endclickprintexclude-->
          </div>
        </div>
		
        <!-- 0 --> 
                <div class=""row"">
          <div class=""col-sm-10 col-sm-offset-1"">
			      	 				<ul type=""disc""> 
    <li><i>RadarView</i><i> </i> <i>visualisation/validation software </i> <i>enhanced</i><i> to help </i> <i>ATC </i> <i>integrators and sensor providers</i><i> </i> <i>to </i> <i>deploy</i><i>,</i><i> configur</i><i>e, optimise</i><i> and maint</i><i>ain</i><i> radars in air traffic</i><i> </i> <i>surveillance</i><i> applications</i></li> 
    <li><i>RadarView </i> <i>software now </i> <i>include</i><i>s</i><i>: </i> <i>extended </i> <i>support for </i> <i>ADS-B</i><i> and Surveillance Co-ordination Function (SCF) data</i><i>;</i><i> target detection statistics to verify radar performance</i><i>; radar coverage </i> <i>capability</i><i> to</i><i> </i> <i>optimise location for radar or sensor based on line-of-sight visibility;</i><i> </i> <i>and support for </i> <i>next generation </i> <i>MSSR as well as SSR radars</i></li> 
   </ul> 
   













                         					        	<p>Cambridge Pixel, a developer of radar display, tracking and recording sub-systems, has enhanced its RadarView radar visualisation software to help air traffic control (ATC) integrators and sensor providers to deploy, configure, optimise and maintain radars in air traffic surveillance applications.</p> 
    












		                     					        	<p>The ready-to-run PC-based RadarView display software has been optimised for the ATC market with the addition of new features including extended support for ADS-B (ASTERIX CAT-21) and surveillance co-ordination function (ASTERIX CAT-17) data. SCF messages are used to co-ordinate the operation of multiple Mode S sensors in an installation.</p> 
    












		                     					        	<p>Cambridge Pixel has also added target detection statistics to verify radar performance so that, for example, the percentage of valid detections per scan can be viewed, and radar coverage capability is included to optimise the location for a radar or sensor based on line-of-sight visibility.</p> 
    












		                     					        	<p>The RadarView software also now supports the next generation of Monopulse Secondary Surveillance Radars (MSSR) from companies such as Easat, Indra, Hensoldt, and Raytheon, as well as traditional SSRs.</p> 
    












		                     					        	<p><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">David Johnson</span></span>, CEO of Cambridge Pixel, said: ""Our enhanced RadarView software is a highly flexible tool for ATC integrators or sensor providers that require a low cost, ready-to-run primary radar display application to help them to deploy, configure, optimise and maintain radars in air traffic surveillance applications.</p> 
    












		                     					        	<p>""RadarView is already used by companies such as Saab ATM, <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Kelvin Hughes</span></span> and leading MSSR providers for their installations as it gives them early visibility of the functionality of radars and sensors ahead of final commissioning.""</p> 
    












		                     					        	<p>RadarView allows radar video and camera images to be viewed in multiple windows using standard PC and graphics technology. The software tool receives, processes and scan converts multiple channels of radar video in normal PPI (plan position indicator) view, and, for more specialist requirements, supports B-Scan and A-Scan formats - the latter is especially useful for radar configuration and set-up. Information from Asterix messages is presented as a customisable overlay on the PPI views.</p> 
    












		                     					        	<p>Cambridge Pixel also provides its HPx-346 card for customers that want to convert analogue radar signals, from a legacy system for example, into a standard open network data stream such as ASTERIX CAT-240.</p> 
    












		                     					        	<p>RadarView is part of Cambridge Pixel's world-leading SPx suite of software libraries and applications which provide highly flexible, ready-to-run software products or 'modules-of-expertise' for radar visualisation, radar video distribution, plot extraction and target tracking. This provides a powerful set of processing and display components for capture and presentation of radar video using the capabilities of modern multi-core processors and graphics processor units (GPUs).</p> 
    












		                     					        	<p>Cambridge Pixel's engineering team has decades of experience of developing complex radar processing and display systems for naval, air traffic control, vessel traffic, security, surveillance and airborne radar applications.</p> 
    












		                     					        	<p>Its systems have been implemented in mission-critical applications with companies such as BAE Systems, Frontier Electronic Systems, Blighter Surveillance Systems, Harris, Hanwha Systems, <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Kelvin Hughes</span></span>, Lockheed Martin, Navtech Radar, Raytheon, Saab Sensis, Royal Thai Air Force, Sofresud and Tellumat.</p> 
    












		                     					        	<p>For more information about Cambridge Pixel's RadarView software, please visit <a class=""linkOnClick"" data-include=""695125551"" target=""_blank"" href=""http://www.cambridgepixel.com/"" rel=""nofollow"">http://www.cambridgepixel.com</a> or call: +44-(0)-1763-852749 or<br> email: <a class=""linkOnClick"" data-include=""695125551"" href=""mailto:enquiries@cambridgepixel.com"" rel=""nofollow"">enquiries@cambridgepixel.com</a>.</p> 
    












		                     					        	<p><b>Media photo</b><b>s</b><b>:</b></p> 
    












		                     					        	<p><a class=""linkOnClick"" data-include=""695125551"" target=""_blank"" href=""https://www.cambridgepixel.com/images/News/pr-radarview2018_1.jpg"" rel=""nofollow"">https://www.cambridgepixel.com/images/News/pr-radarview2018_1.jpg</a></p> 
    












		                     					        	<p><a class=""linkOnClick"" data-include=""695125551"" target=""_blank"" href=""https://www.cambridgepixel.com/images/News/pr-radarview2018_2.png"" rel=""nofollow"">https://www.cambridgepixel.com/images/News/pr-radarview2018_2.png</a></p> 
   <p style=""font-weight: bold"">Data sheet:</p> 
    












		                     					        	<p><a class=""linkOnClick"" data-include=""695125551"" target=""_blank"" href=""https://www.cambridgepixel.com/products/RadarView/"" rel=""nofollow"">https://www.cambridgepixel.com/products/RadarView/</a></p> 
    












		                     					        	<p><b>About Cambridge Pixel</b> (<a class=""linkOnClick"" data-include=""695125551"" target=""_blank"" href=""http://www.cambridgepixel.com"" rel=""nofollow"">http://www.cambridgepixel.com</a>)</p> 
    












		                     					        	<p>Founded in 2007, Cambridge Pixel is an award-winning developer of sensor processing and display solutions including primary and secondary radar interfacing, processing and display components for military and commercial radar applications. It is a world-leading supplier of software-based radar tracking and scan conversion solutions through its modular SPx software, and HPx hardware product range. Based near <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Cambridge</span></span></span> in the UK, the company operates worldwide through a network of agents and distributors.<br> </p>  












		                     					        	<p> SOURCE Cambridge Pixel </p> 












		                 </div>
  </div>
  </section>"
http://www.prnewswire.co.uk/news-releases/shell-kicks-off-search-for-most-promising-low-carbon-uk-smes-695125511.html,Shell Kicks Off Search for Most Promising Low Carbon UK SMEs,"<section class=""release-body container  no-margin-bottom "" itemprop=""articleBody"">
    <div class=""row"">
                <div class=""col-sm-10 col-sm-offset-1"">
    	                   		 		 		 		 		 
		 		  		 	 					        	<p><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">LONDON</span></span></span>, <span class=""xn-chron"">October 4, 2018</span> /PRNewswire/ --</p> 
    












		                     										        	 				<ul type=""disc""> 
    <li><b>Total of £350,000 no-strings funding</b><b> </b> <b>for six of the UK</b><b>'</b><b>s most promising low-carbon SMEs</b> </li> 
    <li><b>Shell Springboard Low-Carbon Business of the Year will receive </b> <b>top prize of </b> <b>£150,000</b> </li> 
    <li><b>Applications </b> <b>close on</b><b> </b> <b>October </b> <b>29, </b> <b>2018 </b>  </li> 
   </ul> 
   













		                     							        <!--startclickprintexclude-->
                <!--endclickprintexclude-->
          </div>
        </div>
		
        <!-- 0 --> 
                <div class=""row"">
          <div class=""col-sm-10 col-sm-offset-1"">
			      	<p>Today, Shell opens applications for <a class=""linkOnClick"" data-include=""695125511"" target=""_blank"" href=""http://www.shellspringboard.org/"" rel=""nofollow"">Shell Springboard 2019</a>: a national programme that awards £350,000 no-strings funding to support cutting-edge low-carbon UK Small and Medium Enterprises (SMEs).</p> 
    












                         					        	<p>Alongside the funding, the programme also helps wining SMEs open doors and attract investor interest by generating positive publicity and providing a respected 'quality assurance' stamp. Last year's winner Seawater Greenhouse, whose cool house technology allows crops to grow in arid regions, has further expanded its work in Somaliland, while 2017's winner, Upside Energy, has recently secured an Innovate UK grant worth £470,000.</p> 
    












		                     					        	<p><b><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Sinead Lynch</span></span>, </b> <b>Shell UK Country Chair said:</b> <i>""</i><i>If you</i><i>'</i><i>ve got a brilliant low-</i><i>carbon</i><i> innovation, we really want to hear from you.</i><i> </i> <i>While we don</i><i>'</i><i>t have any equity in the businesses we support th</i><i>r</i><i>ough Shell Springboard</i><i>,</i><i> we </i> <i>want</i><i> to see them </i> <i>scale-up</i><i>, attract private investors and play </i> <i>a</i><i> part in shifting the UK to a low-carbon economy.</i><i>""</i><i> </i></p> 
    












		                     					        	<p>Shell Springboard seeks out and supports UK-based SMEs that reduce carbon emissions, are innovative and economically viable. For example, previous Shell Springboard winner bio-bean, a company creating sustainable biofuels and biochemicals from coffee waste, is now selling in major retailer outlets across the country and have collaborated with TFL to power public buses.</p> 
    












		                     					        	<p><b><span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Charlie Paton</span></span>, Director of Seawater Greenhouse</b>, <b>the 2018 Shell Springboard National Winner, said:</b> <i>""</i><i>Shell Springboard is an amazing programme that has built investor confidence in our business. Through the programme we met other high performing low-carbon SMEs, honed our pitching skills and received constructive feedback from the judges.</i><i>""</i></p> 
    












		                     					        	<p>By helping businesses in the low-carbon sector, both the UK and Shell stand to benefit from stronger economic growth and a deeper pool of innovators able to develop solutions for a lower-carbon world. Since 2005, Shell Springboard has provided over £4 million to more than 100 innovative low-carbon enterprises. More than eight in every ten (84%) Shell-supported companies are still in operation within five years, compared to the national average of approximately 45%.</p> 
    












		                     					        	<p>Shell will be accepting applications to the Shell Springboard programme until <span class=""xn-chron"">10am</span> on <span class=""xn-chron"">October 29</span>. Interested low carbon SMEs are invited to apply online at <a class=""linkOnClick"" data-include=""695125511"" target=""_blank"" href=""http://www.shellspringboard.org"" rel=""nofollow"">http://www.shellspringboard.org</a>.</p>  












		                     					        	<p> SOURCE Shell UK </p> 












		                 </div>
  </div>
  </section>"
http://www.prnewswire.co.uk/news-releases/methodsense-inc-ceo-wins-global-leadership-award-with-business-worldwide-magazine-695129481.html,MethodSense Inc. CEO Wins Global Leadership Award with Business Worldwide Magazine,"<section class=""release-body container  no-margin-bottom "" itemprop=""articleBody"">
    <div class=""row"">
                <div class=""col-sm-10 col-sm-offset-1"">
    	                   		 		 		 		 		 
		 		  		 	 					        	<p><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">LONDON</span></span></span>, <span class=""xn-chron"">October 4, 2018</span> /PRNewswire/ --</p> 
    












		                     										        	<p>The chief executive of life science consulting firm MethodSense has gained global recognition for outstanding leadership in the Business Worldwide Magazine (BWM) 2018 CEO Awards. <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Rita King</span></span> was named <i>'</i><i>Healthcare CEO of the Year </i> <i>-</i><i> <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">USA</span></span></span></i><i>'</i> for her sterling work at the helm of the <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">North Carolina</span></span></span>-based company.</p> 
    












		                     							        <!--startclickprintexclude-->
                <!--endclickprintexclude-->
          </div>
        </div>
		
        <!-- 0 --> 
                <div class=""row"">
          <div class=""col-sm-10 col-sm-offset-1"">
			      	<p>The 2018 Business Worldwide CEO Awards identify and honour the Most Respected C-level executives across the globe from a variety of different sectors. Unlike many business awards that focus on the overall achievements of specific companies, the approach here is to focus instead on the personalities at their helm, inspiring others to achieve similar successes.</p> 
    












                         					        	<p>MethodSense offers life science and medical device regulatory compliance; guiding medical device, biotech and pharmaceutical companies and supporting them through the commercialisation process and beyond. It's an industry that's notoriously difficult to navigate, with many submissions taking years to be approved by regulatory bodies like the Food and Drug Administration (FDA). Through their comprehensive methods, MethodSense assists in all aspects of regulation, compliance and commercialization efforts. MethodSense seeks to simplify the process of bringing, or keeping, a medical device or combination product to market, enabling them to commercialize their innovations.</p> 
    












		                     					        	<p>In a career spanning more than 26 years, <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Rita King</span></span> has garnered an impressive international reputation as a regulatory expert. She has participated in numerous national and international committees and is a founding member of the Underwriters Laboratories team. A highly sought-after speaker, her thoughts on regulatory matters have been published around the globe, and her unparalleled approach to problem solving resonates throughout the company.</p> 
    












		                     					        	<p>""What differentiates MethodSense is our strong staff of biomedical engineers and technologists who not only understand the regulations but very quickly become experts on the products we support,"" she told Business Worldwide Magazine. ""The second and very critical differentiator is our people-focused approach to clients. MethodSense invests in understanding the client, the client's future and individual team members. Through this understanding, and coupled with our regulatory and technical skills, we deliver services that meet the client's specific needs.""</p> 
    












		                     					        	<p>More information about MethodSense can be found on the company website - <a class=""linkOnClick"" data-include=""695129481"" target=""_blank"" href=""http://methodsense.com/"" rel=""nofollow"">http://methodsense.com/</a><u> </u></p> 
    












		                     					        	<p>An article on the company can also be found on BWM website:</p> 
    












		                     					        	<p><a class=""linkOnClick"" data-include=""695129481"" target=""_blank"" href=""https://www.bwmonline.com/2018/08/22/regulating-pharma-shapes-industry-for-the-better-2/"" rel=""nofollow"">https://www.bwmonline.com/2018/08/22/regulating-pharma-shapes-industry-for-the-better-2/</a></p> 
    












		                     					        	<p>For more details on Business Worldwide Magazine Awards 2016, go to <a class=""linkOnClick"" data-include=""695129481"" target=""_blank"" href=""http://www.bwmonline.com/awards/"" rel=""nofollow"">http://www.bwmonline.com/awards/</a></p> 
    












		                     					        	<p><b>About Business Worldwide Magazine</b><br> Business Worldwide Magazine is the leading source of business and dealmaker intelligence throughout the world. Our quarterly magazine and online news portal enables an established audience of corporate dealmakers to track the latest news, stories and developments affecting the international markets, corporate finance, business strategy and changes in legislation. This readership includes of CEO/CFO - Banks, Corporate Lawyers and Venture Capital/Private Equity Companies to name a few.<br> <a class=""linkOnClick"" data-include=""695129481"" target=""_blank"" href=""http://www.bwmonline.com"" rel=""nofollow"">http://www.bwmonline.com</a><br> </p> 
    












		                     					        	<p><b>Contact</b><br> <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">David Jones</span></span><br> Awards Department<br> E: <a class=""linkOnClick"" data-include=""695129481"" href=""mailto:david.jones@bwmonline.com"" rel=""nofollow"">david.jones@bwmonline.com</a><br> </p> 
    












		                     					        	<p>W: <a class=""linkOnClick"" data-include=""695129481"" target=""_blank"" href=""http://www.bwmonline.com"" rel=""nofollow"">http://www.bwmonline.com</a></p>  












		                     					        	<p> SOURCE Business Worldwide Magazine </p> 












		                 </div>
  </div>
  </section>"
http://www.prnewswire.co.uk/news-releases/elsevier-to-provide-point-of-care-tools-for-nhs-wales-695129631.html,Elsevier to Provide Point of Care Tools for NHS Wales,"<section class=""release-body container  no-margin-bottom "" itemprop=""articleBody"">
    <div class=""row"">
                <div class=""col-sm-10 col-sm-offset-1"">
    	                   		 		 		 		 		 
		 		  		 	 					        	<p><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">LONDON</span></span></span>, <span class=""xn-chron"">October 4, 2018</span> /PRNewswire/ --</p> 
   <p style=""text-align: left""><i>This agreement will see the implementation of Elsevier</i><i>'</i><i>s ClinicalKey, ClinicalKey Nursing and Journals</i><i> Consult</i><i> solutions for all NHS Wales employees</i> </p> 
    












		                     										        	<p><a class=""linkOnClick"" data-include=""695129631"" target=""_blank"" href=""http://www.elsevier.com/"" rel=""nofollow"">Elsevier</a>, the information analytics business specializing in science and health, has been awarded an NHS Wales Tender for Point of Care tools.</p> 
    












		                     							        <!--startclickprintexclude-->
                <!--endclickprintexclude-->
          </div>
        </div>
		
        <!-- 0 --> 
                <div class=""row"">
          <div class=""col-sm-10 col-sm-offset-1"">
			      	<p>Elsevier's e-resources, <a class=""linkOnClick"" data-include=""695129631"" target=""_blank"" href=""https://www.elsevier.com/solutions/clinicalkey"" rel=""nofollow"">ClinicalKey</a> and <a class=""linkOnClick"" data-include=""695129631"" target=""_blank"" href=""https://www.elsevier.com/solutions/clinicalkey-for-nursing"" rel=""nofollow"">ClinicalKey Nursing</a>, were accessible from <span class=""xn-chron"">Monday, October 1</span> to all 92,000+ NHS Wales staff, including clinicians and health professionals, contract holders, community pharmacists, dentists, and hospice workers; students on placement and departments of Welsh Government. This follows an expansion of the NHS Wales e-Library for Health which is managed by NHS Wales Informatics Service.</p> 
    












                         					        	<p>ClinicalKey and ClinicalKey Nursing will be available to all NHS Wales staff instantly from within the NHS Wales network through the <a class=""linkOnClick"" data-include=""695129631"" target=""_blank"" href=""http://howis.wales.nhs.uk/elibrary"" rel=""nofollow"">e-Library intranet site</a> (accessible on NHS Wales network only) and via OpenAthens from home or public Wi-Fi via the <a class=""linkOnClick"" data-include=""695129631"" target=""_blank"" href=""http://www.wales.nhs.uk/elibrary"" rel=""nofollow"">e-Library internet site</a>.</p> 
    












		                     					        	<p>The e-Library is aimed at supporting effective healthcare delivery by providing evidence-based, relevant, and timely information to NHS Wales staff. This expansion of the e-Library will ensure it continues to improve learning, education and training culture, service, research and development, and innovation within NHS Wales.</p> 
    












		                     					        	<p>""The NHS Wales Informatics Service recognizes that clinicians need access to current, credible information and search tools to provide the best evidence-based care to their patients,"" said <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Tim Hawkins</span></span>, Managing Director, Clinical Solutions EMEALAAP, Elsevier. ""With ClinicalKey suite of solutions, we're pleased to support NHS Wales with the most relevant and recent healthcare information. ClinicalKey empowers healthcare professionals to deliver a more collaborative, consistent care experience that supports more positive clinical outcomes.""</p> 
    












		                     					        	<p>ClinicalKey improves and standardizes clinical care and saves time by delivering fast, concise answers and deep access to evidence whenever and wherever healthcare professionals require. ClinicalKey is updated on a daily basis as new information is published, ensuring that every decision made is informed and based on the most current evidence. ClinicalKey ensures consistency in policy and practice by disseminating the latest evidence-based practice and with all the information in one place, duplication of content is avoided. Incorporating international guidelines such as NICE which ensures consistency in policy and practice, ClinicalKey supports better answers for important decisions with smart search capability providing healthcare professionals with relevant answers to direct diagnosis, to support point-of-care quick answers.</p> 
    












		                     					        	<p><b>About Elsevier</b> </p> 
    












		                     					        	<p><a class=""linkOnClick"" data-include=""695129631"" target=""_blank"" href=""https://www.elsevier.com/"" rel=""nofollow"">Elsevier</a> is a global information analytics business that helps institutions and professionals advance healthcare, open science and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&amp;D performance, clinical decision support and professional education, including <a class=""linkOnClick"" data-include=""695129631"" target=""_blank"" href=""https://www.elsevier.com/solutions/sciencedirect"" rel=""nofollow"">ScienceDirect</a>, <a class=""linkOnClick"" data-include=""695129631"" target=""_blank"" href=""https://www.elsevier.com/solutions/scopus"" rel=""nofollow"">Scopus</a>, <a class=""linkOnClick"" data-include=""695129631"" target=""_blank"" href=""https://www.elsevier.com/solutions/scival"" rel=""nofollow"">SciVal</a>, <a class=""linkOnClick"" data-include=""695129631"" target=""_blank"" href=""https://www.elsevier.com/solutions/clinicalkey"" rel=""nofollow"">ClinicalKey</a> and <a class=""linkOnClick"" data-include=""695129631"" target=""_blank"" href=""https://evolve.elsevier.com/education/sherpath/"" rel=""nofollow"">Sherpath</a>. Elsevier publishes over 2,500 digitized journals, including <a class=""linkOnClick"" data-include=""695129631"" target=""_blank"" href=""http://www.thelancet.com/"" rel=""nofollow""><i>The Lancet</i></a> and <a class=""linkOnClick"" data-include=""695129631"" target=""_blank"" href=""http://www.cell.com/"" rel=""nofollow""><i>Cell</i></a>, 38,000 e-book titles and many iconic reference works, including <a class=""linkOnClick"" data-include=""695129631"" target=""_blank"" href=""https://www.elsevier.com/books/grays-anatomy/standring/978-0-7020-5230-9"" rel=""nofollow""><i>Gray</i><i>'</i><i>s Anatomy</i></a>. Elsevier is part of <a class=""linkOnClick"" data-include=""695129631"" target=""_blank"" href=""http://www.relx.com/"" rel=""nofollow"">RELX Group</a>, a global provider of information and analytics for professionals and business customers across industries. <a class=""linkOnClick"" data-include=""695129631"" target=""_blank"" href=""https://www.elsevier.com/"" rel=""nofollow"">www.elsevier.com</a></p> 
    












		                     					        	<p><b>Media contact</b><br> <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Chris Bell</span></span>, Marketing Manager<br> Elsevier<br> +44-78-27-843-578<br> <a class=""linkOnClick"" data-include=""695129631"" href=""mailto:c.bell@elsevier.com"" rel=""nofollow"">c.bell@elsevier.com</a><br> </p>  












		                     					        	<p> SOURCE Elsevier </p> 












		                 </div>
  </div>
  </section>"
http://www.prnewswire.co.uk/news-releases/astrazeneca-becomes-the-first-lhasa-member-to-realise-the-benefits-of-mirabilis-through-saas-695131961.html,AstraZeneca Becomes the First Lhasa Member to Realise the Benefits of Mirabilis Through SaaS,"<section class=""release-body container  no-margin-bottom "" itemprop=""articleBody"">
    <div class=""row"">
                <div class=""col-sm-10 col-sm-offset-1"">
    	                   		 		 		 		 		 
		 		  		 	 					        	<p><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">LEEDS, England</span></span></span>, <span class=""xn-chron"">October 4, 2018</span> /PRNewswire/ --</p> 
   <p style=""text-align: left"">Lhasa Limited, an educational charity which creates state-of-the-art <i>in silico</i> prediction and database systems, today announced that AstraZeneca has become the first organisation to adopt Mirabilis through Software as a Service (SaaS).</p> 
    












		                     													        <!--startclickprintexclude-->
                <!--endclickprintexclude-->
          </div>
        </div>
		
        <!-- 0 --> 
                <div class=""row"">
          <div class=""col-sm-10 col-sm-offset-1"">
			      	<p>Requiring no customer installation, and no additional servers or other expensive hardware, Mirabilis through SaaS has been made available quickly to AstraZeneca, providing them with rapid access to this unique solution, without compromising the confidentiality of their own proprietary information. The Mirabilis SaaS offering uses the Amazon Web Services (AWS) cloud platform, which is widely used by the pharmaceutical industry because of its exceptional security, scale and global reach.</p> 
    












                         					        	<p><a class=""linkOnClick"" data-include=""695131961"" target=""_blank"" href=""https://www.lhasalimited.org/products/Mirabilis.htm"" rel=""nofollow"">Mirabilis</a> uses an industry-standardised approach to provide a scientifically robust calculation of purge factors of potentially mutagenic impurities in a synthetic route. Crucially, it can be used to satisfy ICH M7 Control Option 4 by producing an estimated purge factor for removal of an impurity by a synthetic process. Based on the principles established by Teasdale <i>et al.</i><sup>[</sup><sup>1</sup><sup>]</sup><sup>,</sup><sup>[</sup><sup>2</sup><sup>]</sup><i>,</i> Mirabilis is the result of collaboration between Lhasa Limited and a number of pharmaceutical companies (including AstraZeneca), is built on expert knowledge and is semi-automated to improve the efficiency of purge analysis.</p> 
    












		                     					        	<p>Dr. <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Andrew Teasdale</span></span>, Senior Principal Scientist at AstraZeneca said: ""Being able to implement Mirabilis efficiently and effectively without the need for new hardware is a huge positive in allowing us to leverage this important tool"".</p> 
    












		                     					        	<p>Dr, <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">James Willans</span></span>, Chief Technology Officer at Lhasa Limited, said: ""I am delighted that AstraZeneca are adopting Mirabilis SaaS and are able to realise the business value of Mirabilis without being concerned with software installation and maintenance. AstraZeneca's adoption of Mirabilis SaaS is a significant milestone in Lhasa's SaaS journey and ensuring that our best-in-class solutions are instantly available to our members"".</p> 
    












		                     					        	<p><b>About Lhasa Limited</b> <br> </p> 
    












		                     					        	<p>Lhasa Limited was founded in 1983 as a not-for-profit organisation and educational charity to promote the use of computer-aided reasoning in chemistry and the life sciences. It facilitates collaborative data sharing projects with its members in the pharmaceutical and other life science industries.</p> 
    












		                     					        	<p>Lhasa is a pioneer in the production of expert, knowledge-based systems for forward thinking scientists, and continues to draw on its 35 plus years of experience in knowledge development to create user-friendly, state-of-the-art <i>in silico</i> prediction and database systems for use in metabolism, toxicology and related areas of science.</p> 
    












		                     					        	<p>For more information on how Lhasa Software as a Service can streamline your impurity qualification process please contact <a class=""linkOnClick"" data-include=""695131961"" href=""mailto:info@lhasalimited.org"" rel=""nofollow"">info@lhasalimited.org</a> or call +44-113-394-6020.</p> 
    












		                     					        	<p><b>For further press information contact <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Liz Lepley</span></span> at Lhasa Limited (</b><b>+44-0113-394-</b><b>6020)</b> </p> 
    












		                     					        	<p><sup>[</sup><sup>1</sup><sup>]</sup> Teasdale et al. (2010) 'A Tool for the Semiquantitative Assessment of Potentially Genotoxic Impurity (PGI) Carryover into API Using Physicochemical Parameters and Process Conditions', Organic Process Research &amp; Development, vol. 14, pp 943-945.</p> 
    












		                     					        	<p><sup>[</sup><sup>2</sup><sup>]</sup> Teasdale et al. (2013) 'Risk Assessment of Genotoxic Impurities in New Chemical Entities: Strategies To Demonstrate Control', Organic Process Research &amp; Development, vol. 17, pp 221-230.</p>  












		                     					        	<p> SOURCE Lhasa Limited </p> 












		                 </div>
  </div>
  </section>"
http://www.prnewswire.co.uk/news-releases/zecotek-closes-divisional-equity-financing-of-2000000-based-on-100-million-valuation-695138811.html,"Zecotek Closes Divisional Equity Financing of $2,000,000 Based on $100 Million Valuation","<section class=""release-body container  no-margin-bottom "" itemprop=""articleBody"">
    <div class=""row"">
                <div class=""col-sm-10 col-sm-offset-1"">
    	                   		 		 		 		 		 
		 		  		 	 					        	<p><span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">VANCOUVER, British Columbia</span></span></span>, <span class=""xn-chron"">October 4, 2018</span> /PRNewswire/ --</p>
<p style=""text-align: center;"">NOT FOR DISTRIBUTION TO <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">UNITED STATES</span></span></span> NEWSWIRE SERVICES OR FOR DISSEMINATION IN <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">THE UNITED STATES</span></span></span>.</p>
 












		                     													        <!--startclickprintexclude-->
                <!--endclickprintexclude-->
          </div>
        </div>
		
        <!-- 0 --> 
                <div class=""row"">
          <div class=""col-sm-10 col-sm-offset-1"">
			      	<p><strong>Zecotek Photonics Inc.</strong> (""<strong>Zecotek</strong>"" or the ""<strong>Company</strong>"") (TSX-V: ZMS) (Frankfurt: W1I)<strong>,</strong> a developer of leading-edge photonics technologies for healthcare, industrial and scientific markets, is pleased to announce its has <strong>now</strong> closed on the previously announced divisional equity financing of <span class=""xn-money"">$2 million</span>. The financing, announced on <span class=""xn-chron"">July 18, 2018</span>, was completed by selling a 2% equity interest <strong>in</strong> the Company's wholly owned subsidiary, Zecotek Imaging Systems Pte. Ltd. to an industrial business group based in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">China</span></span></span> for net proceeds of <span class=""xn-money"">$2 million</span>.</p>
 












                         					        	<p>""The funds raised in this divisional equity financing will be used to continue the manufacturing of the new generation series of solid-state micro-pixel avalanche photo diodes and transistors (MAPD/T),"" said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Photonics Inc. ""We have partnered with the Malaysian Institute of Microelectronics Systems and are moving to full production and commercialization. Medical imaging, high energy physics and other industrial applications, such as agriculture, genomics and LIDAR for autonomous cars, recognize the significant performance advantages of our MAPD/T. We are working with experts on a revised strategy to better reflect the values built at the subsidiaries level in our existing markets and industries. We will leverage the competitive advantages of our sensing and scanning technologies to establish new standards and benchmarks for product quality control essential to the industries associated to the newest Canadian market trends.""</p>
 












		                     					        	<p>The divisional financing was based on the appraised pre-commercialized value of Zecotek Imaging Systems of approximately <span class=""xn-money"">$100 million</span>. Recent M&amp;A activity in the photo detector manufacturing marketplace is a clear indication of the increasing market interest and valuations of new generation solid-state micro-pixel avalanche photo diodes technologies. More and more organizations are adopting solid-state photo diodes and transistors and are increasingly moving away from photomultiplier tubes.</p>
 












		                     					        	<p>Zecotek's patented MAPD/T offers significant performance-cost advantages over competing photomultiplier tubes (PMT) and other solid-state, silicon-based photo detectors known as SiPM. The new generation MAPD/T have low manufacturing cost, excellent timing resolution and photon detection efficiency - key characteristics for the new configurations of high resolution PET medical scanners. Solid-state MAPD/T also offer superior recovery time, unique radiation hardness and display of the highest possible linearity making them prime components for the improved detector designs required in high energy experiments at the Chinese Institute of High Energy Physics (IHEP) and CERN. Zecotek's pioneering MAPD technology can also be used to manufacture two-dimensional arrays of solid-state photo detectors, which allows for the manufacture and implementation of both very large-area detectors and compact position-sensitive arrays.</p>
 












		                     					        	<p><strong>About Malaysian Institute of Microelectronic Systems</strong> </p>
 












		                     					        	<p>MIMOS is <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Malaysia's</span></span></span> premier Applied Research and Development Centre in Information and Communications Technology, Industrial Electronics Technology and Nano-Semiconductor Technology. As a strategic agency under the Ministry of Science, Technology and Innovation (MOSTI), MIMOS contributes to raising <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Malaysia's</span></span></span> competitiveness by pioneering market creation for Malaysian technopreneurs through patentable technology platforms, products and solutions. Over the past 12 years, MIMOS has filed more than 2,000 Intellectual Properties in various technology domains and across key socio-economic areas. Serving a central role in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Malaysia's</span></span></span> transformation journey and ICT Vision, MIMOS endeavors to create a culture of innovation by nurturing relationships with internal and external stakeholders, in the spirit of smart partnerships and inclusive growth models and strategies. For more information visit: <a class=""linkOnClick"" data-include=""695138811"" target=""_blank"" rel=""nofollow"" href=""http://www.mimos.my"">http://www.mimos.my</a> .</p>
 












		                     					        	<p><strong>About Zecotek</strong> </p>
 












		                     					        	<p>Zecotek Photonics Inc (TSX-V: ZMS; Frankfurt: W1I) is a photonics technology company developing high-performance scintillation crystals, photo detectors, positron emission tomography scanning technologies, 3D auto-stereoscopic displays, 3D metal printing, and lasers for applications in medical, high-tech and industrial sectors. Founded in 2004, Zecotek operates three divisions: Imaging Systems, Optronics Systems and 3D Display Systems with labs located in <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Canada</span></span></span>, Korea, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Russia</span></span></span>, <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Singapore</span></span></span> and <span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">U.S.A.</span></span></span> The management team is focused on building shareholder value by commercializing over 50 patented and patent pending novel photonic technologies directly and through strategic alliances with Hamamatsu Photonics (<span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Japan</span></span></span>), the European Organization for Nuclear Research (<span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">Switzerland</span></span></span>), Shanghai EBO Optoelectronics Technology Co. (<span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">China</span></span></span>), NuCare Medical Systems (<span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">South Korea</span></span></span>), the <span class=""xn-org"">University of Washington</span> (<span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">United States</span></span></span>), and National NanoFab Center (<span class=""xn-location"" itemprop=""contentLocation"" itemscope itemtype=""http://schema.org/Place""><span itemprop=""geo"" itemscope itemtype=""http://schema.org/address""><span itemprop=""addressLocality"">South Korea</span></span></span>). For more information visit <a class=""linkOnClick"" data-include=""695138811"" target=""_blank"" rel=""nofollow"" href=""http://www.zecotek.com/"">http://www.zecotek.com</a> and follow <a class=""linkOnClick"" data-include=""695138811"" target=""_blank"" rel=""nofollow"" href=""https://twitter.com/zecotek"">@zecotek</a> on Twitter.</p>
 












		                     					        	<p><em>This press release may contain forward-looking statements that are based on management</em><em>'</em><em>s expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated. </em>  </p>
 












		                     					        	<p><em>Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at</em> <a class=""linkOnClick"" data-include=""695138811"" target=""_blank"" rel=""nofollow"" href=""http://www.zecotek.com/""><em>http://www.zecotek.com</em></a></p>
 












		                     					        	<p><strong>For Additional Information Please Contact:</strong><br> Zecotek Photonics Inc.<br> <span class=""xn-person"" itemscope itemtype=""http://schema.org/Person""><span itemprop=""name"">Michael Minder</span></span><br> T: +1(604)783-8291<br> <a class=""linkOnClick"" data-include=""695138811"" rel=""nofollow"" href=""mailto:ir@zecotek.com"">ir@zecotek.com</a></p>  












		                     					        	<p> SOURCE Zecotek Photonics Inc. </p> 












		                 </div>
  </div>
  </section>"
